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Chapter 1
General introduction
 The human brain is a complex system maintaining homeostasis of diverse functions 
of the body. However, small deviations from the normal functioning of the brain during 
development may impose risk for disorders later in life, such as autism, epilepsy, intellec-
tual disability and attention deficit hyperactivity disorder (ADHD). Risk factors are typically 
classified as environmental and genetic factors [1, 2]. Known environmental factors include 
deprived nutrition, physical trauma and oxygen deprivation at birth, whereas genetic fac-
tors include mutations from familial inheritance, sporadic mutations, copy number variants 
(CNVs) and epigenetic defects. An increasing number of genes are being studied in relation 
to brain disorders. However, most often we lack insight to how these gene factors contrib-
ute to disease. Moreover, how defects in each brain cell type contribute to developmental 
defects of the brain is often not understood. Neurodevelopment in humans starts at an early 
embryonic stage and continues many years after birth. To understand the mechanisms un-
derlying human neurodevelopmental disorders, proper disease models are required, which 
mimic the small deviations that may occur during different developmental stages of the 
human brain. Human induced pluripotent stem cells (iPSCs) derived from patients provide 
new tools for studying mechanisms underlying disease, with the final goal to understand 
disease and improve therapy. In this thesis, the potential of iPSC-derived cells to develop 
new disease models for a neurodevelopmental disorder called Tuberous Sclerosis Complex 
(TSC) is explored. This thesis further contributes to 1) the characterization of developmental 
stages in iPSC-derived in vitro models and 2) the involvement of multiple brain cell types in 
neurodevelopmental disorders like TSC.
1.1 Human pluripotent stem cells
 A stem cell is a cell that can self-renew and differentiate into specialized cells [3]. 
The capability to develop into various cell lineages and cell types forms its potency. The 
potency of stem cells decreases during differentiation. The variable types of potencies are; 
1) totipotency: cells can differentiate into embryonic and extra embryonic tissue i.e., an en-
tire organism e.g.; Zygote; 2) pluripotency: cells can differentiate into any desired cell type 
of the body e.g., embryonic stem cells; 3) multipotency: cells can differentiate to a specific 
lineage or tissue e.g., neural stem cells; and 4) unipotency: cells can only differentiate into 
one or more specialized cell type e.g., neuronal precursors [4].
 In 1998, the first human embryonic stem cell (hESC) line was generated from the 
inner mass cells of a blastocyst stage 14 [5], which was donated in the process of in vitro 
fertilization (IVF). Among the different potency stages, hESCs fall in the category of pluripo-
tent stem cells as they can differentiate into any cell type, but cannot make extra embryonic 
10
Chapter 1
tissue (e.g. placenta). The pluripotency of in vitro generated hESC lines was assessed by their 
capacity to differentiation into cells of the three germ layers of embryonic development [6, 
7]. Research on hESCs paved the way to study human cellular properties in vitro [5]. Studies 
have demonstrated hESC potential in regenerative medicine [8, 9] where transplantation of 
hESC-derived neural cells was shown to rescue disease phenotypes in rodent models [10, 
11]. In the last two decades, labs worldwide also showed the prospects of hESCs by gener-
ating various cell types, including brain cells, cardiomyocytes and retinal pigment cells from 
them for regenerative therapies [11-15]. 
 The pitfalls in hESC research include firstly 1) ethical concerns that rose against use 
of human embryos [16, 17], since hESCs are derived from inner mass cells of an early stage 
embryo, leading to its destruction. Several countries like Germany and France restrict gen-
eration of hESC lines citing this necessity to destruct a human embryo [16]. 2) Next, the 
unavailability of enough disease related hESC lines. To study disease phenotypes a progress 
towards deriving stem cells with disease-causing mutations was a logical step for human 
disease research. Although, several groups used disease-specific human embryos derived 
from IVF or pre-implantation genetic diagnosis (PGD) procedures [18-20], the limited avail-
ability of donors and pregnancies that went through PGD prevents the mainstream applica-
tion of this method [21]. 3) Furthermore, immune rejections in regenerative therapy, since 
the transplanted cells may be rejected by the recipient’s immune system. Indeed allogeneic 
engraftment procedures had to be combined with immunosuppressive therapy for the recip-
ient, leading to long-term side effects [22, 23]. To overcome immune rejection of hESC-de-
rived cells techniques like somatic cell nuclear transfer (cloning) could be used, where the 
nucleus of a somatic (patient) cell is placed in an enucleated egg (donor) cell and devel-
oped into a hESC line. However, this method is technically challenging and still encounters 
ethical issues such as need for human egg donors [24, 25]. 4) Finally, genetic instability in 
hESCs. Multiple studies report duplications of DNA regions; chromosomal abnormalities 
[26] and chromosome translocation defects in neural cells derived from hESCs [27]. These 
studies indicate genomic instability in hESCs [28] limiting their use for research and therapy. 
 Taken together although hESCs showed potential in regenerative therapies, the ethi-
cal issues, scarcity of hESC lines with specific disease-related mutations, immune rejections 
in regenerative therapies and genomic instability impeded the progress of human disease 
research and therapy using hESCs. 
1.2 Human iPSCs: advantages and challenges 
 In 2006, Shinya Yamanaka and colleagues reported that adult mouse somatic cells 
could be reprogrammed back into an embryonic stem cell-like state. In 2007, they report-
ed a similar study for human cells [29, 30]. Yamanaka and colleagues used a set of factors 
namely OCT3/4, SOX2, KLF4 and c-MYC, for reprogramming human skin cells (fibroblasts) 
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into induced pluripotent stem cells (iPSCs). These stem cells were reported to be similar to 
hESCs on several aspects like morphology, proliferation, gene expression, epigenetic status 
of pluripotency, and telomerase activity [30]. The invention of the iPSC technology led to 
Yamanaka winning the Nobel Prize for Physiology or Medicine in 2012. 
Human iPSCs possess advantages over hESCs by overcoming major limitations of hESC re-
search. 
1) The ethical concerns encountered by hESCs research are eliminated by hiPSCs, since they 
can be derived from donor-/ patient- somatic cells e.g., skin cells, blood cells, and do not 
involve an embryo. 
2) Next, patient iPSCs overcome necessity for disease-specific human embryos since they 
help to study neurological disorders in patient’s own genetic background and provide closer 
insight to human disease mechanisms when compared to hESCs, existing rodent or primate 
models. Specifically, patient iPSCs have been widely used for in vitro modeling of neuro-
logical disorders. One of the first studies showed neuronal deficits like diminished synapses 
and neuronal degeneration in neuronal cell cultures derived from a spinal muscular atro-
phy (SMA) patient iPSCs [31]. A study of neurons derived from Rett patient iPSCs showed 
a reduced number of synapses, altered calcium signaling and excitability [32]. Another 
study-modelled aging in PD patient-derived iPSCs and showed aging-related phenotypic 
defects of PD e.g., pronounced dendritic degeneration and enlarged mitochondria [33]. 
Similarly, patient iPSCs-derived neurons demonstrated neuropathological features of FTD 
and ALS patients [34]. Hence, there is now ample evidence that iPSCs are valuable tools 
to help understand disease mechanisms underlying neurodegenerative and neurodevelop-
mental disorders. This also facilitates the process of drug development using in vitro models, 
which express disease phenotypes in a dish. 
3) Finally, generation of various brain cell types from patient-own cells for cell replacement 
therapies are one of the promising applications of iPSCs. In comparison to hESCs, iPSCs 
overcome the necessity of immune suppression in recipients due to allogeneic transplanta-
tions i.e., cells derived from a matching donor. A comparative study on autologous i.e, cells 
from same individual and allogeneic iPSC transplantation in non-human primates showed 
the advantages of autologous grafts in reducing immune response over allogeneic grafts in 
the brain [35]. Similarly, neurons derived from autologous iPSCs of a non-human primate 
Parkinson’s disease (PD) model were shown to survive up to 2 years, innervate the host brain 
and provide long-term functional recovery [36]. Next to that, iPSC based transplantations 
are also beneficial in rescuing glial deficits. Transplantation of iPSC-derived oligodendrocyte 
(OL) precursors induced myelin formation in the recipient and rescued hypomyelination in 
a mouse model of congenital hypomyelination [37]. Transplantation in Amyotrophic lateral 
sclerosis (ALS) mouse models showed that a hiPSC derived astrocytic precursors increase 
life span [38] and that neural stem cell populations derived from iPSCs can reduce pheno-
typic defects like neuromuscular dysfunction and improve life span [39]. 
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 Overall, it is indicative that iPSCs overcome major limitations of hESC research. Fur-
thermore, current studies ensure that patient iPSC-derived in vitro models and regenerative 
therapies are moving in the right direction and help understand human neurological diseas-
es and therapy.
 While iPSC technology provides valuable tools for disease modelling and for devel-
oping personalized medicine, there are also challenges to be explored. Firstly, choosing and 
generating appropriate controls for patient iPSCs-derived cell types is a challenge for in vitro 
studies. Although major studies so far used control iPSCs from unaffected family members, 
healthy individuals, advantages of using isogenic control iPSCs i.e., controls generated after 
correction of disease-causing mutations in the patient iPSCs were discussed in a Rett patient 
iPSCs based study [40]. Gene correction techniques like CRISPR/Cas, Transcription activa-
tor-like effector nucleases (TALENs), and Zinc finger nucleases (ZFNs) could help generation 
of these isogenic controls. 
 In addition, gene editing to introduce disease-causing mutations in control iPSCs 
could also be valuable for understanding gene function in relation to disease phenotypes 
[41]. Targeted genetic deletion or corrections of mutation in genes like TSC, C9orf72 using 
techniques like ZFNs and CRISPR-Cas9, have proven advantageous in research of diseases 
like TSC and ALS [42, 43].
 Secondly, the variability among iPSC lines of different donors and multiple iPSC 
clones from the same donor is typically high [44]. Two studies compared multiple iPSC lines 
from several donors. One reported variations in endogenous pluripotency and transgene 
expression among individuals and clones of same individuals [44]. The other reported var-
iability in terms of karyotype and transgene expression and differentiation efficiency [45]. 
These sources of variability in iPSC studies might include epigenetic changes during iPSC 
reprogramming, culture conditions and could further hinder comparison of control and pa-
tient cells [21]. However, these variabilities could be diminished by using larger groups of 
patient and control iPSC lines, and generating isogenic controls or controls from genetically 
related/-controlled healthy individuals [21, 46, 47].
 Thirdly, lag in differentiation state of iPSC-derived cells is a limitation. For instance 
presence of proliferating immature cells leads to differences in functional maturation state 
of individual cells in a culture network. Specifically in neurodegenerative disorders like 
ALS, variable state in maturity makes it difficult to distinguish mature cells showing signs 
of degeneration from younger cells that are not yet mature. To overcome, this limitation a 
study showed fluorescence-activated cell sorting (FACS) of post mitotic neurons from neural 
progenitors [48]. Similarly, trans-differentiated cells, which are cells derived from other ter-
minally differentiated cell types could overcome lags in variable differentiation state [21]. 
Furthermore, these variations in individual cell maturity might also lead to tumour develop-
ment of transplanted populations, although new strategies like generating iPSCs with miR-
NA, small molecules and coding mRNAs, which reduced iPSC tumorigenicity by avoiding 
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induction of oncogenes are suggested to overcome these [49]. 
 Finally, epigenetic memory of the tissue of origin, since iPSCs are derived from an-
other mature cell type [50] and altered DNA methylation among hESCs and iPSC lines is a 
limitation [51, 52]. While these observations affect on-going iPSC research, it emphasizes 
iPSC potential to preferentially differentiate into tissue of cell origin. However, passaging 
(i.e., subculturing) the iPSC lines multiple times widely attenuated this epigenetic memory 
for tissue of origin [50] indicating the necessity to avoid use of iPSC cells from early-passage 
stages.
 In summary, while the hESC research was intensified in the past for deriving multiple 
cell types with purpose of regenerative therapies, iPSCs bring better opportunities to under-
stand disease phenotypes in vitro, drug development as well as therapy using patient-spe-
cific cells. Indeed, iPSC research overcomes various limitations faced by hESC research. 
Furthermore, as discussed each challenge faced by iPSC research is followed-up by studies 
and strategies to overcome/ eliminate them. Overall, in comparison to hESCs, the iPSCs and 
related techniques like gene editing provide a better and more valuable platform in human 
disease research.
1.3 Neuroectoderm induction and development
 The neural precursors during the gestation period emerge as rosette-forming cells, 
arranged in a transverse pattern in the neural tube (neuroectoderm) during embryonic devel-
opment. They possess an epithelial cell-like structure with tightly packed junctions and are 
therefore called neuroepithelial stem (NES) cells [53]. Based on position and timing, cells in 
the neural tube may differentiate into NES cells and later form radial glial (RG) cells or other 
intermediate neural precursor cells [54]. During development, early NES cells generate the 
first set of neurons in the brain [55], and following NES; the RG cells can evolve into differ-
ent neuronal and glial populations [56]. In addition, RG cells have important functions in 
guiding neuronal migration from germinal layers to the mantle region of the brain and spinal 
cord [56, 57]. The NES cells express rosette-specific markers like Pro-myelocytic leukemic 
zinc finger (PLZF), Dachshund family transcription factor 1 (DACH1) and tight junction 
marker ZO-1 [58, 59] which distinguish them from the RG cells that express astroglial-like 
markers like glutamate aspartate transporter (GLAST), brain lipid-binding protein (BLBP), 
Vimentin, radial-glial cell marker-2 (RC2), CD44, A2B5 and glial fibrillary acidic protein 
(GFAP) [58, 59]. Interestingly, transcription factors like PAX6, which are often termed as 
neural-rosette markers [60] are also shared by RG cells and are important for their neuro-
genic regulation in human cortex [61]. Despite of differences in marker expression between 
NES and RG cells [58] there are enough evidences that both precursor population gives rise 
to both neuronal and glial cells [54, 58, 62, 63]. Hence, the neuroepithelium or neural tube 
consists of distinguishable populations of NES and RG cells, which give rise to interchange-
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able lineages of cells and form various brain regions.
 The neural tube is under the influence of several growth factors, which provide ante-
rio-posterior and dorso-ventral patterning during development [57, 64]. Specifically, gradi-
ents of Wnt, bone morphogenic proteins (BMPs) and sonic hedgehod (SHH) are necessary 
for dorso-ventral patterning, retinoids (RA) are required for anterio-posterior axis as well as 
hindbrain formation and FGF signalling is important for posterior patterning [64]. Although 
neural precursors show symmetric self-renewal early on, they adopt to asymmetric prolifer-
ation followed by migration to specific regions of the brain. The number of cells present in 
the brain depends on the proliferative rate of the precursors and therefore, it also controls 
the amount of neurons, astrocytes and OLs in total [65]. The proliferation rate of neural stem 
cells is directed by certain transcription factors, like Sex determining region Y-box 2 (SOX2) 
[66]. Other important growth and patterning factors, like epidermal growth factor (EGF) and 
transforming growth factor-alpha (TGFb), are reported to regulate different stages of neural 
stem cell proliferation and development [67, 68]. Effects of other mitogens/ growth factors 
like basic fibroblast growth factor (FGF2), which retain neural stem cells in a proliferative 
state [68, 69] and control the start of differentiation into neuronal and glial cells, have been 
studied extensively [70]. Furthermore, many studies indicate that neural developmental pro-
cesses involve not one, but many different factors for effective patterning, maturation and 
functioning [71-73]. For instance FGF signaling is known to work in association with other 
pathways like Wnt, hedgehog [64, 74]. Overall, studies indicate that multiple factors play 
role in brain development and known effects of each factors is crucial for deriving cells of 
interest for in vitro neural differentiation protocols.  
 The definition to regional identity and precursor lineages are often complex to de-
termine. For instance, while different studies use NES cells to generate cortical neurons, 
a study based on human fetus showed that cortical neurogenesis is dependent also on a 
group of RG cells and neuron-restricted progenitors. This study shows expression of LeX+ 
cells (a marker for early neural progenitors), which co-localized majorly with RG like cells 
expressing BLBP, GFAP and Vimentin. These LeX+ RG progenitors showed transitory inward 
current sensitivity to TTX (a sodium channel blocker) indicating their differentiation towards 
neurons. Furthermore, the human fetal brain also expressed a substantial population of 
proliferating neuronal-restricted progenitors, which only expressed beta-III-tubulin and dou-
blecortin (DCX) [63]. Rodent studies suggest that neural stem cells go via regional/ lineage 
specific intermediate precursors before reaching terminal differentiation stages. A cDNA 
array technology based study showed differential expression of about 40 genes between 
neural stem cells (NSCs) and OL precursors cells (OPCs) derived from them, where some 
genes like PDGFR-a, PLP, and MBP are associated to OL maturation [75]. In contrast to the 
Mo., et al study it was reported that multipotent NES cells go through intermediate restrict-
ed A2B5 precursor stage; a marker also expressed by radial-glial cells [58], and were able 
to differentiate into terminally differentiated glial cells but not neurons [76]. While stage 
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specific precursors are reported; on the contrary, OLIG2 precursors were shown to give rise 
to multiple cell lineages including OLs, motor neurons (MNs), a subset of astrocytes and 
ependymal cells in mouse brain [77]. Since, rodent studies have provided major insights to 
brain development, translational lags among rodent and human models needs to be filled, 
e.g., in the human brain GFAP+ RG progenitors are present in very early stages of cortex 
development, whereas in rodents they appear much later in corticogenesis [78, 79]. Alto-
gether, it is crucial to consider the selection of progenitors for neuronal differentiations, e.g., 
cortical neurogenesis is comprised of both NES and RG cells whereas in vitro differentiation 
protocols often ignore precursor lineages and focus on terminal differentiated cells. To move 
forward in the field of cortical neuronal differentiation high-throughput analysis of gene ex-
pression and regional identity of precursors is much desirable. 
 Standard in vitro protocols for generating NES/ neural progenitors (NP) cells from 
hPSCs are based on aforementioned patterning factors like RA, BMPs, FGFs, SHH and WNT 
proteins [64], in combination with mitogens like EGF and FGF2 [54, 60, 80, 81] and me-
dium supplements like N2:B27. N2 and B27 are commonly used neural induction supple-
ments, which contain growth hormones that help generation, maturation and survival of 
neural precursors. Apart from these factors existing hPSC differentiation protocols also ana-
lyzed different cell culture conditions, such as adherent and non-adherent culturing systems 
[60, 80, 82, 83]. So, differentiation of NES cells towards specific neural lineages in vitro 
depends on a gradient of morphogens as well as plating conditions [54]. Current protocols 
for iPSC differentiation often use dual SMAD (i.e., TGFb and BMP) inhibitors [84] and RA 
based neural induction methods for variable neural cell types ranging from neurons, OLs to 
astrocytes [60, 80, 83, 85, 86]. Differentiation protocols with detailed analysis of neuronal 
networks have been published, however as mentioned earlier these protocols do not focus 
on precursor populations. For instance cortical excitatory neuron networks [60, 87] and 
excitatory-inhibitory neuron networks [88] derived from dual SMAD inhibition were only 
assessed for morphological rosette formation and PAX6, Nestin expression at neural precur-
sor stages. Indeed, it should be take into consideration if cortical neurons derived from just a 
single type of progenitors would be comparable to human cortex, which arises from a much 
complex network of NES, RG and intermediate progenitors [63, 79]. Hence, to understand 
how neural precursors with either NES, RG or intermediate cell identities are generated; 
insights to neural inducers that generate these lineages are of importance. Therefore, in this 
thesis we performed a comparative study among effects of few known neural induction 
factors on hPSCs to understand their regional identity (expression of NES and RG markers) 
and differentiation potential (towards cortical neurons and astrocytes). A schematic of in 
vitro disease modelling from hPSCs and list of range of factors involved in differentiation of 
neural cell types is shown in Figure 1. 
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Fig 1 – Schematic of hPSC-derived neural cell types and their applications. Human ESCs can be de-
rived from the blastocyst stage. Human iPSCs can be derived by reprogramming any mature cell type 
(e.g., skin cells/ fibroblasts, blood cells) into pluripotent state by reprogramming with pluripotency 
factors like SOX2, OCT3/4, KLF4 and c-Myc. Gene-editing techniques, like CRISPR/Cas, are used to 
understand specific gene functions. Gene editing can also be performed on hESC/iPSCs to correct gene 
defects of patient cells (isogenic controls) for in vitro studies and/or further be used for transplantation 
therapies. List of frequently used growth factors during differentiation of neuroepithelial stem (NES) 
and radial glial (RG) cells, neuronal/glial progenitors and mature neuronal and glial cells are indicated.
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1.4 Neuronal differentiation
  A variable class of neurons drives the normal brain activity. Individual brain disor-
ders are often linked to deviations in development or functioning of one or more class of 
these neurons. Neurons can be classified based on functions, morphology and molecules 
into different types. Molecular classification is specified by neurotransmitter release and 
determines type of neurotransmission. The functional properties of neurons are the most 
important, since neurons with similar morphology or neurotransmitter expression might not 
manifest same function [89]. Indeed, a gradient of patterning factors in the brain (Section 
1.3), which also drive survival and maturation are involved in patterning of such class of 
neurons. Brief classifications of neuronal types are listed in Table 1. Other optimal classifi-
cations based on neuronal splitting have also been reported earlier [90]. Consequently, to 
study a specific brain disorder in vitro, it is inevitable to derive the right class of neurons 
involved. In purpose of this thesis we further focus on cortical excitatory and inhibitory 
functional neurons.
 The layers of the brain cerebral cortex are composed of different types of neurons, 
which range from having various neurotransmitters like g-amino butyric acid (GABA), glu-
tamate, and acetylcholine to various structures like bipolar, multipolar pyramidal neurons. 
The neurotransmitters GABA and glutamate drive the major inhibitory and excitatory func-
tions of the cortical neurons, respectively. Furthermore, synchronization of excitatory and 
inhibitory neuronal activity in the cortical and sub-cortical regions is crucial for proper 
development of these networks [91, 92]. Abnormal brain synchrony, imbalance of excita-
tory-inhibitory networks and hyperexcitability is often related to pathophysiology of several 
neurodevelopmental disorders like ASD [93-95], epilepsy [96] and schizophrenia [97, 98]. 
The excitatory glutamatergic and inhibitory GABAergic neurons form anatomical and phys-
iologically divergent networks of neurons in the cortex. The excitatory glutamatergic pro-
jection neurons are generated by cortical progenitors in the pallium, whereas the inhibitory 
GABAergic interneurons originate in the ventral telencephalon or sub-pallium [99]. The 
GABAergic interneurons arising from sub-pallium are segregated into three spatially seg-
regated regions namely medial, caudal and lateral ganglionic eminences (MGE, CGE and 
LGE). After birth, the interneuronal precursors tangentially migrate to other brain regions 
[100]. On contrary, glutamatergic neurons arise in the neocortical preplate, which segre-
gates into upper to deep cortical layers with specific regional identities [99, 101]. From early 
stages through adulthood, the cortical layers contain specific types of projection neurons, 
while a scala of inhibitory neuronal subtypes are present in all cortical layers [102].  The cell 
identities of these sub-lineages of excitatory and inhibitory neurons are in part established 
already during progenitor stages prior to migration [103]. Hence, excitatory and inhibitory 
neuronal population of the cortex arises from pallial and sub-pallial regions via multiple 
progenitors stages as also discussed earlier in section 1.3 and develop into an organized net-
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work. Therefore, to derive ideal in vitro disease models for neurodevelopmental disorders, 
a part of this thesis explores a differentiation protocol for cortical neurons, which follows 
developmental stages.
Classification Types  Description 
Functional Sensory 
neurons 
 Carry impulses from body parts to the CNS. 
Motor neurons  Carry impulses from CNS to muscles and glands 
outside the nervous system.  
Interneurons  Carry impulses between neurons.  
Morphological Unipolar  A neuron that projects a single process from the 
cell body. 
Bipolar  A neuron that projects two processes from the 
cell body. 
Multipolar  A neuron that projects more than two processes 
from the cell body, e.g., pyramidal. 
Molecular Amino acids  e.g., Glutamate, Glycine, GABA, Aspartate. 
Biogenic 
amines 
 e.g., Serotonin, Dopamine, noradrenalin, 
adrenaline, histamine.  
Neuropeptides  e.g., Somatostatin, Substance P, Met-enkephalin, 
beta-endirphin. 
Cholinergic  Acetylcholine. 
	
Table 1 – Classification of types of neurons based on function, morphology and neurotransmitter. The 
subtypes of each class, their general description and/or a few examples of specific neuronal types 
are listed here.
 Existing protocols use brain patterning factors like SMAD inhibitors, RA and SHH for 
deriving cortical excitatory-inhibitory neuronal networks from hPSCs. Ventralizing factors 
like SHH are commonly used for differentiation into GABAergic neurons [11, 104]. Glu-
tamatergic neurons are derived from neural progenitors using spontaneous differentiation 
[60], or by inhibiting SHH using antagonists like Cyclopamine [105] in N2:B27 medium. 
While there are several studies, which derived one of these lineages of neurons from hPSCs, 
a few studies derived a network of excitatory-inhibitory neurons. A recent study generated 
a synchronized network of cortical excitatory-inhibitory neurons from hiPSCs in co-cul-
ture with primary human astrocytes [88]. This study used spontaneous differentiation of 
dual SMAD induced neural precursors in N2:B27 based medium to derive both lineages of 
neurons. While functional analysis showed presence of both glutamatergic and GABAergic 
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neurons this study only showed expression of TBR1, SATB2, CTIP2 markers in the devel-
oping cultures which all belong to glutamatergic neuronal lineages. Similarly, apart from 
GAD65 expression only glutamatergic synapses using VGLUT1 puncta’s were analysed in 
these cultures [88]. This emphasizes that spontaneous N2:B27 inductions majorly generate 
glutamatergic neurons and ventralizing factors like SHH indeed induce robust networks of 
GABAergic neurons. To achieve mixed networks of cortical neurons, a part of this thesis 
studied partial short phase induction of neural precursors with SHH and Valproic acid (VPA; 
known to increase GABA neurogenesis in brain [106]). This induction phase lead to expres-
sion of both glutamatergic (CTIP2, SATB2) and GABAergic (PROX1, MEIS2) lineage of neu-
rons at protein and RNA levels [107]. In addition to functional analysis for presence of both 
excitatory and inhibitory neurons current protocol shows quantification of both VGLUT1 
and VGAT puncta’s. Xu. et al., showed induction of inhibitory-excitatory networks from hP-
SCs using timed administration of RA [108]. In parallel to current study Xu. et al., showed 
expression of cortical inhibitory and excitatory developmental markers like FOXG1, LSH2, 
GSX2, NKX2.1 and TBR1, CTIP2, SATB2, BRN2. This study also showed functional charac-
teristics of the neurons and furthermore studied neurotoxicity using NMDA and oxygen-glu-
cose deprivation. Overall, these in vitro studies show differential methods to achieve similar 
cell populations of interest. Although, current protocols generate mixed cortical neuron 
cultures, we lacked protocols that generated a network with pure neurons (no glia) and are 
suitable for single cell analysis. To address this, two different co-culture models (direct and 
indirect) with astrocytes were generated in the current study with a low-density of pure neu-
rons, which provides single cell resolution. Therefore, also for studies that require co-cul-
turing of e.g., diseased neurons with control astrocytes or vice verse these co-cultures are 
suitable. 
1.5 Autism – Tuberous sclerosis complex (TSC)
 Neurodevelopmental disorders are characterized by impairments in communication, 
learning ability, social interaction, repetitive behaviors and cognitive defects and in many 
cases seizures. Autism spectrum disorders (ASD) is a group of neurodevelopmental disorder 
occurring in about 6 out of 1000 children [109]. As discussed earlier suggested risk factors 
for the development of ASDs include environmental factors like infectious diseases during 
pregnancy, maternal deficiencies as well as genetic factors. Several genetic mutations are 
widely studied and recent studies also focus on de novo mutations in addition to inherited 
genetic abnormalities in patients [110, 111]. There are various types of treatments like spe-
cialized behavioral therapies and drug based medications developed for ASD patients. In 
spite of several antipsychotic, antidepressant drugs used in clinic to treat patients, autistic 
symptoms of some ASD patients still remain unmanageable [112]. Deep brain stimulation 
(DBS) has been suggested by several studies for severe autism, especially in cases of patients 
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with aggressive self-destructive behaviors [113]. Indeed, severity and disease mechanisms 
vary among different ASD patients and experts recommend individualized treatment for 
patients. Table 2 describes the variety of symptoms and genes involved in different forms of 
ASD [114]. Brain connectivity is an important aspect in neurodevelopmental processes, and 
often linked to autism [115]. Functional neuroimaging suggests the involvement of dysfunc-
tional brain connectivity in the onset of ASDs [116]. There are several ASDs, where disease 
mechanisms underlying individual defective brain cell types are still poorly understood. 
Hence, we need more insights into the developmental stages of ASDs, as well as specif-
ic neuronal and glial cell defects. Overall, ASD patients show developmental defects and 
symptoms with varied severity. Therefore, generation of iPSC-based models from multiple 
patients with different genetic backgrounds and disease symptoms could aid these studies. 
To help understand developmental defects in ASDs cortical developmental neuronal cul-
tures derived from patient iPSCs could help understand developmental phenotypic defects 
and therefore improve therapy. 
 Tuberous sclerosis complex (TSC), which is one among the ASDs, is a neurodevelop-
mental disorder with above 61% patients developing autism. It is an autosomal dominant, 
rare genetic disease causing benign hamartomatous lesions in multiple organs [117]. It 
affects approximately 1:6000 and is caused by mutations in one or both tumour suppressor 
genes TSC1 and TSC2, which code for the hamartin and tuberin proteins, respectively. About 
90-95% patients affected by TSC show neurological problems including epileptic seizures 
[118]. Mosaic mutations as well as NMI (no mutation identified) are reported in several TSC 
cases [119, 120]. Variable disease severity and symptoms have been reported in TSC, even 
between individuals of the same family [121]. Few neuropathological features of the disease 
used in diagnosis and characterization of the disease include subependymal nodules (SENs), 
and cortical tubers [122]. SENs are a form of grey matter heterotopia where nodules of grey 
matter are formed close to the ependymal of lateral ventricles and cortical tubers are areas 
of malformed tissue typically involving grey-white matter interface. Manifestations of TSC-
like cortical tubers are reported to be present from the second trimester onwards [123, 124]. 
Apart from neuronal defects glial cell abnormalities like subependymal giant cell astrocy-
toma’s (SEGA) and white matter abnormalities have also been reported in TSC cases [125, 
126]. About 88-100% of TSC patients are reported to have cortical tubers [127] and mental 
retardation and seizure frequency are related to amount of cortical tubers present [128]. The 
next abundant neuropathological lesions in TSC patients are SENs [129]. Overall, TSC is a 
complex neurodevelopmental disease involving both neuronal and glial defects. The TSC1 
and TSC2 proteins form a heterodimer complex and bind to a third subunit TBC1D7 to form 
the TSC complex. This complex acts as a GTPase activating protein (GAP).  Specifically, the 
TSC2 protein consists of the GAP domain and most phosphorylation sites, whereas the TSC1 
acts as a stabilizer of the complex and prevents TSC2 degradation [130]. Although the com-
plex regulates protein synthesis and cell properties, due to presence of GAP domains and 
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phosphorylation sites the TSC2 protein is considered more important as also TSC2 patients 
show excessive disease severity [131].
Disorder name Gene(s) 
involved 
Phenotypes 
Fragile X 
syndrome 
FMR1  Protruding ears, elongated face, learning and 
intellectual disabilities, developmental delays, 
Autism.  
Rett syndrome MECP2  Cognitive impairment, developmental delays, 
epilepsy, Autism. 
Tuberous 
sclerosis 
TSC1, TSC2  Multiple organ disorder, learning and intellectual 
disabilities, obsessive-compulsive disorder 
(OCD), epilepsy, Autism. 
Cornelia de 
Lange 
syndrome 
SMCIA  Facial and vision abnormalities, heart defects, 
cleft palate, aggressive behaviour, Autism. 
Cohen 
syndrome 
COH1  Ocular defects, obesity, intellectual disabilities, 
epilepsy, Autism. 
Timothy 
syndrome 
CACNA1C  Congenital heart disease, immunodeficiencies, 
cognitive impairment, Autism. 
Angelman 
syndrome 
UBE3A  Facial dysmorphism, developmental delays, 
ataxia, hyperactive characteristics, epilepsy, 
Autism.  
Smith-Magenis 
syndrome 
17p11.2 del  Facial dysmorphism, aggressive behaviour, 
Autism. 
Dup15q 
syndrome 
Dup15q11-
q13, GABRB3 
 Facial dysmorphism, cognitive impairment, 
developmental delays, Autism. 
	  
Table 2 – List of a few major autism spectrum disorders (ASD), including genes involved and pheno-
typic defects in the patients is presented. Adapted from Yoo.H et al.
 A major function of the TSC protein complex is the regulation of a serine-threonine 
kinase called mammalian target of rapamycin (mTOR). The mTOR kinase exists as two dis-
tinctly functional complexes namely, mTOR complex 1 and 2 (mTORC1 and mTORC2), 
which have different downstream binding partners [132]. Major cellular pathways like phos-
phatidylinositol 3-kinase (PI3K), PI3K-phosphoinositide-dependent kinase 1 (PDK1) AKT, 
ERK and AMP-activated protein kinase (AMPK) regulate the TSC complex. The mTORC1 is 
activated by growth factors such as insulin, via the PDK1-AKT pathway. AKT phosphoryl-
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ates TSC2 at multiple sites and inhibits TSC complex, which acts as a GAP for Ras homolog 
enriched in brain (RHEB). In the active form, the TSC complex inhibits RHEB from binding 
and activating mTORC1 by converting RHEB-GTP to RHEB-GDP. Therefore, the TSC com-
plex acts as a negative regulator of mTORC1 [133]. In comparison to mTORC1, the acti-
vation of mTORC2 is poorly understood [133]. The mTORC1 phosphorylates downstream 
targets like S6K and 4E-BP, which are involved in controlling protein synthesis by regulating 
mRNA translation and ribosome biogenesis [133]. Several pharmacological compounds are 
known to regulate mTOR activity. Rapamycin an immunosuppressant drug rapidly inhib-
its mTORC1, whereas prolonged rapamycin treatment inhibits mTORC2 [134]. Analogs of 
rapamycin (rapalogs) like temsirolimus, deforolimus and everolimus are used for treatment 
of TSC [135]. Apart from rapamycin and rapalogs other regulators of mTOR are also report-
ed e.g., Guanabenz (Figure 2), an antihypertensive drug. Guanabenz inhibits Gadd34-PP1 
phosphatase and was shown to prevent OL death caused by TSC ablation induced ER stress 
via PERK-eIF2a-Gadd34-PP1 phosphatase [136]. Overall, the mTOR pathway is linked to 
many different pathways, controls several cell properties and is regulated by a number of 
known drugs. A depiction of mTOR-TSC protein pathway and related regulators is shown in 
Figure 2 [133, 136].
 The mTOR pathway is specifically known to play a crucial role in brain develop-
ment, by regulating cell growth, migration, synaptic transmission and maturation of neurons 
[137, 138]. Neuron associated defects in TSC like neuronal hyperactivity; seizures, axon-
al length, dendritic arborization and network imbalance are extensively studied in rodent 
models [139-141]. Focusing on human studies, a group reported that surgically removed 
cortical tubers from TSC patients showed increased axonal growth, hypomyelination and 
mTORC1 hyperactivity [142]. So far only 2 hPSC-based studies have been done; one used 
gene editing in TSC gene on hESCs and other used one TSC patient derived iPSCs. The gene 
editing study generated hetero- and homozygous TSC2 gene deleted lines; the homozygous 
iPSC line-derived neuronal cultures showed severe defects on neural rosette morphology, 
soma size, hyperactive network, whereas heterozygous lines showed mild alterations [43]. 
The patient iPSC based model with heterozygous TSC mutations showed altered neurite 
length, increase astrocyte proliferation, hyperactive mTOR pathway and hypertrophy but 
network activity and neuron-glial interactions in TSC were not studied [143]. Therefore, 
we still need more human heterozygous models for iPSC-derived neurons that can mimic 
autosomal dominant mutations in TSC patients to study the multiple neuron-glial defects in 
TSC. In the current study both TSC1 and TSC2 patient iPSCs-derived neural mono-cultures 
(i.e., only neurons) were generated to assess presence of known TSC phenotypic defects in 
network activity, morphology, cell proliferation and hypertrophy. Moreover, the effects of 
mTOR regulators like rapamycin and IGF1 were assessed on the neuronal mono-cultures to 
understand potential of iPSC-derived cultures in drug development. 
 Rodent studies have indicated glial cell involvements in TSC pathology, such as ab-
Chapter 1
23
normalities in white matter [144, 145], astrocytes [146], and oligodendrocytes [136, 147, 
148]. Tubers derived from TSC patient brain tissue were reported to consist of giant astro-
cytes [149]. Heterozygous deletion of TSC gene in mouse and human iPSC models lead to 
increased proliferation of astrocytes [121, 143]. To study the effects of TSC loss at develop-
mental stages, the TSC2 gene was selectively deleted from radial glia progenitors (TSC2flox/
ko; hGFAP-Cre). These mice expressed enlarged dysplastic neurons and glial cells, hypomy-
elination, astrocytosis and an increase in TBR2 progenitors in the cortex. These histological 
abnormalities were dependent on hyperactive mTOR pathway and therefore indicating that 
loss of TSC and mTOR dysfunction at developmental stages does lead to TSC defects [150]. 
Furthermore, mosaic loss of TSC1 in Nestin+ neural progenitors leads to the formation of 
giant cells in the cerebral cortex as well as abnormalities in lysosomes and mitochondria 
[151]. Astrocyte-specific TSC1 inactivation in mice resulted in abnormal neuronal organi-
zation and epilepsy [146]. Aspects of astrocyte related mechanisms like gap junction con-
ductance, transporter molecules have also been reported in several studies. Astrocytic loss 
of TSC1 lead to decrease in astrocytic connexin protein (Cx43) and caused impairment of 
gap junction coupling in astrocytes [152]. Conditional KO of TSC1 in GFAP caused de-
creased expression and function of astrocytic glutamate transporters leading to epilepsy via 
increased extracellular glutamate levels and neuronal death [153]. Furthermore, astrocytes 
derived from a similar TSC1GFAP CKO mice show increased expression of radial glia marker 
BLBP, and several development associated proteins like DKK3, CDK5 on gene and protein 
levels [154]. Therefore, next to neuronal deficits astrocytic involvement in TSC pathology is 
extensively studied. 
 Interestingly, there are only few studies that focused on developmental mechanisms 
behind defective neuron-OL interactions in TSC e.g., hypomyelination. OL maturation in 
developing brain is dependent on positive and negative axonal signals. Inhibitory signals 
for growth associated proteins like GAP-43, Notch signaling arises in parallel to progression 
of myelination, whereas GAP-43 levels were up regulated and negatively influenced MBP 
expression in TSC patient derived tissue [142]. A couple of studies showed neuronal loss 
of TSC1 in mice lead to hypomyelination [139] and neuronal loss of CTGF/CCN2 in a TSC 
mouse model also regulates myelination [148]. While these studies formulate defects in TSC 
OL pathology, specific mechanisms e.g., mTOR related maturation/ differentiation pathways 
in OLs like PSA-NCAM, Notch signaling are less explored. Overall, while neuronal and as-
trocytic defects, such as epilepsy-related changes, proliferation, hypertrophy and functional 
deficits are widely studied in rodent models the complex interplay among neuronal and 
OL cells in TSC disease phenotypes are insignificantly studied. Although, the role of TSC 
protein in neuron-OL communication and myelination is reported in rodent models [121] 
we lack appropriate human cell systems, which model both neuron and OL cell defects and 
interactions in TSC. Therefore, a part of this thesis was focused on generating a neuron-OL 
based model system using TSC patient iPSC-derived cells, which would be beneficial to 
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study these interactions. In addition, the effects of mTOR-TSC regulators like rapamycin and 
guanabenz in these co-cultures were also evaluated. 
Fig 2 – TSC and mTOR pathway interactions. TSC complex interacts with several proteins like AKT, 
ERK, WNT, and AMPK. Upon insulin pathway activation, via PI3K-PDK1-AKT pathway, the TSC 
complex is inhibited by AKT. TSC complex negatively regulates both mTORC1 and mTORC2. While 
mTORC1 is regulated by TSC via RHEB, regulation of mTORC2 is poorly understood. Downstream 
regulators of mTORC1 like S6K, ULK1, 4E-BP regulates processes such as translation and ribosome 
Chapter 1
25
biogenesis. Hyperactivation of mTOR is regulated by rapamycin, an immunosuppressant drug that 
inhibits both mTORC1 and mTORC2, although differently. ER stress activated via PERK-eIF2a-ATF4 
pathway due to excess protein translation at mTOR hyper activated state leads to activation of ap-
optotic pathway and death of maturing OLs. This process could be inhibited by Guanabenz, which 
inhibits eIF2a via GADD34-PP1 and prevents OL cell death. Adapted from Shimobayashi.M et al., 
2014, Jiang.M et al., 2016. 
1.6 Integration of iPSC-derived cells in rodent models 
 In recent times, the iPSC technology extends from simple 2D in vitro cultures to 
complex 3D organoid cultures and is used for the purpose of disease modeling, drug devel-
opment, toxicological studies as well as regenerative medicine. Human iPSCs-derived cells 
can be grafted for different purposes. In vivo integration and survival of transplanted stem 
cells in animal models is a crucial step before achieving successful regenerative therapy in 
humans. Next to that, studying cellular and functional properties of the engrafted cells in 
brain microenvironment also supports disease understanding and in vitro disease modeling. 
Histological analysis of transplanted cells proves advantageous in understanding cell fate, 
survival and integrative function in a complex in vivo milieu [11]. A brain microenviron-
ment stimulates neuronal functioning [155] and supports maturation over long periods of 
time better than in vitro models. For instance, in disorders like Autism that require mature 
synchronized neural network models to understand defects of higher motor functions and 
intellect, use of humanized mice with autistic patient iPSC-derived cells could be valuable. 
It is speculated that maturation of iPSC products would be enhanced in a brain microenvi-
ronment compared to in vitro cultures, although experimental proof is necessary for valida-
tion. Since, humanized mouse models have shown susceptibility to immune response for 
even autologous iPSC transplantations [156], use of immunocompromised mice for such 
studies is recommended at the moment. In this thesis RAG-null mice were used to track cell 
incorporation of iPSCs derived neurons and OLs several months after transplantation. It is 
further shown that transplanted TSC patient iPSC-derived cells express TSC phenotypes in 
these rodent models.
 While the promise of iPSCs is significant, several limitations have been raised as 
also discussed in Section 1.2. Studies suggest that iPSC-derived cell products are less effi-
cient and generate more variable population of cells over multiple batches in comparison 
to hESCs [157]. Such variabilities were independent of reprogramming transgenes used in 
deriving the iPSCs and could serve as a source of unpredictable/ variable outcomes of au-
tologous cell transplantation therapies [157]. The fact that rodent iPSCs have been used to 
generate an adult mice, point out to the potential of iPSCs efficiency at least in the uterine/ 
ovary environment [158]. Therefore, improvements in culture environment of iPSCs could 
be a viable step. On contrary, while immune rejection could be a potential hazard in cell 
replacement process, it could also be used as a fail-safe system against tumorigenicity in 
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regenerative therapies [159]. 
 Overall, iPSC based regenerative therapy is shown to improve phenotypic defects in 
rodent and primate models, but use of transplantation for in vivo modeling of neurodevel-
opmental disorders is rather a new application. More specifically this thesis assesses the po-
tential of co-transplantation of TSC patient iPSCs-derived neurons and OLs in expectancy to 
model complex neuron-glia interactions in an in vivo environment, next to in vitro models 
presented. Altogether, this thesis demonstrated future potential of TSC iPSCs-based in vitro 
and in vivo disease models and their use for wide range of applications from research and 
development (R&D) to clinical stages. 
1.7 Aim of the thesis
 The overall goal of this thesis is to study the potential of iPSCs in modelling neu-
rodevelopmental disorders like TSC. We currently lack in vitro models, which characterized 
neural precursors and intermediate stages for differentiation towards a balanced cortical 
neuronal network. Hence, in this thesis an in vitro model for human cortical neuronal net-
works with a multi-stage characterization of the cells was generated. These cultures of cor-
tical neurons were then used to model morphological and functional defects of TSC patient 
iPSC-derived neurons. Furthermore, to model neuron-glial interactions in TSC, the human 
cultures were expanded to one of the first co-culture models of TSC neurons and OLs. To test 
the application of these in vitro models for therapy development, the modulatory effects of 
GFs and drugs were also studied. 
 In chapter 2, the properties of NES cells generated via different neural differentiation 
protocols were investigated. This study was aimed at understanding how use of different 
GFs and patterning molecules like SMAD inhibitors, RA and FGF2 will affect the identity 
of precursor populations and presence of NES/ RG cell subtypes. Five different protocols 
were chosen, including adherent and embryoid body-forming non-adherent cultures and 
compared in marker expression patterns for regional identity and lineage specificity of indi-
vidual neural inducers. Further, the ability of these precursors to differentiate into neuronal 
and glial cells was studied to understand lineage commitment. Overall, the goal of this study 
was to understand if multiple induction methods/ factors under in vitro cultures give rise to 
variable regional identity and potency in precursors. 
 In chapter 3, after identification of a NES cell population for versatile neural precur-
sor generation; a protocol to generate a mixed population of cortical neurons was designed. 
The NES cells generated from dual SMAD induction were further induced with SHH and 
VPA. After maturation of 8 weeks in presence of maturation factors BDNF, GDNF, IGF1 and 
cAMP as well as rat astrocytes the neuronal cultures formed networks of mixed excitatory 
and inhibitory neurons. To analyze if the neuronal networks exhibited properties of a de-
veloping cortical neuron network RNA analysis at multiple stages was performed and fur-
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ther electrophysiology, calcium imaging, and quantification of VGAT and VGLUT1 synaptic 
puncta was used to assess the network. To assess the robustness of differentiation proteome 
analysis was performed, which showed identical proteome among batches of neurons and 
the presence of pure neuronal networks in indirect cultures. Therefore, it was concluded 
that partical induction of SHH and VPA in hPSC-derived NES cells lead to development of 
cortical neuronal-like networks and maturation into balanced inhibitory-excitatory neurons. 
 In chapter 4, the cortical neuronal networks were used to model neuronal defects 
in TSC. TSC patient iPSCs-derived only neuronal cultures (mono-cultures) were studied for 
changes in the dendritic, axonal, synaptic density and neuronal network activity. While 
increased network activity in TSC neurons was quantified, which were regulated/ rescued 
by rapamycin the mono-cultures did not present with known TSC morphological defects. 
Furthemore, to assess neuron-OL cultures for TSC phenotypes this thesis generated one of 
the first human iPSCs based models to study neuron-OL interactions in TSC. Interestingly in 
contrast to the mono-cultures, TSC neurons in these co-cultures showed increased axonal 
density as well as total cellular hypertrophy. TSC OL properties were also studied in these 
co-cultures, were defects in OL proliferation and maturation were quantified. Finally, rapa-
mycin also showed regulatory effect in the co-cultures. Overall, TSC patient iPSC-derived 
neuronal and glial cells showed multiple TSC defects in complex neuron-OL co-cultures as 
well as increased network activity in the neuron mono-cultures, which were all altered by 
mTOR regulators. 
 In chapter 5, human iPSCs-derived neuronal cells were transplanted in WT RAG-
null mouse brain to study maturation changes over long periods of time and in a complex 
microenvironment. The maturation rate of transplanted cortical neural precursors at 2.5 
and 4 months post transplantation was studied. Compared to 2.5 months post injection, an 
enhanced maturation of neuronal cells after 4 months was observed. To study human neu-
ron-glia interaction, co-transplantation of a mixed population of neuronal and OL precursor 
cells was used. It was shown that both neurons and OLs migrated well into different brain 
regions in vivo. Next, TSC patient neurons with TSC OLs or control neurons with control 
OLs were transplanted. TSC groups showed increased neurite length and OL proliferation 
in line with the in vitro study experiments. Overall, it was confirmed in both in vitro and in 
vivo studies that TSC patient iPSCs-derived cells are able to mimic defective cell properties 
of TSC. 
 Finally, in chapter 6 the experimental findings of this thesis including advantages and 
limitations of the models described and their future potential in therapy and drug develop-
ment are discussed. 
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2.1 Abstract
 The neural tube consists of neural progenitors (NPs) that acquire different character-
istics during gestation due to patterning factors. However, the influence of such patterning 
factors on human pluripotent stem cells (hPSCs) during in vitro neural differentiation is often 
unclear. This study compared neural induction protocols involving in vitro patterning with 
dual SMAD inhibition, single SMAD inhibition and retinoic acid (RA) administration. While 
all derived NP populations expressed known NP markers, only a subset could be differen-
tiated to neural lineages tested. Cortical neuronal products generated from 1) dual SMAD 
NPs exhibited greater expression of glutamatergic lineage markers, 2) single SMAD NPs 
exhibited less mature neuronal phenotypes, and 3) RA NPs exhibited an increased GABAe-
rgic phenotype. Further, although most tested NPs generated astrocytes, astrocytes derived 
from the RA-induced NPs had the highest GFAP expression. Differences between NP pop-
ulations included differential expression of regional identity markers HOXB4, LBX1, OTX1 
and GSX2, which persisted into mature neural cell stages. This study suggests that patterning 
factors regulate how potential NPs may differentiate into specific neuronal and glial cell 
types. This challenges the utility of generic neural induction procedures, while highlighting 
the importance of carefully selecting specific NP protocols. 
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2.2 Introduction
 Human pluripotent stem cells (hPSCs) can generate different neural cell types in vit-
ro. To generate intermediate neural progenitors (NPs), multiple in vitro neural induction pro-
tocols have been developed [1-4], and often involve dual SMAD inhibition. Downstream 
activation of transforming growth factor b (TGF b) and bone morphogenetic proteins (BMP) 
signaling is mediated by SMAD proteins, which transduce extracellular signals to the nu-
cleus and activate downstream gene transcription. However, single SMAD inhibition has 
also been shown capable of generating NP populations [5]. Additionally, neural induction 
procedures lacking SMAD inhibition, such as administration of retinoic acid (RA) may also 
generate NP populations [6]. Despite reports on methods producing NP populations, the 
actual regional identity and differentiation potential of NPs generated via current in vitro 
protocols is often unclear. Given the labor-intensive nature of establishing neural differenti-
ation protocols for hPSCs, a study of existing protocols would be valuable.
 At different time points and locations, various signaling molecules, also called pat-
terning factors, combine to determine the regional identity and differentiation potential of 
NP populations in the developing neural tube of the central nervous system (CNS) [7-14]. 
Patterning factors include wingless-related integration side proteins (WNTs) [15, 16], BMPs 
[17, 18], fibroblast growth factors (FGFs) [19-24], sonic hedgehog (SHH) [25] and RA [26, 
27]. FGF signaling is known to be an important inducer of posterior regionalization [28, 
29]. Gradual expression of WNT [30, 31] and BMP [32, 33], both members of the TGF b 
superfamily, are required for anterior-posterior patterning. Furthermore, RA is an important 
inducer of hindbrain and spinal cord development [34, 35]. Along the length of the neu-
ral tube, floor plate-expressed SHH stimulates ventral structures [36], while roof plate-ex-
pressed WNTs and BMPs are crucial for dorsal development [37, 38]. In conclusion, similar 
to neural patterning in the CNS, it might be expected that administration of patterning fac-
tors in vitro may similarly affect the characteristics and potency of hPSC-derived NPs.
 Here we performed a comparative study of neural induction protocols, involving 
dual SMAD inhibition, single SMAD inhibition, and RA administration, as well as different 
plating conditions such as adherent and non-adherent (i.e. embryoid body (EB)) cultures. We 
demonstrate that all neural induction protocols resulted in NP populations that expressed 
known NP cell markers. However, the NP populations showed variations in differentiation 
potential towards neuronal and glial cell types. Additional analysis, including embryonic 
regional marker expression, showed differences in characteristics of the generated NP pop-
ulations. The results of this study indicate that neural induction protocols should be chosen 
carefully to obtain NP populations with appropriate potency for research goals.
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2.3 Material and methods
Extra information, including cell culture techniques, and used antibodies and primers, can 
be found in supplementary materials and methods.
2.3.1 Pluripotent stem cell culturing
Human embryonic stem cells (hESCs, H1 and H9; WiCell) were maintained in E8 media 
(Life Technologies) on GelTrex- (Life Technologies) coated plates, and passaged with 0.5mM 
EDTA in PBS (Life technologies). The medium was supplemented with 10 µM ROCK inhib-
itor (RI) (SellecChem) after passaging.  
2.3.2 Neural induction protocols
To test different NP induction procedures, we chose 5 different culture conditions based on 
commonly used growth factors and medium supplements, together with different culturing 
techniques (adherent and non-adherent) [1, 5, 6]. Our study design compares the following 
NP cell induction protocols (Figure 1).
Condition 1 (Single SMAD inhibition; non-adherent; C1-SS): To create embryoid bodies 
(EBs), hESC colonies were fragmented using 0.5 mM EDTA in PBS and plated in the ratio 
of 2:1 wells on anti-adhesive (AA) poly-2-hydroxyethyl methacrylate (Sigma) coated plates. 
The cells were cultured in N2B27 medium supplemented with FGF2 (20ng/ml; Peprotech), 
FGF4 (20ng/ml; R&D), Noggin (200ng/ml; Peprotech) and RI (10 µM) and 2/3 of the me-
dium was changed every other day. RI was omitted from the medium after 3 days in all EB 
protocols. On day 10, the EBs were plated on GelTrex-coated 6WP. Initial plating of EBs 
was considered passage 0 (P0) and NPs were maintained in the same induction medium 
until used for neuronal/ glial differentiations. The plated EBs formed rosette-like structures. 
These cells were used for immunocytochemical (ICC) analysis, and passaged to P1 at day 14 
using Accutase (Sigma-Aldrich). At day 18, RNA samples were collected, and the cells were 
frozen to use for further neuronal and glial differentiations. 
Condition 2 (RA administration; non-adherent; C2-RA): EBs were created and handled as 
described for Condition 1, with the exception that the cells were cultured in N2B27 medi-
um supplemented with T3 (40ng/ml; Sigma), FGF2 (4ng/ml) and EGF (20ng/ml; Peprotech). 
On day 3, the medium was switched to N2B27 supplemented with T3 (40ng/mL), FGF2 
(4ng/mL), EGF (20ng/mL) and RA (10µM; Sigma). The EBs were plated on day 10, passaged 
to P1 at day 14, and frozen at day 18. From day 10 onwards, RA and FGF2 were omitted 
from the medium. 
Condition 3 (Dual SMAD inhibition; adherent; C3-DS): hESC colonies were fragmented 
with 0.5mM EDTA in PBS and plated in the ratio of 3:2 on GelTrex-coated 12WP in 1.5ml 
E8 medium supplemented with RI (10µM; considered as day -3). From day -3 to 0, half of 
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the media was refreshed daily. At day 0, medium was switched to N2B27 medium supple-
mented with Dorsomorphin (1µM; Tocris bioscience), SB431542 (10µM; Selleckem) and 
refreshed entirely every day for 12 days. When rosette-like structures formed, NP cells were 
passaged using dispase (Sigma) or manually picked and transferred into a PLO/Laminin- 
(20µg/ml) coated 6WP. NP cells were maintained the same induction medium and passaged 
using TrypLE and defined trypsin inhibitor (DTI; both Life technologies). The day rosettes 
were plated was treated as P0.
Condition 4 (non-adherent; C4): EBs were created and handled as described for Condition 
1, with the exception that the cells were cultured in N2B27 medium supplemented with 
FGF2 (4ng/mL). The EBs were plated on day 10, passaged to P1 at day 14, and frozen at day 
18. The cells received the same medium throughout the entire neural induction. 
Condition 5 (adherent; C5): Neural induction of hESCs was performed as described for Con-
dition 3, with the exception that the cells were induced in N2B27 medium supplemented 
with FGF2 (20ng/mL) from day 0 to 12. 
2.3.3 Mixed neuronal differentiation
NP cells (P2) from all the 5 protocols were differentiated towards neurons. An earlier de-
scribed mixed cortical neuronal differentiation protocol was used [39] with the modifica-
tion of neuronal density at 125K cells/ well of 12WP. 
2.3.4 Astrocyte differentiation
NP cells from all the 5 protocols were differentiated towards astrocytes, using a glial differ-
entiation protocol described previously with small adaptations [6, 40]. In short, P2 NP cells 
were thawed to begin astrocyte differentiation protocol and cultured in N2B27 medium 
without vitamin A (N2B27-vitA) supplemented with T3 (40ng/ml) and EGF (20ng/ml) on 
GelTrex-coated plates. The medium was refreshed completely every other day. When con-
fluent, the cells were passaged using Accutase and plated at density of 1000K cells/ well of 
6WP. After 4 passages (~20 days), the medium was switched to N2B27-vitA supplemented 
with T3 (40ng/ml), EGF (5ng/ml), FGF2 (5ng/ml), Noggin (50 ng/ml Peprotech), Vitamin C 
(50µg/ml, Sigma) and Laminin (1µg/ml, Sigma). After 5 days, EGF and FGF2 were omitted 
from the medium. After 3 passages, the medium was switched to astrocyte medium (Scien-
Cell, Sanbio b.v.) for another 2 passages. At the end of the protocol (~55 days), the cells 
were collected for ICC and RNA analysis.  
2.3.5 Immunocytochemistry
Cells on coverslips were fixed with 4% paraformaldehyde (PFA, Electron microscopy scienc-
es) in PBS for 15 min at room temperature (RT). Fixed cells were washed (3-6 times with PBS 
over 30 min), blocked with blocking buffer (PBS, 0.1% BSA, 5% NGS, 0.3% Triton) at RT for 
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1 hr, and then incubated with primary antibodies in the blocking buffer overnight at 4oC. Af-
ter washing (3-6 times with PBS over 30 min), secondary antibodies were added (in blocking 
buffer) and incubated for 1-2 hrs at RT. Then the cells were washed (3-6 times in PBS over 
30 min) and incubated with DAPI (in PBS) for 2-3 min at RT. Finally, the cells were washed 
(2 times with PBS) and slides were mounted with Fluormount G solution (Southern Biotech). 
Fluorescent images were taken using a Carl Zeiss 510Meta confocal with 40x (1.2 Numeri-
cal Aperture) oil objective or Leica DM500 B fluorescent microscope, and processed using 
LAS-AF lite and Adobe Photoshop. 
2.3.6 RT-PCR and Q-PCR
P1 NP cells, day 75 astrocytes and day 18 neurons were collected from one well of a 
6WP, and RNA isolated by incubation in Trizol, followed by chloroform-isopropanol extrac-
tion. cDNA synthesis was performed using Superscript IV (Life Technologies), and RT-PCR 
products amplified using Phire III Polymerase (Fisher Scientific). For Q-PCR experiments, 
reactions were run for 30 cycles at an annealing temperature of 60°C using SYBR green 
(SensiFast; Sybr-HI-Rox mix) on Light cycler 480 (Roche) equipment. Obtained CP values 
were used to calculate relative fold change over housekeeping genes EIF4G3 and GAPDH. 
Expression levels in hESCs were used as a baseline.  All primers are listed in supplementary 
material. 
2.3.7 Statistical analysis 
We performed an ANOVA test with Tukey post-hoc correction for multiple testing using 
Prism 7.
2.4 Results
2.4.1 Different neural inductions generate NP-like cells
 All five neural induction conditions (Figure 1) generated cell populations with ro-
sette-like structures. Rosettes derived from plated EBs (C1-SS, C2-RA and C4) were observed, 
directly in and around the plated EBs and differed in size. In the adherent C3-DS and C5, the 
rosettes were observed randomly throughout the induction-well with rosette-like structures 
of different sizes. In all inductions, the cells outside the rosette-like areas showed varying 
morphologies. To test the different NP populations for expression of known NP cell markers, 
ICC was performed for NP markers SOX2, PAX6 and Nestin, early glial marker SOX9, rosette 
marker PLZF and tight junction marker ZO-1 (Figure 2). While all NPs expressed the studied 
markers, these were not homogeneously expressed in all NP populations. All NPs showed 
homogeneous expression of Nestin and SOX2, both inside and outside rosette-like areas. 
SOX9 expression was abundant, but not homogeneously expressed in C1-SS, C2-RA, C4 
and C5 NPs, and absent in C3-DS NPs. Regions of SOX9-positive cells were observed both 
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in the rosettes and in the surrounding cells. SOX9 expression often, but not always, over-
lapped with PAX6 expression, which was present in all conditions. PAX6 expression was 
observed both in and around the rosette-like structures, with varying intensities and amount 
of cells. Staining for tight-junction protein ZO-1 was observed in the center of rosettes in 
all conditions. Furthermore, ZO-1 expression was observed in regions outside rosette-like 
areas in all NPs, whereas PLZF expression was restricted to the rosette areas (Figure 2A-H). 
QPCR analysis confirmed expression of SOX2, Nestin, PAX6, BLBP, PLZF, HES5, DACH1 
and SOX9 in the generated NP cultures, although their levels varied between the different 
NP populations (Supplementary figure 1). C4 and C5 NPs showed low expression in all 
markers tested. In conclusion, all conditions generated NP populations expressing all NP 
cell markers, although levels of the different NP markers varied. 
Fig 1 – NP induction protocols. A schematic representation of the different NP cell induction pro-
tocols adopted from published differentiation protocols (C1-SS, C2-RA and C3-DS) [5, 6] [1]. C4 
is an adaptation of C2-RA to assess the efficiency of N2B27 medium with reduced growth factors, 
i.e. FGF2 only. C5 is an adaptation of C3-DS to assess induction efficiency of N2B27 medium with-
out SB431542 and dorsomorphin, but with FGF2 administration. All NPs were maintained in their 
specific neural induction medium until day 18 (non-adherent conditions) and day 20 (adherent 
conditions).
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Fig 2 – Expression of known NP markers in the various neural induction conditions. (A-E) Repre-
sentative images of ICC analysis of SOX2, Nestin, PAX6, SOX9, ZO-1 and PLZF for C1-SS, C2-RA, 
C3-DS, C4 and C5 NPs at passage P0 (n=3). The scalebar is 25 µm.
2.4.2 NPs differentiate into glial lineage 
 To assess the differentiation potential of derived NP populations, we first used them 
to generate astrocytes according to established protocols [6, 39, 40]. At day 55 of astrocyte 
differentiation, the C1-SS, C2-RA and C3-DS NP-derived cultures showed typical astro-
cyte-like morphologies and strong expression of the astrocyte markers GFAP, S100B, CD44, 
Nestin and SOX9; and low expression of OLIG2 as shown by ICC (Figure 3A – C). C4 and C5 
NPs failed to differentiate into glial cells, and were omitted from further studies. In C2-RA-
derived cultures, expression of GFAP was already observed around day 10, while the other 
conditions showed GFAP expression at least 15 days later (> day 25 of astrocyte differenti-
ation). After switching to the astrocyte medium around day 40, GFAP expression increased 
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in all conditions, with C2-RA astrocytes still showing the highest GFAP expression. RT-PCR 
analysis showed expression of Nestin, BLBP, S100B, ALDOC, Aquaporin-4, GLAST, GFAP 
and CD44 in all derived cultures, which supports astroglial lineage induction. Interestingly, 
expression of spinal cord marker HOXB4 was present in astrocyte cultures derived from C2-
RA NPs, where expression of midbrain / forebrain marker OTX1 was shown in astrocytes 
generated from C1-SS and C3-DS NPs. Overall, C1-SS, C2-RA and C3-DS NPs were able 
to generate astrocytes, based on typical astrocyte morphologies and expression of known 
astrocyte markers, but with differences in expression of regional markers HOXB4 and OTX1. 
Fig 3 – Glial differentiation potential of the NP populations. (A – C) Representative images of day 
55 astrocytes derived from C1-SS, C2-RA and C3-DS NPs, analyzed by RT-PCR for neural stem cell 
marker Nestin, radial glial marker BLBP, regional markers HOXB4 and OTX1 and astrocyte markers 
S100B, ALDOC, AQP4, GLAST, GFAP and CD44, and by ICC for GFAP, OLIG2, Nestin, S100B, 
CD44 and SOX9 (n=3). The scalebar is 50 µm.
2.4.3 Different neuronal lineage potential of NPs
 To assess the potency of the NP populations to differentiate into neuronal cell line-
ages, we differentiated P2 NPs derived via C1-SS, C2-RA and C3-DS into neurons accord-
ing to an established protocol [39]. C4 and C5 NPs failed to differentiate into neuronal 
cells, and were omitted from further studies. NP populations of C1-SS, C2-RA and C3-DS 
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showed immature neuronal morphology at 18 days after start of neuronal differentiation, 
and matured into dense networks of neuronal cells when co-cultured with rat astrocytes for 
an additional 4-5 weeks. At day 56, expression of pre-synaptic marker Synaptophysin1 and 
dendritic marker MAP2 were present in all cultures (Figure 4A – F).
 To analyze NP-derived neuronal populations for regional identity marker expression, 
we performed QPCR analysis on neuronal precursors (18 days after NP cell stage) for gangli-
onic eminence markers PROX1, GSX2, cortical glutamatergic lineage markers CTIP2, TBR1, 
TBR2, SATB2 and pre-synaptic marker VGAT and VGLUT1 (Fig 4). The presented levels are 
relative to expression levels in hPSCs. We showed that all cultures expressed PROX1 and 
CTIP2, although the levels varied between the cultures (Fig 4G, 4I). Ganglionic eminence 
marker GSX2 was only expressed in C2-RA and C3-DS cultures (Fig 4H). C3-DS neurons 
showed a significantly increased expression of TBR1 and TBR2 (Fig 4J, 4K), and a non-sig-
nificant increase in VGLUT1 expression (Fig 4L), compared to C1-SS and C2-RA neuronal 
cells. C2-RA neurons showed the highest VGAT expression, although not significant (Fig 
4M). 
 Overall, we found that C1-SS, C2-RA and C3-DS NPs were able to generate neu-
ronal populations. However, 1) C1-SS neuronal derivatives showed the lowest expression of 
pre-synaptic markers selected, 2) C2-RA neurons showed the highest expression of VGAT, 
suggesting a higher number of GABAergic presynaptic terminals compared to the other cul-
tures, and 3) C3-DS neuronal cultures showed a significantly increased expression of TBR1 
and TBR2, as well as an increased VGLUT1 expression indicating an increased cortical glu-
tamatergic identity compared to the other cultures.
Fig 4 – Neuronal differentiation potential of the NP populations. (A - F) ICC analysis for dendritic 
marker MAP2 and pre-synaptic marker Synaptophysin1 of neuronal cultures derived from C1-SS, 
C2-RA and C3-DS NPs. (G, H) Fold change RNA expression in day 18 neuronal precursors com-
pared to hESC stage for ganglionic eminence markers PROX1, GSX2 (I –K) cortical layer markers 
CTIP2, TBR1, TBR2 and (L, M) GABA-/ glutamatergic- pre-synaptic markers VGAT and VGLUT1 
measured by QPCR from C1-SS, C2-RA and C3-DS cultures (n=3). Significant changes in I and J 
were obtained by one-way ANOVA and Tukey’s posthoc test with * for p<0.05 and ** for p<0.005. 
The scalebars are 20 µm.
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2.4.4 Neural cell induction protocol affects the regional identity 
 To investigate the regional specificity present at neural induction stages, we analyzed 
C1-SS, C2-RA and C3-DS NP populations for CNS regional markers HOXB4, LBX1, OTX1, 
GSX2, DLX2, EMX1, EN1, FOXG1, LHX6, NKX2.1, NKX2.2, PAX6, PROX1, TBR2 and for 
housekeeping gene EIF4G2 (Figure 5 and Supplementary Figure 2).  C2-RA NPs showed a 
significant increase in HOXB4 and LBX1 expression compared to C1-SS and C3-DS NPs 
(ANOVA p<0.05; Tukey’s posthoc p<0.01 and p<0.02 respectively; Figure 5B and C). In 
contrast, OTX1 expression was significantly lower in C2-RA NPs compared to C1-SS and 
C3-DS NPs (ANOVA p<0.03; Tukey’s posthoc p<0.04; Figure 5D). Further, C1-SS NPs had a 
significantly lower GSX2 expression compared to C2-RA and C3-DS NPs (ANOVA p<0.001; 
Tukey’s posthoc p<0.005; Figure 5E). The other markers tested did not show significant dif-
ferences amongst C1-SS, C2-RA and C3-DS NPs (Supplementary Fig 2). Overall, expression 
levels of regional identity markers HOXB4, LBX1, OTX1 and GSX2 showed significant dif-
ferences between NPs of C1-SS, C2-RA and C3-DS.
Fig 5 – Regional identity of the NP populations. (A) Schematic representation of a lateral view of 
embryonic brain development based on rodent E11 (adapted from [8, 41-43]), where local gradients 
of morphogens (depicted with colored panels) result in regional expression of transcription factors 
(depicted with striped and dotted panels). PSPB = pallial sub-pallial boundary, ANR = anterior neu-
ral ridge, DTB = diencephalon telencephalon boundary, ZLI = zona limitans intrathalamica, DMB = 
diencephalon mesencephalon boundary, IsO = isthmic organizer, MHB = mesencephalon hindbrain 
boundary, Pth = prethalamus, Th = thalamus, Ptec = pretectum, R = rhombomere. (B - E)  Fold 
change RNA expression in NPs of C1-SS, C2-RA and C3-DS compared to hESC stage for regional 
markers HOXB4, LBX1, OTX1 and GSX2 in showing significant differences as measured by ANOVA 
and Tukey’s posthoc tests where * is p<0.05, ** is p<0.005 (n=3).
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2.5 Discussion
 The developing neural tube consists of NP populations with varying potentials to 
differentiate into different neural cell types [14, 44-47]. While there are many protocols 
available to generate NPs in vitro [48], the differences between the obtained NP cells, as 
well as their resemblance to in vivo NP populations, i.e., regional specificity and differen-
tiation potential, are often unclear. In this study, we compared neural induction conditions 
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involving dual SMAD inhibition, single SMAD inhibition, and administration of RA, as well 
as adherent versus non-adherent methods. We demonstrated that all neural induction pro-
tocols generated rosette-like structures that expressed known NP markers. However, not 
all NP-like populations differentiated into mature neural cell types. Furthermore, NP and 
NP-derived cells showed differences in regional marker expression and potential to differen-
tiate into glial or neuronal phenotypes. These findings suggest that in vitro patterning factors 
and culture conditions induce NP populations with different properties. 
 Each method of neural induction generated NP-like cells that expressed commonly 
used NP cell markers. However, neural inductions involving only FGF2 administration were 
less robust. Furthermore, not all NP populations exhibited the same potential for neural 
differentiation. While NP cells generated via single SMAD inhibition (C1-SS) produced as-
trocyte-like cells with morphologies and expression patterns representative of astroglial cells 
and neurons with proper morphologies, neuronal populations exhibited lower expression 
levels of mature neuronal markers, compared to neurons generated with NPs induced via 
RA administration or dual SMAD inhibition (C2-RA and C3-DS). These two latter NP popu-
lations also showed generation of astrocyte-like cells with all typical astroglial characteris-
tics. Therefore, we confirm that protocols involving dual SMAD inhibition (C3-DS) and RA 
administration (C2-RA) generate multipotent NP populations. 
 NP cells generated via different neural induction protocols showed distinct regional 
marker expression. RA-induced NPs expressed a significantly increased level of spinal cord 
and hindbrain markers HOXB4 and LBX1, in line with actions of RA in vivo [49-52]. Like-
wise, forebrain and midbrain marker OTX1 was significantly lower than in NPs generated 
via the single and dual SMAD inhibition conditions, confirming caudal identities after RA 
administration. Interestingly, differential HOXB4 and OTX1 expression levels remained into 
the astrocyte lineages. NP cells induced via single SMAD inhibition showed a significantly 
decreased expression of lateral ganglionic eminence (LGE) marker GSX2 compared to the 
other NPs analyzed. As Activin is a strong inducer of GSX2 expression [53], these levels 
could have been suppressed by Noggin administration, which has been shown to inhib-
it Activin/Nodal signaling [54]. Altogether, patterning factors during neural induction can 
generate NP populations with distinct expression profiles of regional markers, which may 
remain in NP derivatives.
 NP cells generated via single SMAD inhibition (C1-SS) did not successfully generate 
mature neuronal phenotypes expressing glutamatergic and GABAergic synaptic markers 
VGLUT1 or VGAT in a cortical differentiation protocol. Earlier studies showed that Noggin 
is involved in inducing the anterior telencephalic fate of the neural plate [55, 56] and pro-
motes dopamine neuron differentiation from hPSCs [57]. So this could explain unsuccessful 
generation of mature cortical neuron identities of C1-SS NPs. Additionally, administration 
of FGF2 and FGF4 might have inhibited differentiation into neurons with cortical identities 
even further. Studies in animals have shown that FGF4 regulates Wnt-1 and FGF8 morph-
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ogens, which have complex regulating functions and control the border of midbrain-hind-
brain regions [58] (Figure 4). Together, this suggests that single SMAD inhibition in com-
bination with FGF4 and FGF8 could be more successful in producing other, non-cortical, 
neuronal populations. Furthermore, a previous study showed that this neural induction con-
dition could successfully generate cells of the oligodendrocyte lineage [5], which explains 
OLIG2 expression during astrocyte differentiation. Hence, this study in combination with 
earlier findings suggest that that while single SMAD inhibition with Noggin can generate 
multipotent NP populations, they may be less efficient in producing cortical neurons.
 NP populations generated via either RA administration (C2-RA) or dual SMAD in-
hibition (C3-DS) both produced mature cortical neurons, although with distinct identities. 
RA-induced NPs generated neurons with significant higher VGAT expression levels than 
other NPs tested. As earlier studies showed induction of heterogeneous populations of GAB-
Aergic interneurons from hPSCs after RA administration [59, 60], this could explain a signif-
icant increase in the expression of the vesicular GABA transporter VGAT in neurons gener-
ated from RA-induced NPs. Dual SMAD inhibition-induced NPs were capable of generating 
neuronal precursors with a significant higher expression of cortical layer markers TBR1 and 
TBR2 as well as glutamatergic pre-synaptic terminal marker VGLUT1 compared to the other 
NPs. This suggests production of cortical neural cell types with relatively greater glutamater-
gic identities, which is in line with earlier studies [1, 39]. This further indicates that, while 
dual SMAD inhibition protocols are often chosen, other methods of neural induction might 
fit research goals better.
 While NP populations induced via single and dual SMAD inhibition or RA admin-
istrations, all generated astrocytes, differences in expression levels were observed. RA-in-
duced NPs generated astroglial cell populations that presented GFAP expression early on 
and showed the highest amount of GFAP-expressing cells throughout the protocol. This 
could be explained by presence of EGF during this neural induction, as earlier studies 
showed it has important roles during astrocyte development [61]. FGF2 is a known inducer 
of SOX9 expression [62, 63] and SOX9 is considered as an important early glial marker 
[64]. Although only the FGF2 conditions generated SOX9-expressing NPs (C1-SS, C2-RA, 
C4 and C5), not all of these were able to generate astrocytes. Given that NP cells induced 
via dual SMAD inhibition (C3-DS) were able to generate astrocytes, this suggests that SOX9 
expression and FGF administration are neither sufficient nor required for astrocyte genera-
tion. Furthermore, while all obtained astroglial cells expressed known astrocytic markers, 
their expression levels were slightly different. Interestingly, NP-derived astrocytes kept the 
regional identity acquired during NP induction. Functional assays, such as co-cultures with 
other neural cell types, could give more insight into the characteristics of the astrocytes that 
were generated from NPs involving single SMAD inhibition, dual SMAD inhibition and RA 
administration. 
 In conclusion, while all 5 neural induction protocols generate NP-like cells, only a 
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subset shows a potential to differentiate into glial and cortical neuronal phenotypes. Signif-
icant differences in regional and neural subtype marker expression indicate production of 
NP and NP-derived cells with distinct characteristics, which in some cases persist during 
differentiation procedures. Analysis suggests that 1) dual SMAD inhibition induces NPs ca-
pable of generating astrocytes and neurons with high glutamatergic cortical identities, 2) RA 
administration induces NP cells capable of generating high GFAP-expressing astrocytes with 
caudal identities, and neuronal populations with a relative increase in GABAergic features, 
and 3) single SMAD inhibition generates NPs that can develop into astrocytes, but are less 
successful in adapting to mature cortical neuronal phenotypes. In order to better identify 
differentiation potential into neuronal and glial cell phenotypes, more in-depth characteri-
zation of in vitro generated NP cell populations is necessary. Additionally, though NP cells 
are regionally patterned, their differentiation potential towards certain cell fates may be 
flexible and capable of being influenced by other environmental factors [65, 66]. Therefore, 
future studies are needed to give more insight into subtype specificity by specific patterning 
factors and different cultures conditions. Finally, this study indicates that NP cell generation 
protocols should be selected carefully in hPSC-based studies. 
2.6 Supplement information
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Fig S1 – QPCR of NP markers in different inductions. (A-H) Relative fold change of RNA expression 
compared to hESCs for C1-SS, C2-RA, C3-DS, C4 and C5 for NP markers SOX2, Nestin, PAX6, BLBP, 
PLZF, HES5, DACH1 and SOX9. Significant differences on B were determined by one-way ANOVA 
where * is p<0.05 (n=3).
Fig S2 – QPCR of NP cells for regional identity markers. Relative fold change of RNA expression 
compared to house keeping gene EIF4G2 for DLX2, EMX1, EN1, FOXG1, LHX6, NKX2.1, NKX2.2, 
PAX6, PROX1 and TBR2 of NP cells from C1-SS, C2-RA and C3-DS (n=3).
Medium composition
N2B27 medium – This is a 1:1 mixture of N2 and B27-containing media. N-2 medium 
consists of DMEM/F-12 GlutaMAX, N2 (1x), 5 µg/mL insulin, 1 mM L-glutamine, 0.1mM 
nonessential amino acids, 100 µM 2-mercaptoethanol, 50U/mL penicillin and 50 mg/mL 
streptomycin. B-27 medium consists of Neurobasal, B-27 (1x), 200 mM L-glutamine, 50U 
ml/L penicillin and 50 mg/mL streptomycin. Medium is stored at 4 °C and use it within 3 
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N2B27 medium without vitamin A  – This is the same as N2B27 medium, except B-27 (1x) 
supplement replaced with “B-27 without Vitamin A”(1x) supplement.
N2 medium – DMEM/F12 medium, 1X N2, 0.1 mM nonessential amino acids, 2 mM L-glu-
tamine, 2ug/ml heparin, 100 U/ml Penstrep. Medium was stored at 4 °C and used within 3 
weeks.
Freezing medium – Freezing solution used was 20% DMSO, 40% DMEM/F12, 40% Knock-
out serum replacement (KSR). This medium was used in a 1:1 ratio with the culture medium 
of the cells.  
Passaging techniques
Several cell-passaging protocols were employed throughout the experiment as outlined be-
low (descriptions assume a 6WP).
Standard EDTA protocol (EDTA) – Cells are washed (2x) with 1mL/W 0.5mM EDTA in PBS, 
followed by incubation in 0.5mM EDTA in PBS for 2-3min at 37oC.  EDTA is aspirated and 
cells flushed in E8 medium + Rock Inhibitor (RI, 10uM) using a 5mL pipette before re-plat-
ing in appropriate volume of medium.
Accutase – Medium is aspirated and cells washed (1x) with PBS, before adding 1mL/W 
warm accutase.  Cells are incubated for 3-10min at 37°C until cells come loose from wells 
by gentle tapping on plate.  Cells are removed from the plate by gently titrating with 1mL 
pipette, and then transferred to a 15mL centrifuge tube containing 10mL warm DMEM/F12. 
Cells are centrifuged (1200rpm, 5min, RT), medium is aspirated and pellet is re-suspended 
in appropriate amount of medium before re-plating.
Dispase – Medium is removed from wells so that only 1mL remains, 100uL Dispase added 
and cells incubated for 8 – 10 min at 37C.  The dispase-containing medium is aspirated 
and cells flushed from wells using DMEM/F12 before transfer to 15mL centrifuge tube and 
washed twice with medium. In some cases cells may need to be removed mechanically us-
ing a cell-scraper.  Cells may be gravity sorted (let stand ~10min) or centrifuged (1200rpm, 
5min, RT).  Medium is aspirated and pellet re-suspended in appropriate medium + RI (10uM).
TrypLE – Medium is removed and 300uL/W of TrypLE added, then immediately removed. 
Cells are allowed to sit for 2 minutes at RT, and then loosened from wells by tapping on 
plate, before adding 600uL/W Defined Trypsin Inhibitor.  Cells are transferred to a 15mL 
tube containing 5mL warm NMM, and centrifuged (1200rpm, 15min, RT).  Finally, medium 
is aspirated and cell pellet is re-suspended in appropriate medium +RI (10uM) before plat-
ing.
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Primers
Gene 
name PCR 
Forward 
primer Reverse primer 
EIF4G2 
(Control) RT & Q 
ATTCTTCGTTGTCAAGCCGCCAAA
GTGGAG 
AGTTGTTTGCTGCGGAGTTGTCATCT
CGTC 
 
GAPDH 
(Control) RT & Q 
TCAAGGGCATCCTGGGCTAC CGTCAAAGGTGGAGGAGTGG 
GFAP RT GCAGATTCGAGAAACCAGCC GAGGGCGATGTAGTAGGTGC 
S100B RT GGTGAGACAAGGAAGAGGATGT ACAGGAAAGGTTTGGCTGCT 
AQP4 RT AAGGCGGTGGGGTAAGTGTG CACTGGGCTGCGATGTAGAA 
GLAST RT TCCTAGTCCCGGTTTTGCAT CCAAGGATTGTACCCACAATGAC 
ALDOC RT CCATGCCTGTCCCATCAAGT TGCAAGCCCATTCACCTCAG 
CD44 RT TTACAGCCTCAGCAGAGCAC AGGTGGAGCTGAAGCATTGA 
BLBP RT GGATTGGGAGGAACTCGACC CCCACGCCTAGAGCCTTCAT 
Nestin RT AGCGTTGGAACAGAGGTTGG AGGAGGGTCCTGTACGTGG 
Nestin Q CAGGAGAAACAGGGCCTACA TAAGAAAGGCTGGCACAGGT 
OTX1 RT & Q CACTAACTGGCGTGTTTCTGC GGCGTGGAGCAAAATCG 
HOXB4 RT GTGAGCACGGTAAACCCCAAT CGAGCGGATCTTGGTGTTG 
HOXB4 Q ACGTGAGCACGGTAAACCCCAA ATTCCTTCTCCAGCTCCAAGACCT 
LBX1 Q CGCCAGCAAGACGTTTAAG CTGCCCAAAGATGGTCATAC 
SOX2 Q ATGGGTTCGGTGGTCAAGTC CTGATCATGTCCCGGAGGTC 
DACH1 Q CAATGACTGCACCAACGCAA TGCGGCATGATGTGAGAGTT 
PLZF Q AGACGTACCTCTACCTGTGCT TGTCATAGTCCTTCCTTCATCTCAC 
PAX6 Q AGGTCAGGCTTCGCTAATGG TGCTGATTGGTGATGGCTCA 
HES5 Q AAGCACAGCAAAGCCTTCGT CTGCAGGCACCACGAGTAG 
SOX9 Q CCCCAACAGATCGCCTACAG GAGTTCTGGTCGGTGTAGTC 
PROX1 Q GTCCAATTGCCTTGTGTGCC TCAAACGGCACTGAGCTTGT 
TBR2 Q ACAACTATGATTCATCCCATCAGA AGCGGGCTTGAGGTAAAGTG 
TBR1 Q CAACAGCCTCCTGTCCAACT GAACGGAGCTCCTTGGTAGG 
GSX2 Q TGTCTCGACTCCGGAGGATT TTCACTCGGCGGTTCTGAAA 
SATB2 Q GTGCCTTGGGTAGTCCGC AGAATCGGCGAGTGCAAAGTA 
CTIP2 Q CAGAGCAGCAAGCTCACG GGTGCTGTAGACGCTGAA GG 
VGAT Q GGACTCGTACGTGGCCATAG AGCTCGATGATCTGCGCTAC 
VGLUT1 Q TTCTGGCTGCTCGTCTCCTA GGTTCATGAGTTTCGCGCTC 
LHX6 Q TCGTTGAGGAGAAGGTGCTT CGTCATGTCCGCTAGCTTCT 
EMX1 Q AGGTGAAGGTGTGGTTCCAG AGTCATTGGAGGTGACATCG 
EN1 Q CCGCGCACCAGGAAGCTGAA CAGCGCCAGGCCGTTCTTGA 
FOXG1 Q CCCGTCAATGACTTCGCAGA GTCCCGTCGTAAAACTTGGC 
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3.1 Abstract
 Generation of neuronal cultures from induced pluripotent stem cells (hiPSCs) serve 
the studies of human brain disorders. However we lack neuronal networks with balanced 
excitatory-inhibitory activities, which are suitable for single cell analysis. We generated 
low-density networks of hPSC-derived GABAergic and glutamatergic cortical neurons. We 
used two different co-culture models with astrocytes. We show that these cultures have 
balanced excitatory-inhibitory synaptic identities using confocal microscopy, electrophysio-
logical recordings, calcium imaging and mRNA analysis. These simple and robust protocols 
offer the opportunity for single-cell to multi-level analysis of patient hiPSC-derived cortical 
excitatory-inhibitory networks; thereby creating advanced tools to study disease mecha-
nisms underlying neurodevelopmental disorders. 
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3.2 Introduction
 Cortical neural activity is determined by the complex interplay between excitation 
and inhibition [1, 2]. Distinct populations of specialized neurons originate from different 
neocortical regions. Excitatory projection neurons originate from cortical progenitors in the 
pallium [3], whereas the inhibitory interneurons originate in the ganglionic eminence (GE) 
of the ventral telencephalon [4]. Processes like maturation, neural specification and syn-
apse formation all contribute to normal development of cortical networks [1]. Disruption of 
the balance between excitatory and inhibitory neuronal activity, leading to disturbances in 
network synchrony, is thought to underlie neurodevelopmental disorders, such as epilepsy, 
autism spectrum disorders (ASDs) and schizophrenia [5].
 Patient-derived induced pluripotent stem cells (hiPSCs) hold the potential to model 
disease mechanisms in vitro [6-9], to screen therapeutic targets and to generate autolo-
gous cell populations for cell replacement therapies [10, 11]. Many differentiation protocols 
have been described to produce neuronal cell cultures from human pluripotent stem cells 
(hPSCs) or neuroepithelial stem (hNES) cells [12-16]. Several brain-patterning factors such 
as sonic hedgehog (SHH[17]), retinoic acid (RA[18]), fibroblast growth factors (FGFs[19]), 
insulin growth factors (IGFs[20]) and Wnts [21] have been used to generate specific neural 
cell types. Existing procedures generate mixed neural cultures, but lack derivation of pure 
neuronal cultures with balanced inhibitory and excitatory synaptic activities suitable for 
single cell analysis [22-24].
 We generated low-density hPSC-derived neuronal cultures of GABAergic-glutama-
tergic neurons, which are amenable to multi-level analysis from early developmental to 
functional stages. We performed RNA expression analysis and immunocytochemistry to 
analyze neuronal and synaptic development, and studied functional properties by calcium 
imaging and patch-clamp electrophysiology. To support the maturation of neuronal precur-
sors into functional neurons, rat astrocytes were supplemented using either a direct contact 
or an indirect contact co-culture system. Neuronal cell populations in the indirect co-culture 
mode showed no expression of glial genes, which gives new tools to study neuronal-specific 
changes in functional hPSC-derived cultures. These well-characterized low-density cultures 
will facilitate the study of disease mechanisms underlying neurodevelopmental disorders 
particularly involving inhibitory and excitatory network changes.
3.3 Materials and methods
3.3.1 Cell lines
H1 hESCs (male embryo), control hiPSC lines hVS-88 (74 days old male), hVS-60 (70 year 
old male) and hVS-421 (19 year old male) henceforth referred to as Line A, B, C and D re-
spectively, were cultured with a feeder independent method on Geltrex in Essential 8 medi-
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um (GIBCO). The human ESC line HO1 was obtained from WiCell. The hiPSC control lines 
(hvs-88 and 60) were generated via reprogramming fibroblasts from two healthy individuals 
(fibroblasts were derived from anonymous, non-identifiable donors and therefore exempt 
from IRB approval). One hNES cell line was generated [25] from each stem cell line A, B 
and C. Repetitive differentiation experiments performed from one hNES culture are referred 
to as B1, B2, B3, etc. 
3.3.2 hNES cell generation
To obtain hNES cells, few modifications were made to the protocol described by Shi et al., 
2012 [25]. In short, high-density hiPSC cultures were passaged onto Geltrex (GIBCO)-coat-
ed 12 well plates. When hiPSC cultures reached confluence, they were neural induced with 
Noggin (500 ng/ ml; Peprotech) or its small molecule agonist dorsomorphine (1 µM; R&D), 
and SB431542 (10 µM; Stegment and Selleck chemicals). Neural rosettes were picked man-
ually and cultured in neural maintenance medium (NMM) with FGF2 (20 ng/ ml) and EGF 
(20 ng/ ml; Peprotech) on PLO (20 µg/ ml)/mouse laminin (20 µg/ ml; both from Sigma) 
pre-coated plates. 
3.3.3 Neuronal differentiation
hNES cells from passage 1 to 4 were used for differentiation, induced in neural induction 
(NI) medium [20] with SHH (400 ng/ml; Peprotech) for 4 days, and Valproic Acid (VPA; 
10 µM; Sigma) for 3 days. After induction with SHH and VPA (day 8), cells were passaged 
with accutase (Millipore) and split at 1:2 or 1:3 (depending on the density) on PLO/ laminin 
pre-coated plates. Until day 17 – 19, cells were kept in the same well at high-density in Neu-
robasal medium (Neurobasal medium (Gibco, 21103-049), 1X B-27 (50X, Gibco, 17504-
044), HEPES 18 mM (Gibco, 15630-056), 0.25X Glutamax (100X, Gibco, 35050-038), 100 
U/ ml Pen/strep (100X, Sigma, P0781)) with BDNF (20 ng/ ml), GDNF (10 ng/ ml), IGF1 
(10 ng/ ml; all from Peprotech) and cAMP (10 µM; Sigma). At this point, they were gently 
dissociated using Accutase. Clumps of (proliferating) cells were discarded. The single cell 
suspension of day 17-19 neurons was then frozen or directly plated at 62.5k cells/ 3.8 cm2 
(one well of 12WP) in direct contact or indirect contact mode in the presence of astrocytes 
for maturation. To stop division of hNES cells and to facilitate neuronal maturation, the di-
rect contact co-cultures were treated with 2µM cytosine b-D-arabinofuranoside (AraC) at 
day 25 and 29. Neurons were refreshed twice a week with half of the Neurobasal medium 
containing BDNF, GDNF, IGF1 and cAMP. The concentration of the growth factors in the 
refreshment medium was doubled (enough for the whole well). 
3.3.4 Glial cultures 
For direct contact cultures, 18 mm Menzel glass coverslips were fitted into 12 wells after 
alcohol sterilization and then coated by spraying with PDL-collagen-acetic acid-mix (1:1:3); 
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PDL (0.5 mg/ ml; Sigma), collagen (3.66 mg/ ml; Corning), acetic acid (17 mM; VWR) then 
air dried and UV sterilized for 20 minutes. For indirect contact cultures, 12 well plates 
were picked with a hot needle to make little bumps in four corners of each well, and then 
sterilized in UV light for 20 minutes. Primary astrocytes cultured from P0 pups of pregnant 
female Wistar rats (From Harlan) were passaged once and frozen. When required for co-cul-
tures, the frozen astrocytes were plated on the coated coverslips or in indirect contact wells 
at a density of 25k cells per 3.8 cm2. Astrocytes were let to grow confluent in astrocytes me-
dium (DMEM with Glutamax (Gibco, 31966-021), 10% FCS, NEAA (100x, Sigma, M7145), 
Pen/strep (100x)) for about 5-6 days. At this point (day 7 of the astrocytes), neurons were 
plated directly on astrocyte coverslips for direct contact mode. For indirect contact mode, 
neurons were plated on PLO/ laminin-coated coverslips and the next day (day 19) flipped 
over with neuron side (down) towards astrocytes in the indirect contact wells. For indirect 
contact cultures, the neuron coverslips were replaced into plates with freshly plated astro-
cytes after 3 weeks of co-culturing. Animals were housed and bred according to institution-
al, Dutch and U.S. governmental guidelines. The institutional ethical committee of the VU 
University approved these studies.
3.3.5 Immunofluorescence
Coverslips were fixed with 4% PFA or ice-cold methanol (95% methanol, 5% HAC) after 49 
(direct contact) or 56 (indirect contact) days of differentiation. The immunocytochemistry 
staining process in short, coverslips were blocked for 1.5 hour at RT in blocking buffer (5% 
NGS, 0.1% BSA, 0.3% TritonX-100 in PBS 1X) then incubated with primary antibody in 
blocking buffer for 1 hour at RT followed by overnight incubation at 4oC (primary antibodies 
are listed in Table A in S1 file). After washes (3X for 5 minutes each in PBS 1X) the coverslips 
were incubated with secondary antibody in blocking buffer at RT for 1 hour, and mounted 
with Fluoromount G (Southern Biotech) on glass slides (VWR; Super frost plus). Images 
were acquired using a Carl Zeiss 510 Meta confocal microscope with 40x (1.2 Numerical 
Aperture (NA)) and 63x (1.4 NA) oil objectives. Synaptophysin1, VGAT and VGLUT1 puncta 
analyses were performed with 63x oil objective images using SynD [26]. A minimum of 10 
fields of views (FOVs) was obtained per coverslip. And, synapses were analysed using SynD 
with threshold parameters of 0.5, 0.7, 1.0 and minimum size of puncta’s 0.7, 0.8, 0.8 µm for 
Synaptohpysin1, VGAT and VGLUT1, respectively. Immunocytochemistry was performed 
at RT or primary antibody incubations at 4oC and analysis was performed using Carl Zeiss 
510Meta confocal or Leica DM500 B fluorescent microscope. 
3.3.6 Reverse transcriptase and Quantitative PCR
Two - three wells (each 3.8 cm2) of hNES cells, hiPSCs or neurons were collected at different 
time points (day 5, 8, 18 and 49) and RNA isolated using trizol extraction and iso-propanol 
precipitation method. Equal amounts of RNA per sample were used for cDNA synthesis (1 
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µg). The Q-PCR experiments were performed on Light cycler 480 (Roche) equipment. The 
expression of each marker during differentiation days 8, 18 and 49 is normalized to the 
expression of the same marker at day 5. Primers used for RT- and Q-PCR are listed in Table 
B in S1 file. 
3.3.7 Calcium imaging
Day 49 (direct contact) or 56 (indirect contact) neurons were incubated for 10 minutes at 
37oC, 5% CO2 in Fluo-5-AM ester 1 µM in neurobasal medium without growth factors and 
imaged under constant perfusion at a 0.4ml/minute rate with Tyrode’s solution (concentra-
tion in mM: 119 NaCl. 2.5 KCl, 2 CaCl2, 2 MgCl2, 25 HEPES, 30 Glucose)  in an AxioOb-
server.Z1 Zeiss epifluorescence microscope using a 40X-oil objective (Numerical aperture, 
1.30), 488nm excitation laser, 488±10 BP excitation filter, 525±50 emission filter and 500FT 
beam splitter. Images were acquired at 2Hz rate with a Hamamatsu EM-CCD camera and 
Axiovision 4.8 software. For drug addition, perfusion was stopped and half the volume of 
Tyrode’s was replaced with Tyrode’s containing the corresponding drug twice concentrated 
as the final working dilution. Lastly, drugs were washed away for 20 minutes at the afore-
mentioned perfusion rate. For electrical field stimulation, the stimulation paradigm was set 
using a Master-8 (A.M.P.I.). 30mA pulses were generated with a stimulus isolator (World 
Precision Instruments) connected to two platinum electrodes placed above the region being 
imaged. For analysis, regions of interest (ROIs) were placed on somas and neurites based on 
differences between z-stack maximum and minimum projections using Image J. Duration 
of the calcium events and traces were subsequently determined using “Event Detection 
Analysis” (EvA) with in-house Matlab software scripts as described previously [27]. Drug 
concentrations used are listed in Table C in S1 file.
3.3.8 Electrophysiology
Whole-cell recordings were performed at RT with borosilicate glass pipettes (3.5-6.5 mOhm) 
filled with 125 mM K+-gluconic acid, 10 mM NaCl, 4.6 mM MgCl2, 4 mM K2-ATP, 15mM 
creatine phosphate, 10U/ ml phosphocreatine kinase and 1mM EGTA (pH 7.30). External 
solution contained the following (in mM): 10 HEPES, 10 Glucose, 140 NaCl, 2.4 KCl, 4 
MgCl2 and 4 CaCl2 (pH = 7.30, 300 mOsmol). Recording were acquired with an Axopatch 
200A amplifier (Molecular Devices), Digidata 1322A and Clampex 9.0 software (Molecular 
Devices). Local field stimulation (2 mA, 1 ms) was applied with a bipolar concentric elec-
trode placed in the vicinity of the patched neuron. Offline analysis was performed using 
Clampfit v9.0 (Axon Instruments) and Mini Analysis Program v6.0 (Synaptosoft). 
3.3.9 Mass Spectrometry
Triplicate protein samples of day 56 differentiated neurons in indirect contact co-culture 
mode (n=2) were collected from Line B. The cells were solubilized in 22 µL of Laemmli 
sample buffer. After heating at 950C for 5 minutes, samples were loaded on a 10% SDS gel 
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(mini-Protean 3 from Bio-Rad) and run for 45 minutes at 100 V. The gel was fixed overnight 
in 50% ethanol/3% phosphoric acid, stained in colloidal coomassie blue for 30 minutes, 
washed three times for 10 minutes in water, and each sample lane cut into two fractions and 
chopped into about 1 mm by 1 mm pieces. After destaining in 50 mM NH3 HCO3 - 50% 
acetonitrile/50 mM NH3HCO3 the gel pieces were dried in Speedvac, the tryptic peptides 
were analyzed using Triple TOF 5600+ MS (Sciex) coupled with an Ultimate 3000 LC sys-
tem (Dionex, Thermo Scientific). Peptides were trapped on a 5 mm Pepmap 100 C18 col-
umn (300 µm i.d., 5µm particle size, Dionex) and fractionated on a 200 mm Alltima C18 
column (300 µm i.d., 3 µm). Acetonitrile concentration in the mobile phase in 0.1% formic 
acid was increased from 5 to 18% in 88 minute, to 25% at 98 minute, 40% at 108 minute 
and to 90% in 2 minutes, at a flow rate of 400nL/minute. Peptides were electrospray into 
the mass spectrometer using an ion spray voltage of 5.5 kV and an interface heater temper-
ature of 500C. The MS survey scan range was m/z 350–1,250 acquired for 200 ms. The top 
20 precursor ions were selected for 85ms per MS/MS acquisition, with a threshold of 100 
counts. Dynamic exclusion was 16 s. Rolling CID function was activated, with an energy 
spread of 15 eV. The Human database used was UniProt_2015-02. Label-free quantification 
was activated with LFQ min. ratio count of 1. Match between runs with match time window 
of 0.7 minute and alignment time window of 4 minute were used for all analyses. For other 
parameters the default settings were used. All raw MS data were analyzed by MaxQuant 
software (version 1.5.2.8) with search engine Andromeda. 
3.3.10 Statistical analysis
All the statistical analysis was performed using SPSS and Prism 6 software. All raw data from 
Q-PCR experiments and SynD analysis were normally distributed. Statistical analysis for all 
the raw data was then performed using one-way ANOVA. In cases where significant differ-
ences were obtained in the ANOVA (p< 0.05) a post hoc test was performed. Post hoc tests 
used were Holm-Sidak’s multiple comparisons test and Tukey’s multiple comparisons test. 
3.4 Results
3.4.1 Partial induction with SHH and VPA produces cultures with mature 
neuronal morphologies 
 In order to derive a mixed culture of human GABAergic and glutamatergic neurons, 
hESCs and hiPSCs (S1 Fig) were neural induced into primitive rosette-shaped hNES cells as 
described previously [25]. Between passages 0 to 10 hPSC-derived hNES cell cultures were 
characterized by morphology (Fig 1F and S2F Fig) and expression of hNES cell markers [14, 
28]. Immunocytochemical analysis showed that hNES cells homogeneously expressed the 
rosette marker PLZF, the neural precursor marker PAX6 and the stem cell marker SOX2 (Figs 
1A-E and S2A-E Figs). RT-PCR indicated the expression of rosette specific markers PLZF, 
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DACH1, ZNF312, HES5, stem cell marker SOX2, and neural stem cell markers Nestin and 
PAX6 (Fig 1G and S2G Fig). To generate a mixed glutamatergic and GABAergic network of 
neurons, a ventral GABAergic fate was partially induced using SHH [29, 30] and VPA [20, 
31]. hNES cells were treated with 400ng/ml of SHH from day 0 – 4 followed by VPA from 
day 5 – 7 (Fig 1H). Abundant neurite outgrowth was observed at 8 days (Fig 1I). Between 
days 8 – 18 precursor cells were supplemented with growth factors BDNF, GDNF, IGF1 
and second messenger cAMP to mature the neuronal cultures at a very high density (Fig 
1J). Around days 17 – 19 highly dense neuronal precursors were dissociated, frozen and/or 
plated at low density to differentiate into neuronal networks (Fig 1K). To support maturation 
into functional neurons in low density, neuronal precursors were co-cultured with primary 
rat astrocytes. Human neurons (density of 62.5k cells/ 3.8 cm2 well) and rat astrocytes (den-
sity of 25k/ 3.8 cm2 well) were grown in either direct contact or indirect contact co-culture 
mode [32] as depicted in Figs 1M and 1N respectively. After 49 days of differentiation (Fig 
1L) direct contact neuronal cultures were processed for functional analysis. Day 19 neu-
ronal precursors, when cultured in low-density and in absence of astrocytes failed to mature 
and showed increased neuronal degradation around 35 – 40 days of differentiation. In con-
clusion, partial induction of hPSC-derived hNES cells with SHH and VPA produces cultures 
with mature neuronal morphology.
Fig 1 – hNES cell-derived neuronal culture protocol. hiPSC-derived NES cells were generated and 
characterized by (A-E) immunocytochemistry for PLZF, PAX6, SOX2, (F) morphology as well as (G) 
RT-PCR for SOX2, Nestin, PAX6, PLZF, DACH1, ZNF312 and HES5, and later differentiated into 
low-density neuronal cultures. (H) Schematic representation of the differentiation protocol. (I-L) 
Representative images of differentiating neurons at day 4, 8, 20 and direct contact culture mode 
day 49 are shown. (M, N) Cartoon representation of direct and indirect contact co-culture model. 
Scale bars are 25 µm. See also S1 and S2 Figs for hiPSC characterization and hESC-derived hNES cell 
characterization.
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3.4.2 RNA expression profiling and immunocytochemistry detects identities 
of glutamatergic and interneuron cell lineages of neocortical origin
 To characterize the differentiating neurons for known markers of the pallium, sub-pal-
lium, GE (including CGE, MGE and LGE) and cortical layers, RNA expression levels from 
days 5, 8, 18 and 49 (direct contact) of differentiation were analyzed. During maturation, 
neuronal precursors showed a gradual increase in the expression of most ganglionic em-
inence markers tested (Fig 2A-C). CGE progenitor marker CoupTF2 [33] showed a slight 
increase during early differentiation (day 8) and CGE marker PROX1 [34] showed increased 
expression between day 5 and day 18 (Fig 2A).  Although expression of MGE marker NKX2.1 
was not induced, other MGE markers LHX6 and SATB1, respectively involved in migration 
of neurons from the ventral telencephalon [35] and in enhancing terminal differentiation of 
parvalbumin (PV) and somatostatin (SST) interneurons [36], were increasingly expressed at 
day 18 and 49 of differentiation (Fig 2B). Expression of LGE progenitor markers MEIS2 [37] 
and GSX2, which regulate LGE progenitor maturation [38] showed increases in expression 
at day 49 and day 18, respectively (Fig 2C). The sub-pallium marker ASCL1 stayed at a con-
stant expression level whereas the pre-synaptic proteins VGAT and VGLUT1 showed an in-
creased expression over time (Fig 2D). Differentiated neurons showed increased expression 
of several markers of cortical layer glutamatergic neurons. Throughout the differentiation, 
pallium marker PAX6 showed a constant expression, cortical progenitor marker TBR2 [39] 
was slightly decreased and telencephalic neuron maturation marker BF1 [40] increased 
towards day 49, indicative of maturing neurons (Fig 2E). The cortical upper layer (2 – 4) 
markers CUX1, SATB2 [41] showed increasing levels at day 49, whereas BRN2 progenitor 
expression [42] showed a decreased level (Fig 2F). High expression of the late-onset deep 
layer markers TBR1 and CTIP2 [43] was observed at day 18 and day 49 (Fig 2G). CTIP2 had 
a significant increase at day 49 compared to day 5 and day 8, indicating neural stem cells 
differentiation towards deep layer cortical neurons. Rosette and neural stem cell markers 
HES5, DACH1, PLZF and SOX2 expressed at the hNES cell stage (Fig 1A-G) showed de-
crease in expression during differentiation indicating neuronal maturation (Fig 2H). Specif-
ically, neural stem cell markers HES5 and DACH1 showed a significant reduction from day 
8 to day 49 indicating loss of neural stem cell identity. Finally, we performed immunocy-
tochemical analysis at day 49 for markers of both lineages that showed presence of deep 
layer CTIP2, upper layer SATB2, CGE lineage PROX1, LGE lineage MEIS2 and interneuron 
subpopulation marker Calbindin-positive neurons (Figs 2I-M). To confirm that, all the neu-
rons present in the cultures were human-derived we did a co-stain for human nuclear (HN) 
marker with MAP2 and astrocytic marker GFAP (Fig 2N). Taken together, RNA profiling 
of the developing neuronal cultures and immunocytochemistry at end stages indicate the 
emergence of interneurons of GE lineages, as well as glutamatergic neurons reminiscent of 
different neocortical layers. 
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Fig 2 – RNA and immunocytochemical analysis of hNES cell-derived neuronal cultures in direct 
contact. RNA was isolated at different stages of differentiation (day 5 (n=3), day 8 (n=2), day 
18 (n=3) and day 49 (n=3) altogether from Line B and C. RNA expression profiles of (A) caudal 
(CoupTF2, PROX1), (B) medial (SATB1, LHX6) and (C) lateral (MEIS2, GSX2) ganglionic eminence 
markers. (D) Expression of sub-pallium (ASCL1), and pre-synaptic markers (VGAT, VGLUT1) over-
time during differentiation. (E) Cortical progenitors (BF1, TBR2) and pallium marker (PAX6); (F) 
cortical upper layers (CUX1, BRN2, SATB2); (G) deep cortical layers (TBR1, CTIP2) and (H) rosette 
and neural stem cell (HES5, DACH1, PLZF, SOX2) markers were also assessed in the RNA samples. 
All the primers data was normalized to the expression of housekeeping gene EIF4G2. Error bars rep-
resent standard mean error (SEM) per time point from n=3 in day 5, 18, 49 and n=2 in day 8. One-
way ANOVA was performed and with significant differences (p<0.05) in some gene expressions, a 
post hoc test represents significant differences (in asterisks) among the time points with a p<0.05. 
Immunocytochemical analysis at day 49 (n=2) for Glutamatergic lineage markers CTIP2 (I), SATB2 
(J), CGE marker PROX1 (K), LGE marker MEIS2 (L) and Calbindin (M) with MAP2. (N) Only the 
neuronal population is human-derived as shown by immunocytochemistry for human nucleus (HN), 
GFAP (rat astrocytes) and MAP2. Scale bars are 25  µm.
3.4.3 Low-density neuronal cultures generate balanced numbers of 
excitatory-inhibitory synapses
 To characterize excitatory and inhibitory neuron identity in the cultures, we analyz-
ed dendritic, axonal and synaptic marker expression by immunocytochemistry. At day 49, 
the neuronal cultures (direct contact) showed an abundant network of dendrites and axons 
as shown by dendritic marker MAP2 and axonal marker Smi312 (Fig 3A). To study presence 
of GABAergic neurons, we quantified the number of neurons expressing the GABA-produc-
ing enzyme GAD65/67 (Figs 3A-C) as a fraction of the MAP2-positive cells (0.22 ± 0.5; Fig 
3D). We also quantified the number of synaptophysin1 puncta per neuronal soma, which 
accounted to 298±74 pre-synapses per MAP2 dendritic soma (Fig 3E). We further studied 
the presence of GABAergic presynaptic terminals by co-localization of pre-synaptic protein 
synaptophysin1 puncta with vesicular GABA transporter (VGAT) puncta (Figs 3F-H). The 
fraction of all VGAT puncta to synaptophysin1 puncta on MAP2-positive dendrites was 0.53 
± 0.01 (Fig 3I) and the number of VGAT synapses per dendritic soma (MAP2) was 103±18 
(Fig 3J). Glutamatergic neurons in the cultures were identified by co-localization of presyn-
aptic vesicular glutamate transporter 1 (VGLUT1) with synaptophysin1 puncta, and by pres-
ence of glutamatergic post-synaptic marker HOMER1 puncta (Figs 3K-M). The fraction of all 
VGLUT1 puncta to synaptophysin1 puncta on MAP2-positive dendrites was 0.61 ± 0.05 (Fig 
3N) and the number of VGLUT1 synapses per dendritic soma was 255±89 (Fig 3O). These 
data indicate that the hPSC-derived neurons form a network with both GABAergic and glu-
tamatergic synapses.
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Fig 3 – Immunocytochemical analysis of glutamatergic and GABAergic pre/post-synaptic markers 
in direct contact co-cultures. Immunocytochemical analysis was performed at day 49 from Line B. 
hPSC-derived neurons were analyzed for the expression of (A-C) MAP2, GAD65/67, SMI-312, (F-
H) VGAT and synaptophysin1, (K-M) VGLUT1 and HOMER1. Ratio of (D) GAD65/MAP2-positive 
cells (n=2), (E) Synaptophysin1 puncta per MAP2 soma (n=3) (I) VGAT/synaptophysin1-positive 
puncta (n=3), (J) VGAT puncta per MAP2 soma (n=3) (N) VGLUT1/synaptophysin1-positive (n=3) 
puncta and (O) VGLUT1 puncta per MAP2 soma (n=3) (10 FOV’s per experiment) were quantified. 
Error bars represent SEM. Insets represent closer magnifications. One-way ANOVA was performed, 
no significant difference was found between experiments for GAD65 and VGAT analysis. Significant 
differences with p<0.05 was found between experiments B1, B2 and B3 for VGLUT1 analysis. FOV 
– fields of view; Scale bars are 5 µm.
3.4.4 Low-density neuronal cultures show synaptic activity, produce action 
potentials and Ca2+ transients
 To understand the excitability of the differentiated neurons (direct contact), a voltage 
step protocol was applied to record sodium and potassium currents (Fig 4A). Quantifica-
tion of the peak size of these currents showed that hiPSC-derived neurons on average had 
larger currents than hESC-derived neurons (Fig 4B). The presence of voltage-gated Na+ and 
K+ channels suggests that these neurons can fire action potentials. Indeed, the majority of 
cells generated action potentials in response to step current injections (Fig 4C; >90% of 
hiPSC-derived neurons and 70% of hESC-derived neurons). Cells unable to generate action 
potentials showed smaller sodium responses and responded to a smaller voltage range (-40 
to -10 mV) compared to the cells that could generate action potentials (-30 to +50 mV). 30% 
of hESC-derived neurons and 38% of hiPSC-derived neurons spontaneously elicited action 
potentials in current clamp (Fig 4D). To confirm the presence of functional synapses, we as-
sessed spontaneous activity in the presence of the voltage-gated sodium channel antagonist 
TTX (Fig 4E). We observed that a proportion of the spontaneous events were blocked by the 
GABAA receptor antagonist bicuculline. Subsequent application of AMPA/NMDA receptor 
antagonists AP5 and DNQX blocked all remaining synaptic transmission confirming that 
these cultures contain both GABAergic and glutamatergic neuronal activity. To test network 
connectivity of the differentiated neurons, we applied local field stimulation, which elicit-
ed synchronized postsynaptic currents (Fig 4F). Hence, the majority of these hPSC-derived 
neurons produces action potentials and show synaptic responses.
 Subsequently, we investigated the capability of the neurons to generate spontaneous 
activity in these networks by monitoring Ca2+ transients. We loaded the neurons with Fluo-
5-AM and imaged Ca2+ transients in regions of interest (ROIs) on somas and neurites. We 
observed abundant spontaneous network activity, which was blocked by TTX (Fig 4G, 4I, 4C 
and S4A) and re-established after wash out, except for a few ROIs (17% for both hiPSC- and 
hESC-derived neurons). Addition of bicuculline triggered a change in spontaneous activity 
(Fig 4H, 4J, 4D and S4B) with some neurons increasing (>60% increase in 15% of hiPSC- 
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and in 25% of hESC-derived neurons) and others decreasing frequency of events (>60% 
reduction in 50% of hiPSC- and in 40% of hESC-derived neurons). Subsequent addition of 
AP5 and DNQX blocked spontaneous calcium transients in all hiPSC-derived neurons, but 
remained in 10% of the hESC-derived neurons, suggestive of intrinsic pacemaker activity 
in a small group of neurons. The network also responded to electrical field stimulation with 
increased activity/amplitude correlated to the number of pulses given (Fig 4K and S4E Fig). 
These results indicate that the hPSC-derived neurons trigger action potentials, establish ac-
tive glutamatergic and GABAergic synapses and generate synaptic transmission in the neu-
ronal network.
Fig 4 – Functional analysis of differentiated neurons in direct contact co-cultures. At day 49 we 
recorded Line A-derived (n=2) and Line B-derived (n=2) neurons, which show (A) fast inward Na+ 
currents followed by long-lasting outward K+ currents; current was evoked by voltage steps ranging 
from -90 mV to 50 mV with 10 mV increments. Inset shows fast Na+ currents in absence or presence 
of Na+ channel antagonist TTX (1 µM). (B) Quantification of peak Na+ and K+ currents evoked in 
(A) is shown. (C) We recorded action potentials evoked by a current injection of 100 pA and also 
(D) spontaneously generated action potentials in current clamp mode. (E) Spontaneous post-syn-
aptic events from a single neuron (holding potential at -70 mV in voltage clamp mode) recorded 
in presence of 1µM TTX, TTX + 40 µM Bicuculline and TTX + 40 µM Bicuculline + 50 µM AP5 + 
10 µM DNQX are shown. (F) Postsynaptic current evoked by local field stimulation (2 mA, 1 ms). 
We recorded calcium traces at day 49 of differentiation; (G, H) hiPSC-derived neurons loaded with 
Fluo-5 AM ester. (I) Raster plot showing onset and duration of intracellular calcium events from ROIs 
represented on G; upon TTX addition and 20 minutes after TTX was washed away (J) or traces repre-
sented in H upon bicuculline, bicuculline + AP5 + CNQX addition and 20 minutes after drugs were 
washed away (representative calcium traces for ROI 2 (G, I) and ROI 9 (H, J)) are shown. (K) We 
then analyzed activity dependent intracellular calcium traces (red dotted bars indicate beginning of 
electrical field stimulation and number of pulses applied). Scale bars are 10 µm. Data are represent-
ed as mean ± SEM. See also S4 Fig for hESC-derived neurons calcium imaging experiments.
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3.4.5 Indirect contact co-cultures of neurons form excitatory-inhibitory 
synapses 
 To facilitate neuronal specific analysis in the absence of astrocytes, we grew neurons 
in indirect contact with astrocytes. These cultures manifested morphology of very well con-
nected neurons at early (day 26; Fig 5A) and later differentiated stages (day 56; Fig 5B). At 
day 56, VGAT and synaptophysin1 (Figs 5C-F) as well as VGLUT1 and HOMER1 (Figs 5G-J) 
were expressed in a punctate pattern, suggesting the presence of GABAergic and glutama-
tergic synapses. Similar to the direct contact cultures, the indirect contact cultures were 
positive for the lineage identity markers CTIP2, SATB2, PROX1, MEIS2 and Calbindin at day 
56 using immunocytochemistry (Fig S3I-M). Indeed, these neurons established GABAergic 
and glutamatergic synapses as measured by whole-cell patch clamp electrophysiological 
recordings of spontaneous release (Figs 5K and 5L). Furthermore, Ca2+ transients in indirect 
contact cultures demonstrated a functionally integrated network (Figs 5M and 5O) of mixed 
neurons (Figs 5N and 5P), which showed increased amplitude of response to an increas-
ing number of stimuli (Fig 5Q). We also observed ROIs, which upon bicuculline addition 
showed either increased (20%) or decreased (55%) frequency of activity, and upon bicu-
culline/AP5/DNQX addition showed persistent activity (10%) and did not recover activity 
after TTX wash out (17%). Finally, to study differences between direct and indirect contact 
cultures, we analyzed RNA of both neuronal cultures at end stages for lineage markers of 
GABAergic and glutamatergic neurons. There are no significant differences in the expres-
sion of markers between direct and indirect contact cultures (Figs 3A-H). Although we need 
to consider that the end-stage analysis of direct and indirect cultures was at different time 
points (day 49 and day 56). These observations confirm that hPSC-derived neurons also form 
a functional and mixed synaptic network of GABAergic and glutamatergic neurons, when 
grown with rodent astrocytes in an indirect contact co-culture system. 
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Fig 5 – Characterization of the differentiated neurons in indirect contact co-cultures. In indirect 
co-cultures we differentiated the human neurons in close proximity of rat astrocyte layers (Line B1 
and B2). (A, B) Bright field images of indirect cultures during differentiation day 26 and 56 are 
shown. (C-F) We observed the expression of MAP2, VGAT, synaptophysin1 and (G-J) VGLUT1 and 
HOMER1 co-localizing puncta using immunocytochemistry at day 56. We then analyzed (K) spon-
taneous mEPSCs and mIPSCs (holding potential at -70mV in voltage clamp mode) recorded in 1 µM 
TTX supplemented with 40 µM Bicuculline or 50 µM AP5 + 10 µM DNQX respectively. (L) Quanti-
fication of amplitude, area, time to decay and frequency of mEPSCs and mIPSCs was also analyzed 
(n=2). We then recorded calcium traces of (M, N) neurons loaded with Fluo-5 AM ester from n=2. 
(O) Raster plot showing onset and duration of intracellular calcium events from ROIs represented 
on M and N respectively; upon TTX addition and 20 minutes after TTX was washed away (P) or 
upon bicuculline, bicuculline + AP5 + CNQX addition and 20 minutes after drugs were washed 
away (representative calcium traces for ROI 1(M, O) and ROI 8 (N, P)) are shown. (Q) Analysis of 
activity dependent intracellular calcium traces (red dotted bars indicate beginning of electrical field 
stimulation and number of pulses applied). Scale bars are 10 µm. Data are represented as mean ± 
SEM. See also S5 Fig for indirect contact plate preparation method.
3.4.6 Proteomic analysis of indirect contact co-culture neurons shows low 
variation between replicates
To evaluate the reproducibility of the neuronal differentiation and to check if the indirect 
contact co-cultures produced pure neuronal batches, we performed mass spectrometry anal-
ysis. At day 56, we collected whole cell lysates from triplicate samples of two hiPSC-derived 
differentiations (namely line B1 and line B2). In line B1, 1384 proteins were detected in 3 
replicates; in line B2, 1442 proteins were observed in 3 replicates. Overall the protein ex-
pression profiles between samples as analyzed by hierarchical clustering (Fig 6A), were very 
similar indicative of corresponding expression profiles between the different cell cultures. 
The average coefficient of variation of each sample normalized with respect to the load-
ing was small, ranging between 0.11-0.14 (Fig 6B) indicating similarity of protein expres-
sion between replicates. Typical neuronal-specific proteins, such as MAP2, Beta-3 tubulin, 
Syntaxin, Synapsin, Synaptotagmin and Gephyrin were detected (S1 Table). Proteins were 
analyzed for differences in expression by using the average IBAQ values of the 3 technical 
replicates per line. This revealed the abundant presence (high IBAQ values) of presynaptic 
and growth cone proteins (Fig 6C) such as Synaptophysin, SNAP25 and Neuromodulin. 
Glial proteins such as GFAP, ALDH1L1, GLAST, O4 and PDGFaR were not detectable (S1 
Table), which indicates that by indirect contact co-cultures one can generate pure neuronal 
cell cultures. Taken together, these results indicate little variation in protein expression of 
whole cell lysates between independent experiments and confirmed absence of glial cells 
in the neuronal cultures. 
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Fig 6 – Proteomic analysis of indirect contact co-culture neurons representing reproducible cul-
tures. (A) Hierarchical clustering of protein groups based on expression intensity present in the day 
56 differentiated neurons. Columns represent triplicates from 2 experiments (B1 and B2) normalized 
for loading and appear similar in highly expressed proteins (color key values > 4). (B) Average of 
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the coefficient of variation normalized to loading for all the proteins. (C) Average and standard de-
viations of intensity based absolute quantification (iBAQ) values for pre-, post-synaptic and growth 
cone proteins in day 56 neuronal cultures.
3.5 Discussion
 We present a robust and simple hPSC differentiation protocol to derive a low-density 
culture of cortical glutamatergic and GABAergic neurons, following in vivo developmen-
tal processes. Using electrophysiology, calcium imaging, confocal microscopy, mRNA and 
proteome analysis, we proved functional activity of excitatory-inhibitory networks with re-
producible synaptic balance. Although earlier studies produced mixed neuronal cultures, 
we generated a low-density network with purely cortical neurons. These cultures facilitate 
the analysis of inhibitory and excitatory network changes in patient hiPSC-derived cortical 
networks at single cell resolution.
 To generate complex neuronal networks representative of in vivo cortical brain cir-
cuitries both inhibitory interneurons and excitatory projection neurons should be present. 
To induce interneuron cell fate, we treated the high-density hPSC-derived NES cells with 
SHH and VPA. Previous studies showed that SHH ventralizes the neural tube along the an-
terior-posterior neural axis [29] and thereby induces cortical interneuron specification [44], 
whereas VPA administration to human and rodent PSC cultures increases the expression of 
the GABA-synthesizing enzyme GAD65/67 [20, 31]. To induce pure cultures of hPSC-de-
rived GABAergic neurons, Ma and colleagues used extended treatments with SHH (200ng/
ml) for 14 days and VPA (10 µM) for 7 days [20]. Since we aimed for induction into ventral 
interneuron cell fate in only a subset of the progenitors, we tested short-treatment proce-
dures with SHH (400 ng/ml for 4 days) and retained dorsal identities to achieve spontaneous 
differentiation of glutamatergic neurons as well. To confirm generation of GABAergic and 
glutamatergic neurons following in vivo development [3, 44], we performed RNA expres-
sion profile analyses at different time points of differentiation and immunocytochemistry 
analysis at the end stage. In our neuronal cultures, the interneuron population consists of 
CGE- and LGE-derived cells as indicated by expression of post-mitotic markers PROX1 and 
MEIS2. The cultures also express MGE markers SATB1 and LHX6, but lack MGE marker 
NKX2.1. Since our RNA profiling analysis did not detect NKX2.1, we also did not expect 
Parvalbumin (PV)- and Somatostatin (STT)-positive neurons, as previous studies showed that 
PV and STT is reduced in Nkx2.1 KO mice [22]. We found expression of other GE lineage 
interneuron markers, like Calbindin in both direct and indirect contact co-cultures. The ex-
citatory neurons were representatives of upper and deep neocortical layer cells, as shown 
by expression of the post-mitotic markers CUX1, SATB2, TBR1 and CTIP2, respectively. We 
successfully generated and characterized a protocol to produce a mixture of both cortical 
glutamatergic and GABAergic neurons in line with in vivo development. 
 A reproducible balance in excitatory and inhibitory activity will facilitate the study of 
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cortical networks and neuronal communication. We characterized and quantified the num-
ber of pre- and post-synaptic terminals. End-stage direct cultures demonstrated the presence 
of 50-55% GABAergic (VGAT) and 50-67% glutamatergic (VGLUT1) pre-synaptic terminals 
and 17-27% of neurons expressed GAD65/67, which is representative of human cortical 
development [45]. A subset of the glutamatergic post-synaptic HOMER1-positive puncta 
appeared VGLUT1-negative and may express other glutamatergic transporters like VGLUT2 
[46, 47]. Since indirect cultures did not receive AraC treatment, we suspect that the imple-
mentation of AraC treatments increases maturity levels of these cultures. The hPSC-derived 
neuronal cultures manifested functional neurons by presence of evoked and spontaneous 
action potentials as well as miPSCs and mEPSCs mediated by GABA and NMDA/AMPA 
receptors, respectively in both co-cultures. The peak size of sodium currents showed that 
hiPSC-derived neurons had on average larger currents than hESC-derived neurons, sugges-
tive of a higher maturation state, as reported previously [48]. When spontaneous calcium 
transients were measured, few ROIs increased activity upon TTX wash-out, likely due to a 
rebound effect of this compound [49]. Bicuculline administration changed calcium activity 
indicating functional neurons, as GABAergic neurons are excitatory during development. 
Kuijlaars et al [24] recently presented protocols of hiPSC-derived cortical neuronal cells in 
co-culture with primary human astrocytes. Interestingly, they found increased maturation of 
co-culture systems around day 80 compared to neuronal mono-cultures by studying syn-
chronized calcium influx activity. This confirms that astrocytes are of utmost importance to 
generate functional neuronal networks. Further studies should show when our co-culture 
systems show synchronized activity. Overall, our immunocytochemical and electrophysi-
ological analyses indicate derivation of neuronal networks with mixed glutamatergic and 
GABAergic neuronal activity.  
 Astrocytes are important players in neuronal maturation and activity [50, 51]. Matu-
ration of precursors into functional neurons is therefore regularly facilitated by co-culturing 
with astrocytes [52]. To identify neuronal-specific changes, removing astrocytes at the anal-
ysis stages is however often desired. While we expect that astrocyte-conditioned media will 
not be sufficient to support neuronal maturation of low-density culture of purely neurons, 
we have not explored these culture settings. In the direct and indirect contact cultures used 
for this study, we did not observe astrocyte loss. Furthermore, we were able to generate 
pure hPSC-derived neuronal networks when neuronal precursors were co-cultured with rat 
astrocytes in the indirect contact mode. This was confirmed by mass spectrometric analysis, 
which revealed no presence of human glial proteins after removal of the astrocytes. When 
we cultured neurons in complete absence of astrocytes we noticed generation of glial cells 
from neuronal precursor cells. This indicates that neuronal precursors that are maturing to-
wards functional pure neuronal networks need presence of astrocytes. 
Reproducibility and consistency of protocols is a major limitation in the stem cell differenti-
ation field. We performed one of the first studies using mass spectrometry to test reproduc-
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ibility of hPSC-derived neuronal differentiation procedures. Inspecting the protein profiles 
of the end-stage neurons showed limited intra-line variability, as illustrated by growth cone 
proteins, neuronal (like MAP2 and TUBB3) and pre-synaptic proteins (like synapsin and 
synaptotagmin) analyzed. So we confirmed reproducibility of our hPSC differentiation pro-
cedures, showed that mass spectrometric analysis of indirect contact cultures will facilitate 
neuronal- (or astrocyte-) specific protein analysis and gives important tools to get insight into 
changes in overall maturity levels of neuronal networks. Although, more in depth proteomic 
studies might be required to extrapolate our findings to other hiPSC lines. 
 In conclusion, we derived well-characterized reproducible low-density neuronal 
cultures from hPSCs with inhibitory and excitatory neuronal activity, which represent de-
velopment of human cortical neurons. These protocols provide new tools to study cortical 
neuronal network changes at single cell stage as well as network level. This will facilitate 
studies of disease mechanisms involving imbalance between excitatory and inhibitory ac-
tivity, which is thought to underlie different neurodevelopmental disorders. 
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3.6 Supplement information
Fig S1 – hiPSC characterization. hiPSC clones derived from controls were fixed in PFA and immu-
nostained for (A-D) stem cell/ pluripotency markers OCT3/4, Tra-1-60, Tra-1-81 and SSEA4. (E) 
RT-PCR analysis for stem cell markers TDGF1, UTF1, DNMT3B, REX1, Sall4, DPPA4, DPPA2, ESG1 
and reference gene Eif4g2. (F) hiPSCs were differentiated to 3 germ layers expressing CD31 (meso-
derm), MAP2 (ectoderm) and SOX17 (endoderm). (G) Alkaline phosphatase stained hiPSC colonies 
in bright field. (H) Karyotype of the hiPSC clone. Scale bars are 50 µm.
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Fig S2 – hESC-derived NES cells.  NES were generated from hESCs, characterized by immunocyto-
chemistry for (A-E) PLZF, PAX6, SOX2 (passage 6), (F) morphology (passage 0) and (G) by RT-PCR 
for the markers SOX2, Nestin, PAX6, PLZF, DACH1, ZNF312 and HES5 (passage 7) and later differ-
entiated into low density neuronal cultures. Scale bars are 25 µm.
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Fig S3 – Comparison of RNA expression profile between direct and indirect co-cultures and protein 
profile expression of indirect co-cultures. RNA was isolated from direct co-cultures at day 49 (n=3) 
altogether from Line B and C and indirect co-cultures at day 56 (n=2 from Line B). Comparative RNA 
expression profiles of (A) Caudal (CoupTF2, PROX1), (B) medial (SATB1, LHX6) and (C) lateral 
(MEIS2, GSX2) ganglionic eminence markers. (D) Expression of sub-pallium (ASCL1), and pre-syn-
aptic markers (VGAT, VGLUT1). (E) Comparative expression of cortical progenitors (BF1, TBR2) and 
pallium marker (PAX6); (F) cortical upper layers (CUX1, BRN2, SATB2); (G) deep cortical layers 
(TBR1, CTIP2) and (H) rosette and neural stem cell (HES5, DACH1, PLZF, SOX2) markers were also 
assessed in the RNA samples. All the primers data was normalized to the expression of housekeeping 
gene Eif4g2 and final ratio were normalized to expression of different genes at iPSCs stage. Error bars 
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represent standard mean error (SEM) per time point from n=3 in direct day 49 and n=2 in indirect 
day 56. Immunocytochemical analysis at day 56 (n=2) of indirect co-cultures for Glutamatergic line-
age markers CTIP2 (I), SATB2 (J), GABAergic lineage markers PROX1 (K), MEIS2 (L) and Calbindin 
(M) with MAP2. (N) Representation of GFAP, human nucleus (HN) and DAPI stain in direct contact 
co-cultures. Scale bars are 25 µm.
Fig S4 – Calcium imaging of hESC-derived neurons in continental co-cultures. We recorded calci-
um traces at 49 days of differentiation; (A, B) hESC-derived neurons loaded with Fluo-5 AM ester. 
(C) Raster plot showing onset and duration of intracellular calcium events from ROIs represented 
on A&B respectively; upon TTX addition and 20 minutes after TTX was washed away (D) or upon 
bicuculline, bicuculline + AP5 + CNQX addition and 20 minutes after drugs were washed away 
(representative calcium traces for ROI 1 (A, C) and ROI 1 (B, D)) are shown. (E) Activity dependent 
intracellular calcium traces (red dotted bars indicate beginning of electrical field stimulation and 
number of pulses applied). Scale bars are 10 µm.
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Fig S5 – Sandwich astrocyte plate preparation. To plate rat astrocytes for sandwich co-culture the 
wells were pricked with a hot syringe needle to make little bumps on 4 corners. The plates were 
sterilized, coated (see suppl. methods) and astrocytes were plated on them.
Supplemental tables
Table A: Primary antibodies (Cell culture and tissue) 
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Table B: RT and Q-PCR primers
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Table C: Drugs in calcium imaging
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4.1 Abstract
 Tuberous sclerosis complex (TSC) is a rare disorder with neurodevelopmental deficits 
that results from autosomal dominant mutations of TSC1 or TSC2 genes. TSC patients have 
a hyper activated mTOR pathway and grey and white matter defects in the brain. To study 
cellular mechanisms underlying TSC pathophysiology, we generated iPSC-derived cortical 
neuronal and oligodendrocyte (OL) cultures from patient fibroblasts carrying TSC1 or TSC2 
mutations. TSC patient iPSC-derived neurons had increased network activity, measured as 
both calcium transients and action potential firing. Mono-cultures of only neurons showed 
no significant morphological changes, however in contrast, co-cultures of TSC patient iP-
SC-derived neurons with OLs showed both cell hypertrophy and increased axonal density. 
Additionally co-cultures had increased OL cell proliferation and decreased OL maturation. 
Pharmacological intervention with mTOR regulators, like rapamycin (Rapa), suppressed 
these TSC phenotypes in vitro. Our patient iPSC-based model therefore show a complex 
cellular TSC phenotype arising from the interaction of neuronal and glial cells, and provide 
new platforms for TSC disease modeling and drug development.
Chapter 4
102
4.2 Introduction
 Tuberous sclerosis complex (TSC) is a rare genetic, neurodevelopmental disorder, 
which affects multiple organs [1], causing benign tumors in the brain, eyes, heart, lung, liv-
er, kidney and skin. The neuropathological features in the brain involve cortical tubers and 
subependymal nodules [2]. Many studies also indicate glial-associated phenotypes, includ-
ing giant astrocytoma [3] and white matter abnormalities [2, 4]. TSC is caused by autosomal 
dominant mutations in the genes TSC1 and TSC2, resulting in mTOR pathway hyperactivity 
[5]. The mTOR pathway plays key roles in multiple cellular processes, like cell growth [6], 
and is differentially regulated by factors, such as rapamycin (Rapa) [7], insulin-like growth 
factor 1 (IGF1) [8] and guanabenz (Guana) [9] depending on cell type and maturation state, 
as shown in cellular systems and in vivo models [10, 11]. Clinical studies showed encourag-
ing improvements in TSC patients after Rapa treatment [12]. However, to develop improved 
treatment regimens, we lack detailed understanding of how TSC disease mechanisms affect 
human neuronal and glial cell types.
 TSC has been studied in different rodent model systems, which showed neuronal 
defects, such as distorted synaptic balance, neuronal hyperactivity [13], and axonal defects 
[14], as well as glial defects, like reduced myelin [15], increased oligodendrocyte (OL) 
progenitor proliferation and increased OL death [9, 16, 17]. In human pluripotent stem 
cell (hPSC)-based assays, homozygous mutations for TSC2 in hESC line showed a hyperac-
tive mTOR pathway, increased soma size, neuronal hyperactivity and increased dendritic 
branching [18], while a heterozygous gene disruption of TSC2 presented with mild neuronal 
phenotypic defects [18]. Only one TSC patient iPSC-based study has been presented before, 
which showed increased astrocyte proliferation, and increased soma size and decreased 
neurite length in iPSC-derived neuronal cultures [19]. As TSC neuropathological features 
implicate both neuronal and glial cells, and proper neural development involve complex in-
teractions between different neural cell types, mixed neuron-glia systems would be valuable 
to study the modulatory actions of mTOR pathway inhibitors on TSC disease phenotypes. 
 Here we present a TSC patient iPSC-based model involving neuron-OL co-cultures. 
While increased neuronal activity was quantifiable in neuronal mono-cultures, morpholog-
ical changes, such as increased axonal density and hypertrophy, only became apparent after 
the TSC neurons were co-cultured with human OLs. Treatment of known mTOR regulators 
Rapa, IGF1 and Guana confirmed modulating effects in both neurons and OLs, and validat-
ed our TSC model for future drug screens to design new treatments for TSC patients. 
4.3 Materials and methods
4.3.1 iPSCs and neuronal cultures
TSC patient (P1: GM06149, P2: GM03958) and control fibroblasts (C3: GM23973) were 
obtained from Coriell Biorepository (all teen-age donors) and controls C1 (infant) and C2 
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(teen-age) were obtained from anonymous control donors. The selected TSC patients were 
reported with mental retardation and seizures along with other TSC-related abnormalities. 
iPSC reprogramming was done based on polycistronic construct with OCT3/4, c-MYC, 
SOX2 and KLF4 [20]. All the iPSC lines were cultured in Essential 8 medium (GIBCO) on 
Geltrex (GIBCO). Generation of in-direct contact iPSC-neuronal mono-cultures was per-
formed as described earlier [21] with slight modifications. Neuronal mono-cultures in the 
Std condition medium contained Neurobasal composition with BDNF (20 ng/ml; Pepro-
tech) and cAMP (1 µM; Sigma). The Std+IGF1 and Std+Rapa conditions contained Std me-
dium with IGF1 (10ng/ml; Peprotech) or Rapa (30nM; Sigma), respectively. All the neurons 
were treated once with 2µM cytosine b-D-arabinofuranoside (AraC) at day 26. All neuronal 
conditions were refreshed twice every week with half medium change, and from day 49 to 
56 the Std+IGF1 (10ng/ml) and Std+Rapa (10nM) conditions were treated every day. At day 
56 of differentiation the neuronal coverslips were processed for calcium imaging analysis. 
 For multi-electrode array (MEA) experiments, day-56-neurons from Std conditions 
were re-plated on the MEAs. Prior to cell plating, each array was coated with 200µl of a 
filter-sterilized 0.1% solution of polyethylenimine (Sigma Aldrich) in borate buffer (3.10g 
of boric acid (Fisher Scientific) and 4.75g of sodium tetra borate (Sigma Aldrich) in 1L of 
distilled water) overnight at 37OC. Next day, the solution was removed and the wells were 
washed 3X with sterile water and air-dried for one hour in a sterile biological safety cabinet. 
Then, neurons were dissociated using accutase and were re-suspended at a concentration of 
5000 viable neurons/µl in BrainPhys (B27 1X (Gibco), BDNF (20 ng/ml; Peprotech), ascorbic 
acid (200 nM; Sigma)) media with 10µg/ml laminin (Sigma Aldrich) for Std condition. A 25-
µl droplet of the cell suspension (100,000 neurons) was added to the center of each array, 
directly over the electrode area. MEAs were incubated for 1 hour with the seeded neurons 
followed by gentle addition of 700ul of the culture media. The media was replaced every 
three days with fresh rat astrocyte conditioned medium at 1:1 ratio. Cultures were measured 
50 days post plating on MEAs (i.e. 106-day-old neuronal cultures). For Std+Rapa condition 
a number of arrays were treated with 10nM Rapa for 30min at 37OC and then recorded for 
10 minutes. 
4.3.2 Glial cells and co-cultures
Oligodendrocytes were obtained as described previously [22]. Before neuron-OL co-cul-
tures were generated, we first separately created neuron mono-cultures (62.5K/ 2.0cm2 
density) until day 37 [21] and OL progenitors until day 65. To generate neuron-OL co-cul-
tures, the neuronal coverslips were removed from rat astrocyte feeder plates and OL pro-
genitors were passaged with accutase (Millipore) and plated at a density of 200K/ 2.0 cm2 
on neuronal coverslips. The co-cultures were maintained in Std co-culture medium (DMEM/
F12 and Neurobasal (1:1; both GIBCO), 1% N1 supplement (in-house), 2% B27 supplement 
(GIBCO), 1% NEAA (GIBCO), 60ng/ ml T3 (Sigma), 100ng/ml Biotin (Sigma) medium with 
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NT3 (10ng/ml; Peprotech), mouse laminin (1 µg/ml; Sigma), BDNF (20 ng/ml) and cAMP 
(1 µM). From day 1 to day 7 of co-culture, all cells were refreshed with Std medium. From 
day 8 to 28 of co-culture, cells were refreshed with either Std, Std+Guana (5 µM; Sigma) or 
Std+Rapa (10nM) medium twice a week. At day 28 of co-culture, the cell culture coverslips 
were processed for immunocytochemistry. 
4.3.3 Calcium imaging
At day 56, neuronal mono-culture coverslips were incubated with Fluo-5-AM ester 1 µM 
in neurobasal medium without growth factors for 5 minutes at 37oC and imaged under 
constant perfusion at 0.5ml/minute rate with Tyrode’s solution (119 NaCl. 2.5 KCl2, CaCl2, 
2 MgCl2, 25 HEPES, 30 Glucose; all in mM) in an Axiovert 200M inverted microscope 
(Zeiss) using 40X-oil objective (Numerical aperture 1.3; Zeiss), Polychrome IV light source 
(TILL Photonics), 488/6nm excitation filter (Semrock), 525/50nm emission filter (Semrock) 
and 500nm beam splitter (Semrock). Images (1 image/ sec) were acquired using a Cascade 
512 EM-CCD camera (Roper Scientific) and Metamorph 6.2 software (Molecular devices). 
Total length of 4.5 minutes was recorded per field of view (FOV) and minimum 5 FOVs per 
coverslip were recorded each from 2 to 4 differentiations for 3 controls and 3 TSC lines. For 
analysis, image series were stacked using Z-stack projection in ImageJ and regions of inter-
est (ROIs) were placed on minimum of 12 neurites per FOV. Calcium traces were detected 
using “Event detection analysis (EVA)” with previously described methods in Matlab [23]. 
4.3.4 Multi-electrode array (MEA)
60MEA200/30iR-Tigr MEAs were used. Spontaneous activity was recorded, for a period of 
10 min, every 10 days at 37OC using MC Rack at a sample rate of 25000 Hz. Electrode data 
were filtered online with a 200 Hz high pass and a 5000 Hz low pass filter (both 2nd order 
butterworth). Data were stored as .mcd files, which contain the filtered continuous traces 
for each electrode together with the spikes detected using the online threshold detection 
built into MC Rack. After selecting electrodes for analysis, chosen data was converted to 
asci files for offline analysis using the MC Data tool. Offline analysis was achieved with 
custom scripts written in Matlab. Spikes were detected from filtered data using an automatic 
threshold-based method set at -5.5 ×s, where s is an estimate of the noise of each electrode. 
Spike timestamps were analyzed to provide statistics on the general excitability of cultures. 
The average spike rate (Hz) represents the median of the average spike rate for all electrodes 
(AvgSpkRateE1-n). The average spike rate for each electrode (AvgSpkRateE) was calculated as 
AvgSpkRateE = number of spikes/tmax, where tmax is the total length of the recording in sec-
onds. This is used to control for particularly high or low firing rates. 
4.3.5 Immunofluorescence
For immunocytochemistry neuronal mono-cultures and neuron-OL co-culture coverslips 
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were fixed with 4% PFA for 20 minutes and processed for staining. All the coverslips were 
blocked for 1 hour at RT in blocking buffer (5% NGS, 0.1% BSA, 0.3% TritonX-100 in PBS 
1X), incubated with primary antibody in blocking buffer overnight at 4oC. Next day, after 
washing again with PBS (6 times for 5 minutes each) the coverslips were incubated with 
secondary antibody solution for 2 hours, washed again (6X for 5 minutes) and then were 
mounted with Fluoromount G (Southern Biotech) on glass slides (VWR; Super frost plus)/
glass coverslips. Primary antibodies used were OCT 3&4 (#5279, Santa Cruz), SSEA4 (#MC-
813-70, Hybridomabank), TRA-1-60 (#21705, Santa Cruz), TRA-1-80 (#4381C3, Millipore), 
SMI312 (#837901, Biolegend), MAP2 (#5392, Abcam), Synaptophysin1 (#101-004, SYSY), 
OLIG2 (#9610, Millipore), MBP (#7349, Abcam) and Nissl (#21480, Thermofisher). Images 
were acquired from stained slides using either a Carl Zeiss 510 Meta confocal microscope 
with 40x (1.2 Numerical Aperture (NA)) oil objective or Leica DM6000B fluorescent micro-
scope with 20x magnification. 
4.3.6 Cell property analysis
Cell properties like axonal density, dendritic density, soma size, and number of synapses; 
OLIG2-positive and MBP-positive cells were measured using Columbus 2.5 online software. 
Precisely, images acquired with Confocal and Fluorescent microscope were analysed with 
algorithms for morphology, soma recognition and co-localization tools using pixel density 
measurement and number of objects present, respectively. To quantify the soma sizes and 
morphological parameters, pixel densities were measured in each FOV (10 per condition/ 
coverslip) with magnification of 20X or 40X images. 
4.3.7 Western blot analysis
Cell lysates were collected from feeder free iPSCs at day 3 or 4 after passage and from 
neuroepithelial stem cells between P1 to P5. SDS-PAGE was run on Bolt™ 4-12% Bis-Tris 
Plus Gels (Thermo fishcer scientific). The PVDF membranes were blocked with 5% non-fat 
dry milk in TBS- 0.05% Tween, followed by primary antibody incubations at 1:1000 conc. 
in 5% BSA in TBS- 0.05% Tween and incubated ON at 4°C (Primary antibodies are listed 
in supplement information). The blots were then washed thrice for 10 minutes with TBS-
Tween, re-blocked with milk-TBS-Tween and finally incubated with secondary antibody in 
milk-TBS-Tween for 1 hour at RT. After washing thrice again bands were visualized using 
SuperSignal™ West Femto substrate (Thermo Scientific) on Odyssey Fc imaging system (Li-
cor). Primary antibodies against TSC1 (#6935) and TSC2 (#4308; both from Cell Signaling 
Technology) were used at 1:1000 concentrations. Secondary antibody used was HRP rabbit 
antibody (1:1000; #7074S, Cell Signaling).
4.3.8 Statistical analysis
All the statistical analysis was performed using Prism 7 software. All the raw data was tested 
for normal distribution and then analyzed using unpaired t-test or one-way ANOVA depend-
Chapter 4
106
ing on group numbers. In cases where significant differences were obtained in the ANOVA 
(p< 0.05), a Tukey’s post hoc test was performed.
4.4 Results
4.4.1 TSC patient iPSCs show normal stem cell properties and a decrease in 
TSC protein levels
 To generate iPSC-based models for TSC, we selected fibroblasts from teenage pa-
tients. Patient 1 (P1) carried a heterozygous mutation 2249G>A in the TSC1 gene, resulting 
in a de novo mutation W750X reported earlier [24]; Patient 2 (P2) had a single nucleotide 
duplication (1563dupA in TSC2 gene resulting in frame shift mutation H522T). Control iPSC 
lines were generated from one infant (C1) and two teenagers (C2, C3). Several iPSC clones 
were obtained from each patient and control fibroblast line and verified by sequencing (Fig 
1A-C). To characterize TSC patient and control iPSC for pluripotency, we performed stand-
ard assays, including immunocytochemistry for markers OCT3&4, SSEA4, TRA-1-60 and 
TRA-1-80 and expression of alkaline phosphatase (Fig S1A-F). To investigate whether TSC 
mutations resulted in changed TSC1 and TSC2 protein expression, we performed western 
blot analysis (Fig 1D-E). The level of one TSC patient was obtained by averaging the levels 
of different iPSC clones of that patient: 4 clones for both P1 and P2 (Fig 1D-F). When we 
studied protein changes by comparing the average levels of the patients (P1 & P2) to the 
average levels of the controls (C1-3), a significant reduction in both TSC1 (p<0.03) and TSC2 
(p<0.004) was observed in TSC iPSCs (Fig 1D, E). We selected two iPSC clones hVS-233 
(P1A) and hVS-248 (P1B) from P1, one iPSC clone hVS-417 (P2C) from P2, and control iPSC 
clones hVS-88 (C1), hVS-228 (C2) and hVS-421 (C3) for following experiments. Overall, the 
TSC patient iPSCs showed a significant reduction in TSC proteins compared to the controls, 
but expressed normal stem cell properties. 
Chapter 4
107
Fig 1 – Mutations in TSC genes lead to decreased TSC protein levels in patient iPSCs. (A-C) Se-
quencing of patient iPSC line P1A, P1B and P2. Western blot quantifications of (D) TSC1 and, (E) 
TSC2 protein expression in controls and patients iPSC cells. Individual points indicate the average 
values of the two patients (P1 and P2) and controls (C1, C2, and C3). P1 and P2 represent 4 iPSC 
clones each. Significant difference was obtained in the mean TSC1 and TSC2 protein expression 
level between the control and patient groups (p<0.05, unpaired one-tailed t-test). (F) Western blots 
presenting labeled TSC1 and TSC2 proteins of 4 iPSC clones of TSC patient P1 and P2, and 3 control 
iPSCs (mean ± SEM).
4.4.2 Increased neuronal activity in TSC patient iPSC-derived neuron 
mono-cultures
  Network hyperexcitability has been reported in several models of TSC [13, 25, 26]. 
To investigate neuronal activity in TSC patients, we generated neuronal cultures from con-
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trols C1, C2, C3 and patient lines P1A, P1B, P2 according to established protocols [21]. At 
day 56, we measured spontaneous calcium transients in the neuronal cultures (Std condi-
tions; Fig 2A & 2C). Under Std conditions, the spontaneous calcium influx frequency in the 
networks was significantly higher (p<0.01, Post hoc test) in the TSC neurons (0.12±0.01 Hz; 
Fig 2C & 2E) compared to the control neuron cultures (0.065±0.008 Hz; Fig 2A & 2E). We 
further studied whether mTOR pathway inhibition, by administration of Rapa (Std+Rapa) 
or IGF1 (Std+IGF1), modulated the spontaneous calcium transients (Fig 2B & 2D). The fre-
quency of calcium transients in TSC neuron cultures treated with Rapa (Fig 2D) or IGF1 (Fig 
S3G & S3L) reduced to around 0.09±0.006 and 0.089±0.01 Hz, respectively, whereas the 
frequency in control neurons after Rapa and IGF1 treatment remained around 0.069±0.009 
and 0.07±0.008, respectively (Fig 2B & Fig S3F). The reduction in the total event area in the 
TSC cultures (2.3±0.3) compared to control cultures (4.2±0.9) under Std conditions showed 
a trend towards statistical significance (p=0.08; Fig 2F & S3M). Lastly, event amplitudes be-
tween TSC and control neurons were similar (Fig 2G & S3N). Overall, the increased event 
frequency and decreased event area in the TSC neurons suggests an increase in neuronal 
network activity, which was diminished by treatment with Rapa or IGF1.
 To further assess activity, we measured spontaneous action potential firing of neu-
ronal cultures from controls C1, C2 and patient line P1A differentiated on MEAs. At day 
106 under Std conditions, the neuronal firing (measured as spike rate) was higher in TSC 
neurons (1.09±0.23 Hz; Fig 2K & 2H) compared to the control cells (0.64±0.21 Hz; Fig 2I & 
2H), although not statistically significant. The spontaneous neuronal activity in TSC neurons 
treated with Rapa was reduced to 0.52±0.07 Hz, which showed a trend towards statistical 
significance (p=0.06, unpaired t-test; Fig 2L & 2H). An apparent increase in firing of con-
trol neurons after Rapa treatment was not statistically robust. Altogether, we found higher 
spontaneous neuronal firing in TSC neuron mono-cultures suggesting an increased network 
activity, which was modulated to control levels after Rapa treatment. 
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Fig 2 – Increased network activity in TSC neuron mono-cultures can be modulated by Rapa. Rep-
resentative traces of calcium influx of neuronal cultures generated from control and TSC patients, 
under Std (A, C) and Std+Rapa (B, D) culture conditions. The multicolor traces in A-D represent 
activity in 12 ROIs per FOV. (E) Average calcium event frequency for patient (P1 and P2) and control 
(C1, C2 and C3) neurons under Std and Std+Rapa (mean ± SEM). Average for P1 was obtained from 
P1A and P1B. The average calcium event frequency of every iPSC line is calculated by averaging 
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analysis of 2-4 differentiations. Asterisks in panel E indicate statistical differences found in Tukey’s 
post hoc test where * represents p<0.05. (F) Calcium event amplitude and (G) event area in control 
and patient groups under Std and Std+Rapa conditions. (H) Average spike rate (Hz) at 50 day post 
plating on MEAs under Std and Std + Rapa condition from C1, C2 and P1A (n=4 – 5 independent 
MEAs; mean ± SEM). A representative raster plot showing the activity in control neurons under; (I) 
Std, (J) Std+Rapa conditions and TSC neurons under; (K) Std and (L) Std+Rapa conditions.
4.4.3 No morphological network changes in TSC neuron mono-cultures
 To investigate whether TSC patient iPSC-derived neuron cultures show morpholog-
ical changes, we measured the axonal density in the cultures under Std, Std+Rapa and St-
d+IGF1 conditions at day 56 (Fig 3A & Fig S3A). No significant changes in axonal densities 
(SMI312-positive pixels/ DAPI-positive cell) were observed in the TSC (Fig 3D) compared to 
the control neuron mono-cultures (Fig 3B-E). To assess differences in dendritic and synaptic 
density between TSC patient and control neuron cultures, we performed staining for den-
dritic marker MAP2 and pre-synaptic marker Synaptophysin1 (Fig 3F – I, Fig S3D & S3E). 
No significant changes in the dendritic (Fig 3L) and the synaptic densities (Fig 3M & Fig 
S3K) were found between the TSC and control neuron mono-cultures under Std or Std+Rapa 
conditions. The total number of neurons in the cultures (Fig 3N & Fig S3O) remained around 
50 to 65 per field of view (FOV) for all groups. As hypertrophy is a known phenotype of TSC 
[27], we further measured neuronal soma size (Nissl-positive pixels/ DAPI-positive cell). 
We did not observe differences in the soma size in the TSC compared to the control neuron 
cultures, under Std or Std+Rapa (Fig 3K), or under Std+IGF1 conditions (Fig S3I). Altogether, 
based on no significant changes in the measured parameters, it is suggested that morpholo-
gy properties did not change between TSC and control neuron mono-cultures.
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Fig 3 – No altered morphology in TSC patient neuronal mono-cultures. (A) Schematic of neuronal 
differentiation protocol under the Std and Std+Rapa conditions. (B-I) Immunochemistry of axonal 
marker SMI312, nuclear marker DAPI, dendritic marker MAP2 and pre-synaptic marker Synapto-
physin1 in control and patient neurons in Std and Std+Rapa conditions at day 56. For C1, C2, C2, P1 
and P2 (n=2-4 differentiations each; mean ±SEM). P1 includes P1A and P1B. (J) Total axonal density 
per soma is calculated as the number of SMI312-positive pixels per DAPI-positive soma. (K) Soma 
size is measured as the mean number of Nissl-positive pixels per soma. (L) Total dendritic density per 
soma is calculated as the number of MAP2-positive pixels per DAPI-positive soma. (M) Number of 
synapses is expressed as the number of synaptophysin1-positive puncta per soma. (N) Total number 
of neurons per field of view (FOV) measured by number of Nissl- and DAPI-double positive soma. 
All scale bars are 50 µm.
4.4.4 TSC neuron-OL co-cultures show hypertrophy and an increased neurite 
density
 Axonal changes and hypertrophy have been reported in brain tissue of TSC patients 
[27] and TSC mouse models [15], but were not significantly apparent in mono-cultures of 
neurons, we examined whether these features arise through more complex interactions with 
glia cells, specifically OLs. To measure morphological changes in neuron-glia cultures, we 
grew co-cultures of neurons and OLs from TSC and control cells (CN + CO, CN + PO, PN 
+ CO and PN + PO). We first generated neurons and OLs separately and later co-cultured 
neurons (day 37) and OLs (day 65) under Std conditions for another 28 days and included 
treatments with Rapa (Std+Rapa) or Guana (Std+Guana) from day 7 of co-culture on (Fig 4A 
& Fig S4A). Since, IGF administration could affect OL generation, we used Rapa and Guana 
as mTOR pathway modulators. The axonal density significantly changed between the differ-
ent co-cultures (p<0.004, ANOVA; Fig 4A - D & 4I). The PN + PO culture showed a statis-
tically significant four-fold increase in axonal density compared to the CN + CO (p<0.01, 
Tukey’s post hoc test). CN + PO cultures appeared to be similar to control co-cultures and 
statistically different from PN + PO (p<0.03, Tukey’s post hoc test) cultures (Fig 4A-D & 4I). 
This suggested that the increased axonal density did not arise just through elevated signaling 
from TSC OLs. Consistent with this hypothesis, PN + CO cultures showed a three-fold in-
crease in axonal density compared to CN + CO and CN + PO cultures, although with lower 
statistical significance with a post hoc test. Treatments with Rapa or Guana did not suppress 
the increased axonal density (Fig 4I & Fig S4B). The total number of cells in the co-cultures 
under Std and treated conditions remained the same (Fig S4F). Therefore, when co-cultures 
contained both TSC neurons and TSC OLs, the axonal density significantly increased com-
pared to cultures containing control neurons, which was unaffected by treatment with Rapa 
or Guana.
 The soma size also significantly changed between the different co-cultures (p<0.007, 
ANOVA; Fig 4E - H & 4J). There was a statistically significant difference in soma size be-
tween PN + PO and CN + CO cultures (p<0.02, Tukey’s post hoc test), and between the 
Std and the Std+Rapa condition in the PN + CO culture (p<0.04, Tukey’s post hoc test; Fig 
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4J). The decrease between the Std and the Std+Rapa condition in the CN + PO and PN+PO 
cultures were not statistically significant (Fig 4J). Treatments with Guana did not normalize 
increased soma size (Fig S4C). Altogether, when co-cultures contained both TSC neurons 
and TSC OLs, the soma size significantly increased compared to cultures containing control 
neurons and control OLs. Rapa showed regulating effects on soma size when co-cultures 
contained TSC neurons and/or TSC OLs. Overall, changes in neurite density and hypertro-
phy in TSC patient cells could be measured in mixed neuron-OL populations, which were 
partly altered by mTOR regulators. 
Fig 4 – Hypertrophy and increased axonal density in TSC iPSC-derived neuron-OL co-cultures. (A-
D) Immunocytochemistry images of co-cultures showing SMI312 and DAPI expression in the CN + 
CO, CN + PO, PN + CO and PN + PO groups. (E-H) Nissl soma staining in the co-culture groups. 
(I) Total axonal pixel density and (J) average soma size per cell in co-cultures measured at day 28 of 
co-culturing. Mean levels were obtained by averaging 4-9 repetitions per group (mean ± SEM). All 
scale bars are 25 µm. Asterisks in panel I and J indicate statistical significant differences found in one-
way ANOVA and Tukey’s post hoc test, where * represents p<0.05, ** represents p<0.005. While 
several differences were found using Tukey’s post hoc, only the most important one’s are represented 
in the graph.
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4.4.5 Altered oligodendrocyte properties in mixed TSC neuron-OL 
populations
 As TSC patients show glial dysfunctions, we further investigated whether TSC neu-
ron-OL co-cultures show OL abnormalities. To study whether TSC neuron-OL co-cultures 
affected OL maturation, we analyzed the ratio of MBP/OLIG2-positive cells in the differ-
ent co-cultures with and without Rapa or Guana treatment (Fig 5B – E, 5F & Fig S4D). 
While ANOVA analysis did not show significant changes (Fig 5F), t-test analysis showed 
a significant decrease in OL maturation in PN + PO (0.04±0.003) compared to CN + CO 
(0.13±0.03; p<0.03, t-test) cultures, which improved after treatment with Rapa and Guana 
(0.10±0.03 and 0.07±0.004, respectively; Fig 5F & S4D). Overall, TSC neuron-OL co-cul-
tures showed reduced maturation, which was improved by Rapa and Guana treatment. 
 To study whether co-cultures with TSC neurons and/or OLs affected OL prolifera-
tion, we measured the number of OLs in the co-cultures. We found significant changes in 
the number of OLs (OLIG2/DAPI cells) between the different groups (one-way ANOVA; 
p<0.0001). Post hoc analysis showed a four-fold significant increase (p<0.0002, Tukey’s 
post hoc test) in the number of OLIG2-positive cells in the PN + PO (0.22±0.05; Fig 5E 
& 5G) compared to the CN + CO (0.048±0.01; Fig 5B & 5G) cultures. Additionally, when 
the TSC OLs were co-cultured with control neurons (CN + PO; 0.15±0.01; Fig 5C & 5G), 
a three-time significant increase (p<0.01, Tukey’s post hoc test) in the OLIG2/DAPI-positive 
cells compared to CN + CO cultures was observed. The PN + CO cultures (Fig 5D) showed 
no significant changes in the OLIG2/DAPI-positive cells compared to CN + CO cultures 
(Fig 5G), indicating that TSC patient neurons do not affect proliferation levels of control 
OLs. Interestingly, PN + PO cultures under Std+Rapa conditions was significantly reduced 
compared to PN + PO cultures under Std conditions (p<0.04; Tukey’s post hoc test; Fig 
5G). Treatment with Guana did not normalize OL numbers (Fig S4E). Hence, co-cultures 
containing TSC patient OLs showed increased OL numbers, which was modulated by Rapa. 
Altogether, TSC patient OLs showed a significantly increased proliferation when co-cultured 
with control neurons, which further increased by addition of TSC patient neurons and could 
be normalized by Rapa treatment. 
Fig 5 – Differential proliferation and maturation of TSC OLs in co-cultures. (A) Schematic of neu-
ron-OL co-culture protocol in the Std and Std+Rapa conditions. (B-E) Immunocytochemical images 
of co-cultures showing OL precursor marker OLIG2- and OL maturity marker MBP-positive cells in 
the CN + CO, CN + PO, PN + CO and PN + PO groups. (F) Ratio of MBP/ OLIG2- and (G) OLIG2/ 
DAPI-positive cells in the co-cultures at day 28. Mean levels were obtained by averaging 4-9 rep-
etitions per group (mean ± SEM). All scale bars are 25 µm. Asterisks in panel G indicate statistical 
significant differences found in one-way ANOVA and Tukey’s post hoc test. While several differences 
were found using Tukey’s post hoc only the most important one’s are represented in the graph, where 
* represents p<0.05, ** represents p<0.005, *** represents p<0.001, **** represents p<0.0001.
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4.5 Discussion
  TSC neuropathology is known to involve defects in both neuronal and glial cell pop-
ulations, however the inter-relationships between each neural cell type during TSC disease 
progression is unclear, hampering development of treatment strategies. Here we present 
evidence from TSC patient iPSC-based models that carry mutations in TSC1 or TSC2 for an 
interaction between neurons and OLs leading to changes in axonal density, cellular hyper-
trophy and OL cell proliferation. As a result increases of these parameters are only seen 
in neuron-OL co-cultures. However, increased network activity appears to be altered in 
neuron mono-cultures in the absence of OLs. Administration of mTOR pathway regulators 
reduced the increase in network activity and partly normalized the cellular defects. Overall, 
we present TSC patient iPSC-derived models involving TSC1 and TSC2 mutations, showing 
several known TSC-associated neuronal and OL phenotypes. 
  TSC1 and TSC2 form a heterodimer that inhibit mechanistic target of rapamycin 
(mTOR), which has regulating roles in cellular processes, such as cell size, proliferation and 
survival [11]. Loss-of-function due to mutations in TSC1 or TSC2 leads to increased phos-
phorylation-dependent activation of mTOR protein and its downstream targets like S6K and 
4E-BP [28]. TSC2 protein is regulating important roles due to presence of a GAP domain and 
phosphorylation sites, whereas TSC1 functions to stabilize TSC2 by inhibiting its ubiquiti-
nation [29]. Specific genetic variations in the TSC genes lead to variable disease symptoms 
and severity in patients [30]. TSC2 gene loss is often causing a more severe phenotype [31], 
as also seen in mouse studies [32, 33]. As TSC1 and TSC2 have different functions, there 
is need for model systems that involve either TSC1 or TSC2 mutations. Here, we generate 
TSC patient derived iPSC models involving either TSC1 or TSC2 dominant mutations that 
model at least some of the known effects of TSC mutations in the CNS. These cell models 
substantially expand on previous observations reported by Li et al. (2017), who investigat-
ed iPSC-derived neural stem cell (NSC), neuronal and astrocyte morphological properties 
from a single patient carrying c.1444-2A>C mutation in TSC2. The current study further 
investigated neuron mono-cultures vs. neuron-OL co-cultures, indicating that interactions 
between neurons and OLs are of utmost importance for the development of TSC-associated 
phenotypes. 
 In contrast to Li et al (2017), we observed no significant changes in cell soma size in 
TSC patient neurons when differentiated in neuron only cultures (mono-cultures). To gen-
erate mature networks of excitatory and inhibitory cortical neurons, our neuron mono-cul-
tures were supplemented with rodent wild type astrocytes, to suppress generation of astro-
cytes from the iPSC-derived neural progenitors [21]. This difference in astrocyte feeding, 
and possibly the generation of different neuronal subtypes at other maturity stages, could 
underlie differences in soma effects found between the current study and the Li et al study. 
However, when co-cultured with OLs, we showed substantial differences present in both 
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cell soma size and axonal density. Furthermore, while Li et al investigated proliferation rate 
of NSCs and astrocytes, we focused on the impact of neurons on OL proliferation and mat-
uration in co-cultures as well neuronal cell properties in both mono- and co-cultures. OLs 
have critical roles in regulating neuronal survival, such as the caliber and stability of the 
axon [34], and neuronal assembly [35]. This might further explain why neuron-OL co-cul-
tures (or mixed neural organoid cultures) can maintain neuronal health for longer periods 
of time, while neuron mono-cultures degenerate at certain stages. This also suggests that 
the neurons in mono-cultures vs. the neurons in co-cultures had different maturation states. 
Interestingly, axonal density was highest when both TSC neurons and TSC OLs were pres-
ent. As TSC brain tissue also shows defects in astroglial lineage cells, and Li et al showed 
increased proliferation in astrocyte cultures, future neuron-astrocyte co-cultures are of inter-
est. Together, co-culture model systems give the opportunity to study morphological defects 
in TSC neuronal populations that might be absent in neuronal mono-cultures, and thereby 
supports the use of mixed neural cultures for future screens. 
 TSC neuron mono-cultures showed an increase in spontaneous calcium event fre-
quency. This is consistent with network hyperactivity seen in the TSC mouse model [13] and 
an altered inhibition reported in TSC patient tissue [36]. Our MEA data showed that increase 
in activity is also present at the level of action potential (AP) generation, which is the output 
of the summation of calcium activity. This further verified that TSC protein reduction leads to 
increased neuronal activity, independently of the presence of OLs. Future functional charac-
terization from neuron-OL co-cultures could help study calcium transients in TSC neurons 
with defective morphology properties as well as understand glial involvement in altered 
inhibition, neuronal hyperactivity in TSC. 
  Administration of mTOR pathway inhibitors to the neuron-OL co-cultures, showed 
different modulating effects in the neuronal and OL populations. While Rapa treatment nor-
malized the enhanced OL numbers and increase in soma size, the axonal density remained 
increased in the TSC cultures. Earlier reports showed that the mTOR pathway is differentially 
regulated in different neural cell types [10, 11, 37, 38]. Dose dependent Rapa treatment 
suppresses mTOR hyperactivation and rescues TSC neuronal phenotypes and epilepsy in 
rodent models [39, 40]. Furthermore, it has been shown that Rapa can enhance neurite out-
growth in primary control neurons [41] and that TSC plays a role in neuronal polarization 
[14]. Rodent models also showed that the mTOR pathway regulates OL proliferation and 
maturation [42], as well as glial abnormalities [43]. So our neuron-OL models confirm that 
both neuronal and OL cell types are affected by TSC mutations and that mTOR pathway 
regulators have differential effects on these neural cell populations. As earlier studies indi-
cated that the mTOR pathway also has different modulating functions during development, 
therapeutic effects of compounds can differ depending on the maturation stage of the neural 
cells. 
  A higher amount of OLIG2-positive cells were present in the neuron-OL co-cultures 
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containing TSC OLs and control neurons (CN + PO), compared to control co-cultures (CN + 
CO), which further increased when TSC OLs were co-cultured with TSC neurons (PN + PO). 
This is in line with earlier studies showing axonal influence on OL precursor proliferation, 
maturation and myelination [35, 44], such as neuron-induced secretion of neurotransmitters 
and neurotrophins [45]. For example, neuron-secreted neurotrophins induce proliferation of 
OL precursors via MAP kinase pathway activation, but mediate myelination of mature OLs 
via different combinations of JAK-STAT proteins [46]. Interestingly, a recent study showed 
that TSC expression in neurons regulates OL differentiation via neuronal connective tissue 
growth factor (CTGF) [17]. These studies indicate complex interactions among neurons and 
OLs. Furthermore, Li et al (2017) showed an increase in astrocyte proliferation in cells de-
rived from their TSC2 patient iPSCs, and therefore it would be interesting to see the effects 
of neuronal co-culture on astrocyte proliferation.
 The increased OL proliferation in patient neuron-OL cultures was suppressed by 
Rapa treatment. While these results support Rapa treatment to normalize OL defects in 
patients, the treatment regimen need further study, as earlier reports showed that both in-
creased and decreased mTOR pathway activation negatively affects OL maturation [42, 47]. 
Guana, an antihypertensive drug, was shown to prevent OL cell death and to induce partial 
rescue of myelination defects by altering mTOR-related ER stress via inhibiting Gadd34-
PP1 phosphatase [9]. However, we did not find significant changes after Guana treatment. 
Hence, mixed neuron-OL populations represent TSC phenotypes in OL populations, there-
by providing physiological models to study therapeutic effects of mTOR regulators. 
 In summary, we have used new TSC iPSC-based cell models to show: 1) common 
neuronal defects caused by both autosomal dominant TSC1 and TSC2 mutations in a pa-
tient genetic background; 2) complex neuron-OL interactions in TSC phenotypes; and 3) 
therapeutic effects of compounds such as mTOR regulator Rapa, IGF1 and Guana. This new 
model opens future prospects for the development of disease relevant cell-based assays that 
capture the complex brain interactions underlying TSC and other mTOR-mediated neuropa-
thies. 
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4.6 Supplement figures
Fig S1 – Characterization of TSC patient iPSCs. Characterization of hiPSCs derived from controls (A) 
C1 (hVS-88), (B) C2 (hVS-228), (C) C3 (hVS-421) and TSC patient hiPSC lines (D) P1A (hVS-233; 
Clone A of P1), (E) P1B (hVS-248; Clone B of P1) and (F) P2 (hVS-417) using pluripotency markers 
OCT 3&4, SSEA4, TRA-1-60, TRA-1-80 and alkaline phosphatase. Scale bars of immunocytochemis-
try images and bright field alkaline phosphatase images (last column) are all 100 µm.
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Fig S2 – Western blot analysis of TSC proteins in NES cells. (A) Western blot quantification of (B) 
TSC1 and (C) TSC2 proteins in neuroepithelial stem cells. Individual points indicate the average val-
ues of the different patients (P1B, P2) and controls (C1, C2, and C3).
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Fig S3 – Neuronal properties of Std+IGF1 condition. (A) Schematic of neuronal differentiation 
protocol explaining time line and growth factors added at specific time point for Std + IGF1 (10ng/
ml) condition. (B-E) Immunochemistry of axonal marker SMI312, nuclear marker DAPI, dendritic 
marker MAP2 and pre-synaptic marker Synaptophysin1 in control and patient neurons with Std and 
Std+IGF1 conditions at day 56. Representive traces of calcium influx measured using Flouro-5 dye 
in one field of view (FOV) of C1 (F) and P1A (G) under culture condition Std + IGF1. (H) Total 
axonal density, (I) soma size, (J) total dendritic density per soma and (K) no. of synapses per soma 
measured from Std+IGF1 conditions. (L-N) Average calcium event frequency, event area and event 
amplitude of 2 patients (n=2-4 differentiations each for P1A, P1B and P2) and 3 controls (n=2-4 
each for C1, C2 and C3) in Std + IGF1 condition. (O) Total number of neurons present in control and 
patient lines. Statistical differences in graph L including Std, Std+Rapa was obtained using one-way 
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ANOVA with p<0.0 001. All scale bars are 50 µm.
Fig S4  – Effects of Guanabenz on axonal density, hypertrophy, OL proliferation, and maturation in 
neuron-OL co-cultures. (A) Schematic of neuron-glial co-cultures explaining time point of neurons 
and glial cells with different growth factors involved in the Std+Guana conditions. (B) Axonal densi-
ty, (C) soma size (D) MBP/ OLIG2 ratio and (E) OLI2/ DAPI ratio in co-cultures under Std+Guana 
condition. Statistical differences of all groups including Std, Std+Rapa in Fig 4, 5 were obtained for 
graphs B, D and E using one-way ANOVA where **** is p<0.0001 and * p<0.05. (F) Total number 
of cells in all co-cultures including Std, Std+Rapa groups shown in Fig 4, 5 as measured by DAPI 
staining. Average levels for groups were obtained from total n=4-9 experiments using C1, C2, P1, P2 
for neurons and C1, C2, P1 for OLs.
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5.1 Abstract
 Human iPSC studies create the opportunity to study human disorders in cells with 
native (patient-own) genetic background and to design regenerative cell therapies. In the 
current study, iPSC-derived cell transplantation was used to model Tuberous Sclerosis Com-
plex (TSC) disease phenotypes. TSC patient iPSC-derived neurons and oligodendrocyte 
(OLs) precursors were co-transplanted in immunocompromised RAG-null mice in vivo. 
Transplanted control human neural precursors incorporated GFP labelled neurites into the 
mouse brain and expressed neuronal and synaptic markers. Co-transplantation of control iP-
SC-derived oligodendrocytes and neurons led to adundant incorporation of OLIG2-positive 
oligodendrocytes and GFP neurites 2.5 months post engraftment. Co-transplantated neural 
precursors and oligodendrocytes from a TSC patient had longer neurites and excessive ol-
igodendrocyte proliferation when compared to controls. In conclusion, human iPSC-de-
rived neurons matured in vivo, and co-transplanted neural precursors and oligodendrocytes 
showed cellular abnormalities in TSC neurons and oligodendrocytes. This in vivo TSC model 
could be used in the future to assess cell properties like proliferation, morphology in native 
(brain) tissue and specifically features which are hard to model in vitro, e.g., myelination. 
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5.2 Introduction
 Human induced pluripotent stem cells (iPSCs) provide a platform to model diseases 
better than human embryonic stem cells (ESCs) due to the fact that these cells have the same 
genetic background as patients. Furthermore, iPSC technology avoids immune rejections 
when used in transplantation therapies. So far, iPSCs have been successfully used to model 
several neurodevelopmental and neurodegenerative disorders in vitro [1-4]. In addition, 
in vitro iPSC-based models are of interest for drug development, since newly developed 
drug effects can be studied in vitro on defective neural cell types derived from patient iP-
SCs [5, 6]. However, iPSC-derived in vitro cultures lack to provide a natural brain in vivo 
microenvironment. Human iPSC-derived neural cells integrate well and survive for long 
periods after grafting in mouse brains [7-10]. Various studies showed the potential of iPSCs 
in regenerative therapy, where iPSC-derived cells were shown to improve phenotypic de-
fects and life span in rodent models [11-14]. The potential of transplantation techniques to 
improve specifically either neuronal or glial cell based disease phenotypes [12, 15] is also 
shown. These transplantation studies on rodent models created a platform for future cell 
replacement therapies for human neurodegenerative disorders. Interestingly, a recent study 
generated humanized glial chimeric mouse using schizophrenia patient iPSCs, which gave 
new insights into possible glial pathology in schizophrenia patients [16]. Furthermore, hu-
manized mouse models generated using human iPSC-derived neural progenitors, provide 
opportunities to study structure, and properties of human neurons in vivo [17]. Overall, 
these studies gave prospects for human iPSC disease modelling in a complex, but probably 
more natural and relevant in vivo microenvironment. 
 TSC is known to exhibit both neuronal and glial defects: neuronal morphological 
defects like excess neurite outgrowth, abnormal dendritic arborization as well as glial de-
fects like astrocyte hypertrophy and hypomyelination.[18]. Although, two human stem cell-
based in vitro models for TSC have been developed, defects like myelination are so far not 
explored and are unachievable to model in in vitro culture systems. The current engraftment 
study shows transplantion of neural subtypes derived from iPSCs. Since disease phenotypes 
often involve changes in several cell types the (abnormal) cellular interactions might be 
a central aspect of such disease phenotypes [19-21]. Increasing evidence indicates that 
in neurological disorders, glial defects contribute to neuronal dysfunction as well as vice 
verse [22-24]. As also discussed earlier engraftment studies show improvements in congen-
ital hypomyelination and shiverer mouse models, due to myelination of engrafted human 
iPSC-derived OLs [11, 25]. Similarly, human iPSC-derived OLs and rat primary OLs have 
been shown to myelinate rat dorsal-root ganglion (DRG) neurons and nanofibres in in vitro 
cultures [26, 27]. However, we lack in vitro culture systems to model myelination of human 
neurons by human OLs. Therefore, to model this, 3D mini-brain organoids or humanized 
rodent models are promising options. Hence, co-transplantation of patient iPSC-derived 
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neuronal precursors and OLs to create humanized rodent models provides new tools to 
study multiple human neural cell defects involved in diseases like TSC. 
 The aim of this study was to generate an in vivo disease model for TSC using patient 
iPSC-derived cells. To this end, and include multiple affected cell types in TSC, we co-trans-
planted both neuronal precursors and OL lineage cells derived from control and TSC patent 
iPSCs in an immunocompromised mouse model. Human iPSC-derived neurons and OL 
precursors distributed and integrated into mouse brain. The neural precursors matured into 
cortical excitatory-inhibitory neurons post engraftment. In line with earlier findings in TSC, 
the patient cells showed increased neurite outgrowth [28] and excessive OL proliferation 
[24]. In summary, TSC patient derived neurons and OL showed potential to mimic disease 
phenotypes in vivo after transplantation. Current in vivo disease model for TSC shows ad-
vanced iPSC applications to study brain cells in human neurological disorders. 
5.3 Materials and methods
5.3.1 Cell cultures
TSC patient (Patient 1: GM06149) fibroblasts were obtained from Coriell Biorepository and 
control (C1) fibroblasts from anonymous control donor. iPSC reprogramming was done 
based on polycistronic construct with OCT3/4, c-MYC, SOX2 and KLF4 [29]. All the iPSC 
lines were cultured in Essential 8 medium (GIBCO) on Geltrex (GIBCO). Generation of neu-
ronal precursors from C1 and Patient one clone B (P1B) was performed as described earlier 
[30]. For neuronal injections, day 19 precursors were injected. For neuron-OL injections, 
day 19 neurons were transfected with a lentiviral construct with a synapsin promoter driving 
GFP expression and transplanted at day 25. Glial cells were obtained as described previous-
ly [31]. Around day 60-65 OL/glial progenitors were passaged with accutase (Millipore) and 
prepared for transplantation. 
5.3.2 Transplantation
The local ethical animal committee approved the experimental procedures. Neuronal pro-
genitors (day 19) were dissociated into 50,000 cells in a cell suspension of saline with 
DNAse1 (100µg/ml) per injection. For mixed neuron-OL day 25 GFP labelled neuronal pro-
genitors and day 60-65 OL progenitors from control (C1) and TSC patients (P1B) were dis-
sociated into a 1:1 ratio cell suspension of 40,000 cells in saline with DNAse1 per injection 
of 0.4µl. Injections were done in the striatum and cortex of P0 RAG2-null mice (Taconic). 
P0 mice were placed on clay mold to keep them from moving, cryo-anaesthetized for ap-
proximitely 7 minutes before the injections in the striatum and cortex. The cortex injections 
were bilaterally at the level of the lambda to about ± 1.6mm from the midline and -0.3mm 
depth. The striatum injections were bilaterally at -2.3mm from lambda, at ±1.0 to 1.1mm 
from the midline and -0.7 to -0.8mm depth. For analysis at 2.5 and 4 months post injection, 
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animals were anaesthetized and sacrificed by transcardial perfusion with 4% PFA and the 
collected brains were cryopreserved with 30% sucrose (embedded in OCT; Tissue Tek) for 
immunofluorescence analysis. Brain sections were cut at a thickness of 12 µm using a Leica 
cryostat with 3 sections per slide and used for immunofluorescence analysis. 5 series of 3 
sections was analyzed for neuron-OL groups quantifications. 
5.3.3 Immunohistochemistry
For immunohistochemistry, slides were washed with PBS (6 times for 5 minutes each in 
PBS 1X); optionally treated for 2 minutes Citrate buffer (0.01 M; pH 6) for antigen retrieval 
followed by washing in PBS (5 minutes for 1 time). The slides were then incubated in block-
ing buffer (5% NGS, 0.1% BSA, 0.3% TritonX-100 in PBS 1X) for 1 hour at RT, followed by 
primary antibody in blocking buffer for 30 minutes at RT and then overnight at 4oC. Next 
day after washing again with PBS (6 times for 5 minutes each in PBS 1X) the slides were 
incubated with secondary antibody in blocking buffer for 2 hours and were mounted with 
Flouromount G (Southern Biotech) and glass coverslips (VWR). Primary antibodies used 
were Neurofilament (#8135, Abcam), MAP2 (#5392, Abcam), Synaptophysin1 (#101-004, 
SYSY), OLIG2 (#9610, Millipore), HN (#1281, Millipore) and GFP (#1020, Aves labs). Im-
ages were acquired using either a Carl Zeiss 510 Meta confocal microscope with 40x (1.2 
Numerical Aperture (NA)) oil objective or Leica DM6000B fluorescent microscope with 5x, 
10x, 20x and 40x magnifications. 
5.3.4 Cell property analysis
Cell properties like GFP neurite density, number of OLIG2-positive and HN-positive cells 
were all measured using Columbus 2.5 online software. Precisely, images acquired with 
Confocal and Fluorescent microscope were analysed with algorithms for morphology, soma 
recognition and co-localization tool using pixel density measurement and number of ob-
jects present, respectively. 
5.3.5 Statistical analysis
All the statistical analysis was performed using Prism 7 software. The raw data was analyzed 
using unpaired two-tailed t-test. 
5.4 Results
5.4.1 Network of human iPSC-derived neurons at 2.5 months post 
engraftment
 To examine the ability of human neuronal precursors produced in vitro to integrate 
into mouse brain and mature in vivo, we transplanted control iPSC-derived mixed cortical 
neuronal cells (day 19) into the striatum and neocortex of immunocompromised RAG2-null 
mouse. At 2.5 months post-transplantation, the transplanted animals were transcardially 
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perfused with PFA and brain sections were made to examine survival and cellular incor-
poration of neuronal precursors. Three mice were selected randomly and 5 series of slides 
were taken per animal and stained for a human nucleus (HN) marker, the dendritic marker 
MAP2, the neuronal marker neurofilament (NF), and the synapse marker synaptophysin1. 
HN-positive cells were abundant both at the transplanted site and in other brain regions like 
caudate putamen and olfactory bulb. Specifically in the cerebral cortex (Fig 1A) and olfacto-
ry bulb (Fig 1B) regions with dense HN-positive cells and regions with no HN-positive cells 
were found. Brain regions consisted of densely populated HN-positive cells. These cells 
were positive for MAP2 (Fig 1C) and were surrounded by abundant neurofilament and syn-
aptophysin1 staining (Fig 1D). Expression of GABAergic and glutamatergic synapse markers 
(VGAT and VGLUT1) was observed (data not shown), but this staining was sparse at this 
stage. These results show that after 2.5 months, transplanted iPSC-derived cells adundantly 
express the mature neuronal marker MAP2, had incorporated in the mouse brain and had 
migrated to other brain regions like caudate putamen and olfactory bulb. 
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Fig 1 – In vivo integration of control human neural precursors after 2.5 months. (A) Overview of 
HN-positive cells in the cerebral cortex and (B) olfactory bulb of the mouse brain, (C) HN-positive 
cells showing MAP2 expression and (D) NF expression with NF filaments co-localizing with Synap-
tophysin1 puncta. Scale bars in A, B are 50 µm and C, D are 25 µm.
5.4.2 Human iPSC-derived neuronal precursors mature into excitatory-inhib-
itory neurons at 4 months post engraftment
 To examine the ability of in vitro produced human neuronal precursors to mature 
into inhibitory and excitatory neurons in vivo; we analyzed transplanted control iPSC-de-
rived mixed cortical neurons at 4 months post-transplantation. The analysis of the grafted 
animals showed migration of HN-positive cells into the cerebral cortex (Fig 2A), caudate 
putamen and olfactory bulb. Brain regions were incorporated densely with human cells 
(HN-positive), which also expressed MAP2 (Fig 2C). The HN-positive cells also expressed 
the glutamatergic synaptic protein VGLUT1 (Fig 2D), the GABAergic synaptic protein VGAT 
(Fig 2F), as well as mature GABAergic marker GAD65&67 (Fig 2E). These brain regions with 
HN-positive cells also showed abundant neurofilament and synaptophysin1 (Fig 2B) stain-
ing. Taken together, these results show that at 4 months after transplantation, the iPSC-de-
rived neuronal precursors matured into neurons expressing MAP2 and mature GABAergic 
and glutamatergic markers. 
Fig 2 – In vivo integration of human neural precursors 4 months post transplantation. (A) HN-/
DAPI-double positive cells in cerebral cortex. (B) NF-positive filaments co-localized with synapto-
physin1 puncta and (C) HN-positive cells showing MAP2 expression. (D) VGLUT1, (E) GAD65/67 
and (F) VGAT positive staining of soma’s which also show HN-/MAP2-double positive staining. Insets 
represent magnifications. Scale bars are 20 µm.
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5.4.3 Differential maturation of human neural precursors at 2.5 and 4 months 
post transplantation
 To confirm that iPSC-derived neuronal precursors still mature between 2.5 and 4 
months post transplantation, we analyzed the presence of early neuronal precursor cells 
using the established neural stem cell marker PAX6 [32] (Fig 3A, B). Between 2.5 and 4 
months post transplantation the number of PAX6-positive cells decreased considerably (Fig 
3A, B). After 2.5 months, in all brain regions containing grafted HN-positive cells, such as 
cerebral cortex, caudate putamen and olfactory bulb, we observed rosette-like PAX6-ex-
pressing cells. At 4 months post transplantation the rosette pattern was diminished and the 
number of PAX6-positive cells was considerably reduced. While cells expressed HN- and 
PAX6-double positive staining several HN-positive cells, which did not express PAX6 were 
also present indicating more mature cells (Yellow inset Fig 3A). Overall, a decrease in PAX6 
expressing neuronal precursors and diminished rosette-like morphology of neural precur-
sors was observed between 2.5 and 4 months post transplantation. 
Fig 3 – Expression of PAX6-positive neural precursors at 2.5 and 4 months post transplantation. (A) 
At 2.5 months, the caudate putamen showed HN-/PAX6-positive cells in rosette-like morphology; 
(B) At 4 months post transplantation, the HN-positive cells in the olfactory bulb showed diminshed 
rosette morphology and less PAX6 expression. White inserts zoom of A, B; yellow insert zoom of HN 
and PAX6 stainings. Scale bars are 50 µm.
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5.4.4 Incorporation of human iPSC-derived neurons and oligodendrocytes 
post engraftment
 To examine human neuron-OL incorporation in vivo, we co-transplanted control 
iPSC-derived mixed cortical neuronal cells and OL precursors (CN + CO group) into the 
striatum and neocortex of immunocompromised RAG2-null mice. To discriminate human 
neurons from mouse neurons and OL precursors, the human neuronal precursors were 
transfected with a Synapsin-GFP viral construct before grafting, to track the neurites of hu-
man neurons. HN-/GFP-positive neurons and HN-/OLIG2-positive OLs were distributed in 
several brain regions including ceberal cortex (Fig 4A, B), caudate putamen and olfactory 
bulb (data not shown). Projections of GFP-positive neurites into neighboring regions were 
observed (data not shown). These data show that the iPSC-derived neurons and OLs incor-
porated into several brain regions.
5.4.5 TSC patient iPSC-derived neurons and OLs have altered properties in 
vivo   
 To investigate possible differences in cell properties between TSC and control neu-
rons and OLs, we co-transplanted iPSC-derived neurons and OLs of a TSC patient (P1B) 
obtained as described in chapter 4. We analyzed these mice at 2.5 months post transplan-
tation (Fig 4C, D) in CN + CO versus PN + PO groups for total HN cells present (116±38 
and 49±4). To study axonal outgrowth, we measured the length of GFP-positive neurite pro-
cesses of control and TSC-patient HN-positive cells in the cerebral cortex, caudate putamen 
and olfactory bulb. The HN-positive soma’s co-localizing with GFP staining was quantified 
as individual neurons. The number of GFP-positive neuronal soma per field of view (FOV) 
in control and patient groups was 37±7 and 19±1 indicating higher amount of neurons in 
control cells. Although, the ratio of total number of neurons as calculated by ratio GFP-so-
ma/HN in the 2 groups was approximately equal with 0.44±0.03 and 0.48±0.1 for PN + PO 
and CN + CO (Fig 4E). The number of OLIG2 positive cells per FOV for control and patient 
groups was quantified as 9±3 and 16±3. Next, to quantify number of OLs in relation to total 
HN cells present, the OLIG2-/HN-double positive somata was quantified. A significant in-
crease (p<0.02) in number of TSC OLs in the PN + PO (0.33±0.02) group compared to CN 
+ CO (0.12±0.03) (Fig 4F) was observed. Neurite length of human neurons, as measured 
using GFP pixel density/ GFP soma per FOV (Fig 4G) of patient neurons with patient OLs 
(PN + PO; 7349±1247) was significant higher (p<0.02) than control neurons with control 
OLs (CN + CO; 3504±233). These results indicate that TSC neurons show excessive neurite 
outgrowth and TSC OLs show increased proliferation compared to controls cells in vivo.
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Fig 4  – TSC patient iPSC-derived co-transplants show increased neurite length and OL precur-
sor proliferation. At 2.5 months post-transplantation, incorporation of HN-positive and HN-/OL-
IG2-double positive cells and GFP neurites in both (A) control neuron + control OL (CN + CO) and 
(C) patient neuron + patient OL (PN + PO) groups were quantified. (B, D) Insets show zoom images 
of regions in A and C. (E) Quantification of total number of GFP positive neuronal soma/ HN-Soma 
between CN + CO and PN + PO, (F) OLIG2/HN positive cells and (G) total GFP neurite length/ 
GFP neuronal soma in cortex and olfactory bulb. Neurons and OLs derived from one control (C1) 
and one patient (P1B) iPSC line were used from one differentiation. For groups CN + CO and PN 
+ PO, 2 and 3 animals were used, respectively with n=5 slides and 3 sections per slide. Significant 
differences were obtained using unpaired two-tailed t test with p<0.02.
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5.5 Discussion
 The brain microenvironment consists of components like blood vessels, ECM and 
microglia [33], which supports long-term survival, maturation and functioning of the resid-
ing neural stem cells [33, 34]. Therefore, in vivo human iPSC applications hold potential in 
disease modeling by facilitating longterm survival and provide multiple-cell interactions in 
brain microenvironment to the transplanted iPSC cell products. To assess iPSC cell proper-
ties in vivo, we co-transplanted a mixed population of control or TSC iPSC-derived neurons 
and OLs. The control neuronal cells and control OL (OLIG2-positive) cells showed spreaded 
distribution in different brain regions. Neuron-OL engraftments from a TSC patient showed a 
significant increase in neurite length and OL proliferation compared to control iPSC-derived 
grafts. These observations indicate presence of typical TSC phenotypes as found earlier in 
other TSC model systems including TSC patient iPSC-derived in vitro model in chapter 4 of 
this thesis and therefore support the use of hiPSC in vivo engraftment as a disease model. 
 The neural precursors transplanted into neocortex and striatum of P0 mice remained 
in cerebral cortex regions and also migrated to other brain regions like caudate putamen 
and olfactory bulb. A decrease in PAX6 expression and rosette-like pattern appearance was 
observed between 2.5 and 4 months old mice indicating maturation of the transplanted 
neural precursors over time. At both 2.5- and 4-month stages the abundant groups of HN 
cell soma’s were also positive for neuronal marker MAP2, indicating that a higher amount 
of transplanted neural precursors differentiated into neurons. Although, it should be taken 
into consideration that regions with large number of HN cells were, often surrounded by 
no HN-positive cell regions suggesting limited incorporation in the host brain. Although, 
regions with HN and MAP2 staining also expressed synaptic markers like synaptophysin1 
end stage GABAergic markers like GAD65/67 were only present at 4 months post trans-
plantation indicating more mature state. Specifically, at 4-month stages several HN-positive 
somas were found double positive for synaptic markers like VGAT and VGLUT1, indicating 
that the synaptic marker expression in regions of HN-positive cells could be expressed by 
the human neurons in those regions. Furthermore, this also indicated that neural precursors 
matured into both excitatory and inhibitory cells as described in in vitro cultures of chapter 
3 [30]. Therefore, the transplanted neural precursors matured over time and formed both 
GABAergic and glutamatergic neurons in vivo. 
 The transplantated population of GFP-labelled neuron-glial precursors migrated to 
different brain regions and showed distribution of cells. Interestingly, the total length of neur-
ite outgrowth in PN + PO group was significantly higher than CN + CO groups, although the 
number of GFP positive soma (neurons) was double in control groups (CN + CO) compared 
to patient (PN + PO). Moreover, a ratio of GFP /HN-positive cells in FOV indicated presence 
of similar ratio of neurons present amongst the total human cells. Next, the number of OL 
precursors per FOV showed an abundant increase both when OLIG2-positive cells were 
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counted as well as in the ratio of OLIG2/HN-positive cells. This is in line with earlier study 
that showed an increased in OL precursors (OLIG2-positive cells), caused decreased OL 
maturation (MBP-positive cells) and lead to hypomyelination in a TSC mouse model [24]. 
Finally, the total number of HN-positive cells present in control groups was much higher 
than TSC groups, although the intial amount of transplanted total neural and glial precursors 
was same. This could also denote presence of more astrocytes in the glial populations of 
controls groups since both control and TSC glial cultures show GFAP-positive cells in vitro 
(data not shown), Overall, these transplantation experiments showed the potential of TSC 
iPSC-derived neuronal and OL cells to mimic TSC disease phenotypes in vivo. However, the 
functional/ relative maturity of these cells to in vitro cells and human brain stages still needs 
to be assessed. 
 This study provided a platform for future studies to perform co-transplatation of dif-
ferentiated neuronal and OL cells. Preliminary results from the current in vivo model show 
that the co-transplanted neuronal and OL precursors dictribute well in the mouse brain and 
express mature neuronal markers and OLIG2, an early marker for OLs. While these mice 
were studied only at the age of 2.5 months post transplantation, longer endpoints would 
be necessary to assess potential of in vivo myelination assays of the OL cells. Indeed, while 
cell replacement therapies are a common approach in neurological diseases, using iPSCs 
for in vivo disease modeling is a relatively new approach. In conclusion, this study will help 
generate humanized rodent models for neurodevelopmental disorders using patient iPSCs 
and also provides new opportunities in the future for drug development. 
5.6 Acknowledgements
 We thank Prof. Eleonora Aronica for providing TSC patient material. We thank 
Nina Straat and Joke Wortel for helping with transplantations. We thank Nicole Breeuws-
ma for helping with immunohistochemistry. This study was supported and funded by Am-
sterdam Neuroscience and EU MSCA-ITN CognitionNet (FP7-PEOPLE-2013-ITN 607508). 
VMH was supported by ZonMw VIDI research grant (91712343), E-Rare Joint Call project 
(9003037601) and an European Leukodystrophy Association (ELA) Research Grant (2014-
012L1).
Chapter 5
143
5.7 Bibliography
1. Ebert, A.D., et al., Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature, 
2009. 457(7227): p. 277-80.
2. Marchetto, M.C., et al., A model for neural development and treatment of Rett syndrome using human 
induced pluripotent stem cells. Cell, 2010. 143(4): p. 527-39.
3. Almeida, S., et al., Modeling key pathological features of frontotemporal dementia with C9ORF72 
repeat expansion in iPSC-derived human neurons. Acta Neuropathol, 2013. 126(3): p. 385-99.
4. Miller, J.D., et al., Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell 
Stem Cell, 2013. 13(6): p. 691-705.
5. Tanaka, T., et al., In vitro pharmacologic testing using human induced pluripotent stem cell-derived 
cardiomyocytes. Biochem Biophys Res Commun, 2009. 385(4): p. 497-502.
6. Choi, S.M., et al., Efficient drug screening and gene correction for treating liver disease using pa-
tient-specific stem cells. Hepatology, 2013. 57(6): p. 2458-68.
7. Tornero, D., et al., Human induced pluripotent stem cell-derived cortical neurons integrate in 
stroke-injured cortex and improve functional recovery. Brain, 2013. 136(Pt 12): p. 3561-77.
8. Payne, S.L., et al., In Vitro Maturation of Human iPSC-Derived Neuroepithelial Cells Influences Trans-
plant Survival in the Stroke-Injured Rat Brain. Tissue Eng Part A, 2017.
9. Qian, K., et al., Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo. Stem Cell Reports, 
2017. 8(4): p. 843-855.
10. Tom, C.M., et al., Survival of iPSC-derived grafts within the striatum of immunodeficient mice: Impor-
tance of developmental stage of both transplant and host recipient. Exp Neurol, 2017. 297: p. 118-128.
11. Wang, S., et al., Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a 
mouse model of congenital hypomyelination. Cell Stem Cell, 2013. 12(2): p. 252-64.
12. Kondo, T., et al., Focal transplantation of human iPSC-derived glial-rich neural progenitors improves 
lifespan of ALS mice. Stem Cell Reports, 2014. 3(2): p. 242-9.
13. Nizzardo, M., et al., Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural 
stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. Hum Mol Genet, 
2014. 23(2): p. 342-54.
14. Hallett, P.J., et al., Successful function of autologous iPSC-derived dopamine neurons following trans-
plantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell, 2015. 16(3): p. 269-74.
15. Wernig, M., et al., Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal 
brain and improve symptoms of rats with Parkinson’s disease. Proc Natl Acad Sci U S A, 2008. 105(15): p. 
5856-61.
16. Windrem, M.S., et al., Human iPSC Glial Mouse Chimeras Reveal Glial Contributions to Schizophre-
nia. Cell Stem Cell, 2017. 21(2): p. 195-208 e6.
17. Chen, C., W.Y. Kim, and P. Jiang, Humanized neuronal chimeric mouse brain generated by neonatally 
engrafted human iPSC-derived primitive neural progenitor cells. JCI Insight, 2016. 1(19): p. e88632.
18. Meikle, L., et al., A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and 
ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci, 2007. 27(21): p. 
5546-58.
19. Seifert, G., K. Schilling, and C. Steinhauser, Astrocyte dysfunction in neurological disorders: a molec-
ular perspective. Nat Rev Neurosci, 2006. 7(3): p. 194-206.
20. Barres, B.A., The mystery and magic of glia: a perspective on their roles in health and disease. Neuron, 
2008. 60(3): p. 430-40.
21. Ricci, G., et al., Astrocyte-neuron interactions in neurological disorders. J Biol Phys, 2009. 35(4): p. 
317-36.
22. Nave, K.A., Myelination and support of axonal integrity by glia. Nature, 2010. 468(7321): p. 244-52.
23. Kaminsky, N., et al., Connecting Malfunctioning Glial Cells and Brain Degenerative Disorders. 
Chapter 5
144
Genomics Proteomics Bioinformatics, 2016. 14(3): p. 155-165.
24. Ercan, E., et al., Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous 
sclerosis complex. J Exp Med, 2017. 214(3): p. 681-697.
25. Douvaras, P., et al., Efficient generation of myelinating oligodendrocytes from primary progressive 
multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Reports, 2014. 3(2): p. 250-9.
26. Lee, S., et al., A culture system to study oligodendrocyte myelination processes using engineered na-
nofibers. Nat Methods, 2012. 9(9): p. 917-22.
27. Ehrlich, M., et al., Rapid and efficient generation of oligodendrocytes from human induced pluripo-
tent stem cells using transcription factors. Proc Natl Acad Sci U S A, 2017. 114(11): p. E2243-E2252.
28. Choi, Y.J., et al., Tuberous sclerosis complex proteins control axon formation. Genes Dev, 2008. 
22(18): p. 2485-95.
29. Warlich, E., et al., Lentiviral vector design and imaging approaches to visualize the early stages of 
cellular reprogramming. Mol Ther, 2011. 19(4): p. 782-9.
30. Nadadhur, A.G., et al., Multi-level characterization of balanced inhibitory-excitatory cortical neuron 
network derived from human pluripotent stem cells. PLoS One, 2017. 12(6): p. e0178533.
31. Izrael, M., et al., Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on 
phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci, 2007. 34(3): p. 310-23.
32. Curto, G.G., et al., Pax6 is essential for the maintenance and multi-lineage differentiation of neural 
stem cells, and for neuronal incorporation into the adult olfactory bulb. Stem Cells Dev, 2014. 23(23): p. 2813-
30.
33. Dudvarski Stankovic, N., et al., Microglia-blood vessel interactions: a double-edged sword in brain 
pathologies. Acta Neuropathol, 2016. 131(3): p. 347-63.
34. Blouw, B., et al., The hypoxic response of tumors is dependent on their microenvironment. Cancer 
Cell, 2003. 4(2): p. 133-46.
Chapter 5
145
“Great dreams of great dreamers are always transcended.”
Dr. A. P. J. Abdul Kalam
Chapter 6
General discussion 
 Human pluripotent stem cells (hPSCs) provide an insight into human cell type func-
tions and give a unique opportunity for regenerative medicine. In 2012, the Nobel Prize in 
Physiology or Medicine was awarded to Prof. Shinya Yamanaka and Prof. John B. Gurdon 
for the discovery that mature cells can be reprogrammed into pluripotent stem cells (via 
the induced pluripotent stem cell (iPSC) and the somatic cell nuclear transfer technology). 
Henceforth, hiPSCs provided a platform to investigate cellular defects in patient-originated 
stem cells. To this date, many groups have used patient iPSC-based models to obtain spe-
cific cell types [1-5], isogenic controls from patient iPSCs [6] and gene editing on hPSCs to 
understand specific (disease) gene functions [7-9]. Nevertheless, we still lack iPSC-based 
disease models, which could aid the study of disease phenotypes involving multiple brain 
cells, e.g., human neuronal-glial cultures. The overall goal of this thesis was to generate 
appropriate disease models for Tuberous sclerosis complex (TSC), which is a rare autosomal 
dominant disease under autism spectrum of disorders (ASD). To achieve this we studied 
regional identity and cell properties of hPSC differentiation from neural progenitors (NPs) 
to mature cell stages, which included TSC patient iPSC-derived neurons and glial cells. 
Overall, in this thesis we aimed at analyzing the potential of patient iPSCs as a viable tool 
for modeling neurodevelopmental diseases like TSC. 
 In chapter 2, we assessed the variability amongst differently induced neuroepithelial 
stem (NES) cells or also called neural progenitors (NPs). The hPSC-derived NP/NES cells 
induced via different medium composition, growth factors and culture conditions showed 
differences in regional specificity and differentiation potential into neurons and astrocytes. 
In chapter 3, to model cortical neuronal development, we generated and characterized a 
low-density network of cortical excitatory-inhibitory neurons from hPSC-derived NES cells 
using multi-level analysis. Mixed cortical neuronal cultures showed markers of cortical up-
per to deep layer glutamatergic neurons and of ganglionic eminence-derived interneurons. 
The cultures showed excitatory and inhibitory neuronal synapses as well as functional activ-
ity. We further developed low cost co-culture models, which could help analysis of neurons 
and astrocytes with indirect contact. In chapter 4, we studied the potential use of TSC pa-
tient iPSCs in modelling TSC phenotypes in vitro. At the iPSC stage the cell lines from 2 TSC 
patients showed normal stem cell properties and reduced TSC1 and TSC2 protein expres-
sion. Patient-derived cortical neuron mono-cultures showed significantly increased network 
activity but no significant alterations in the morphological properties. Co-cultures of TSC 
neurons with TSC oligodendrocytes (OLs) showed an increased axonal density, hypertrophy, 
increased OL proliferation and reduced OL maturation compared to control neuron-OL 
groups. Overall, the TSC patient iPSC-derived neuron-glia cell cultures expressed multiple 
phenotypes of TSC in comparison to TSC neuron mono-cultures. Finally, in chapter 5 we 
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assessed the long-term survival, integration and cell properties of transplanted neuronal and 
OL precursors in an immunocompromised mouse model. Transplanted neuronal precursors 
incorporated and migrated to several brain regions and matured overtime into a network of 
inhibitory-exitatory neurons. The transplanted iPSC-derived neurons and glial cells showed 
increased neurite length and increased OL proliferation in vivo compared to controls and 
therefore supported the findings of the in vitro disease model. 
6.1 Modeling neurodevelopment in a dish 
6.1.1 Neural progenitor variability and regional identity
 Neuroepithelial stem (NES) cells in the neural tube comprise a heterogenous popula-
tion of NP cells with varied differentiation potential [10-12]. Gradients of patterning factors 
and mitogens like retinoic acid (RA), sonic hedgehog (SHH), fibroblast growth factors (FGFs), 
wingless-related integration side proteins (WNTs) and bone morphogenetic proteins (BMPs) 
influence differentiation and migration of these cells as discussed in chapter 1 (section 1.3). 
NP cells have been derived in the past by using these patterning factors in combination with 
different culture methods like non-adherent or adherent [13-16]. To assess the intricate dif-
ferences among the NPs generated by these various protocols, in this thesis we performed 
one of the first studies to directly compare NPs from 5 different induction protocols includ-
ing both adherent and non-adherent conditions (3 established and 2 adopted versions). 
An earlier study also compared 3 different induction mediums, yet only in non-adherent 
cultures [17]. Firstly, NPs from all induction protocols of the current study showed similar 
NP cell marker expression, but specific anterio-posterior and dorso-ventral regional iden-
tities. Typically when we used RA, an inducer of hindbrain and spinal cord development, 
the NES cells expressed the posterior hindbrain marker HOXB4 [14]. NP cells induced by 
all other conditions, not induced by RA, expressed midbrain marker OTX1 (Chapter 2; Fig-
ure 5). This is in line with earlier findings that in absence of regional patterning factors, like 
RA, cells are differentiated towards an anterior identity by default [12]. Interestingly B27 
supplement, which was used in most conditions and contains traces of RA (converted from 
vitamin A present in B27), was unable to induce hindbrain identity without supplementing 
additional RA. Similarly, radial glia/ neural crest identity with SOX9 expression was present 
in all neural induction conditions with FGF2 i.e., except dual SMAD (Chapter 2; Figure 2), 
in agreement with other studies showing that FGF2 induces SOX9 in primary chrondocyte 
and C3H10T1/2 cells [18]. These findings stand in contrast to the recent study by A.Chan-
drashekaran et al., where non-adherent induction with dual SMAD inhibitors comparable to 
dual SMAD procedure in current study, showed expression of SOX9-positive progenitors in 
approximately 8% of the NPs, although this increased to 12% in non-adherent dual SMAD 
inhibiton [19]. However, the type of culturing was adherent and the time point in compari-
son for expression of NP markers in the Chandrashekaran et al., study and the current study 
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dual SMAD NPs are different; P4 and P0, respectively. The early radial glial marker, SOX9 
expression, was not necessary for astrocyte differentiation since dual SMAD induced NPs 
did not express SOX9 at precursor stages but were still able to generate GFAP, CD44- and 
S100b-positive astrocytes similar to other conditions that expressed SOX9 at NP stages. This 
is supported by a couple of earlier reports that suggest only subsets of astrocytes are derived 
from radial glia [20, 21]. Together, these findings suggest that NPs can differentiate into sim-
ilar populations of mature CNS cell types inspite of heterogeneity in regional markers. 
 Next, all the 5 different NP populations showed expression of assessed NP markers 
like SOX2, Nestin, PAX6, PLZF and ZO-1, although with different expression levels (Chapter 
2; Figure 2 and S1). Interestingly, NPs that adopt specific brain regional identities on course 
of differentiation continued to express these regional markers even at end-stages, like neu-
ronal and glial cell cultures (Chapter 2; Figures 3 and 4). Specifically, caudal and midbrain 
markers like HOXB4 and OTX1 expressed only in specific conditions and absent in others 
at NP stage, showed the exact expression/ absence pattern in astrocyte cultures (Chapter 
2; Figure 3 and 5). Interestingly, astrocyte cultures derived from the multiple NP inductions 
expressed all the tested astrocyte markers (Chapter 2; Figure 3). Similarly, expression of gan-
glionic eminence marker GSX2 was absent in single SMAD induced NPs and present in RA, 
dual SMAD inductions both at NP and neuronal stages (Chapter 2; Figure 4 and 5). Overall, 
this indicates that NPs carry their regional identity until mature cell stages and highlights 
the necessity to carefully select NP induction protocols based on requirement of regional 
identity in mature cells. 
 Finally, the NPs derived from non-adherent induction conditions (Chapter 2) ex-
pressed more NP markers (Chapter 2; Figure S1) and robust differentiation potential when 
compared to adherent conditions. This was in line with a study comparing dual SMAD in-
hibitors under adherent and non-adherent induction, where non-adherent induction yield-
ed higher amount of PAX6- and Nestin-positive NPs and longer neurites in neurons derived 
from them, however electrophysiological properties among the neurons were similar [19]. 
In line with this, NPs induced adherently by dual SMAD inhibitors in the current study 
showed significantly lower Nestin expression and did not generate SOX9-positive precur-
sors in comparison to non-adherent RA and dual SMAD inductions (Chapter 2; Figures S1 
and 2), yet were able to generate both cortical neurons and astrocytes. To compare other 
induction mediums under both adherent and non-adherent conditions, in the current study 
N2:B27 and FGF2 medium was assessed, where both showed similar NP marker expres-
sion. However these groups of NPs were unsuccessful in generation of neuronal and glial 
cell types. Therefore, induction capability of other effective groups of induction factors in 
addition to dual SMAD study [19] for instance neural induction conditions involving FGF2, 
RA, T3 and EGF under adherent conditions could give insights to variations caused by type 
of culturing on multiple patterning factors. Overall, the current experiments indicate that 
in addition to induction factors, adherent/ non-adherent culturing could also influence NP 
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induction.
6.1.2 Differentiation potential and adaptability
 This thesis investigated a protocol to derive a mixture of excitatory and inhibitory 
cortical neurons from dual SMAD inhibitors-induced NPs. Earlier, SMAD inhibitors in com-
bination with B27/RA were used to derive cortical excitatory neuronal cultures from iPSCs 
in 2D or 3D, which expressed cortical upper to deep layer markers like SATB2, TBR1, CTIP2 
and BRN2 [22, 23]. Other studies from Kuijlaars et al., and Xu et al., have derived cortical 
excitatory-inhibitory neuronal networks using SMAD inhibition, B27, SHH and RA-based 
inductions [24, 25]. These studies showed functional analysis of cultures for presence of 
GABAergic and glutamatergic neurons after 12 to 32 weeks in culture. Although, the for-
mer study did not show presence of any GABAergic lineage of markers [24], the later study 
showed expression of both lineages of markers [25] using immunocytochemistry (ICC). Next 
to that, the established protocols often derive sub-populations of glial cells in addition to 
cortical neurons. For example, parallel to the current study in Chapter 3, Xu et al., generated 
mixed cortical neuronal cultures with expression of GABAergic and glutamatergic lineage 
of markers, which also generated about 10% of the GFAP-positive cells [25]. This creates a 
limitation to study specific patient neuronal or glial properties in combination with control 
neurons/ glia. On the contrary, cortical neuronal cultures described in Chapter 3 were pure 
neuronal, as assessed by proteomic analysis (Figure 6) and showed balanced glutamatergic 
and GABAergic synapses (Figure 3). A combination of Vitamin A/RA with partial induction 
of sonic hedgehog (SHH) and Valproic acid (VPA) was used to derive both excitatory and 
inhibitory neuronal population [26]. The cultures expressed markers for glutamatergic iden-
tity in the cortical layers and ganglionic eminence (GE) interneuron lineages, and functional 
characteristics within 8 weeks when matured in the presence of rat astrocytes. Furthermore, 
the low-density made them more suitable for single cell analysis. Therefore, the cultures 
described in Chapter 3 generated a pure neuronal culture with balanced cortical excita-
tory-inhibitory cells suitable for disease models by enabling study of neuron-/glial-specific 
changes. 
 We also derived astrocytes from dual SMAD inhibitor-induced NPs (Chapter 2). 
While several neuronal induction protocols use SMAD inhibitors, they are less known for 
induction of glial-lineages. Since astrocytes support several aspects of brain development, 
it is not surprising that these cell types contribute to disease phenotypes [27-29]. Recent-
ly, a few new cell culture models involving astrocytes have been presented. An integrated 
3D organoid culture with upper to deep layer cortical neurons and non-reactive astrocytes 
was assessed electrophysiologically, and cells from this culture system were transcription-
ally mapped to in vivo fetal development [22]. Primary rat astrocytes supported an electro-
physiologically active long-term co-culture of human iPSC-derived neurons [30]. Similarly, 
co-cultures of primary human astrocytes supported maturation of iPSC-derived inhibitory 
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and excitatory neurons [24]. These studies cultured neurons and astrocytes in direct contact. 
However, to identify and study neuron-/ glial- specific changes, which influence each other 
under disease scenario, pure neuronal/ glial cultures are often desired at analysis stages. For 
instance co-culturing patient iPSC-derived neurons with control iPSC-derived astrocytes in 
indirect contact could reveal neuron specific defects and vice verse. To accomplish this, we 
adopted a cost-effective culture system for an indirect co-culture of pure neurons and pri-
mary rat astrocytes (Chapter 3; Figure S5). Comparison of these indirect contact co-cultures 
and direct contact cultures showed very similar functional characteristics (Chapter 3; Figure 
4 and 5). Perhaps, the indirect contact cultures were indicative that direct contact between 
neurons and glia is not necessary for functional maturation of neurons. Finally, in addition 
to studies of neuron-/astrocyte-specific changes, the indirect contact cultures could also 
be used to assess proteins secreted by neurons and astrocytes in disease conditions. Future 
studies could involve extension of co-culture protocols for studies on neuroinflammation in 
disorders like ALS [24], by including patient iPSC-derived microglial populations. 
6.2 Brain cell defects in TSC 
6.2.1 Cortical neuronal defects in TSC
 Cortical excitatory-inhibitory imbalance could be caused by a change in either glu-
tamatergic or GABAergic signaling [31]. During cortical development, complex mixtures 
of multiple lineages of developing neurons at different progenitor stages are present [32]. 
During maturation, the determined progenitors differentiate into subtypes with specific 
functions, thereby creating a network of functional cortical neurons. To study and model 
neurodevelopmental defects using patient iPSCs in culture, it is required to mimic this com-
plex network of developing neurons. The cortical neuronal cultures described in this thesis 
(Chapter 3) expressed developmental markers like CTIP2, SATB2, PROX1 and MEIS2 as well 
as mature markers like GAD65, HOMER1 and Calbindin. This made them suitable for stud-
ying neurodevelopmental defects in TSC, although these cultures also contained a subset of 
immature neurons. 
 Disturbances in cortical neuronal balance are suggested to underlie autism-like phe-
notypes, based on studies in animal models of ASD [33, 34], including TSC [35]. Specif-
ically in TSC, the mTOR, a central cellular pathway (negatively regulated by TSC protein 
complex) is hyperactivated due to loss of TSC proteins. In general the mTOR pathway via 
insulin and IGF1 is known to increase mRNA translation in neurons and thereby regulates 
dendritic spine formation, synaptogenesis, neurotransmission and cell growth in neurons 
[36-38]. Due to distorted mTOR signaling, altered neuronal properties like network activity, 
morphological defects in axons and dendrites are some major phenotypes reported in TSC 
rodent models [35, 39-41] and presence of these phenotypes are essential to establish hu-
man cellular disease models for TSC. So far only 2 studies have generated human TSC mod-
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els involving human PSCs. The first study from 2016 used Zinc finger-based gene editing, 
to create a hESC line with a heterozygous and homozygous deletion in TSC2 gene. These 
TSC-mutated hESC-derived cultures showed altered neural rosette formation, increased 
neuronal soma size, hyperactive mTOR pathway and increased neuronal network activity. 
The homozygously mutated neurons were severely defective, while these properties were 
only mildly affected in heterozygously mutated neurons [7]. However, this model does not 
substantiate as an appropriate disease model for TSC, since TSC patients carry autosomal 
dominant mutations (heterozygous). The second study from 2017 used TSC patient iPSCs 
carrying a heterozygous mutation in TSC2. The generated neuronal and astrocyte cultures 
showed altered NP properties, neurite growth, hypertrophy, hyperactive mTOR pathway and 
astrocyte proliferation [42]. While these studies show potential TSC disease models, they 
still lack investigation of neuron-glial interactions in TSC. To achieve this, a part of this the-
sis used TSC patient iPSCs to generate neuron-glial co-cultures in comparison to neuronal 
mono-cultures. 
 In Chapter 4, we described cortical neuronal mono-cultures generated from 2 TSC 
patient iPSCs carrying a mutation in TSC1, or TSC2 genes. Firstly, in comparison to the for-
mer 2 human cell models described, where authors show imparied neural rosette structure, 
organization [7] and hyperactive mTOR as well as increased proliferation in NPs [42], we 
found only a trend in reduction of TSC proteins at NP/ NES stages (Chapter 4; Figure S2). 
However, the patient iPSCs in the current model indeed showed a significant reduction in 
TSC proteins at iPSC stages (Chapter 4; Figure 1). Next, as also described in TSC mouse 
models [43] and TSC patient brain tissue [44] we found significant increase in axonal den-
sity in TSC patient neuron-OL co-cultures (Chapter 4; Figure 4), which were not observed 
in the neuronal mono-cultures (Chapter 4; Figure 3). This makes an emphasis to generate 
neuron-glia based model systems to study TSC defects in the future. Finally, in contrast to 
the existing human TSC models where either only neuronal morphological property [42] or 
synaptic transmission was studied using single-cell patch clamp [7] we were interested in 
network activity. Cortical neurons from both TSC patients showed significantly increased 
network activity than in controls as measured by spontaneous calcium influx and spiking 
activity. This was in line with a former TSC rodent model where TSC-KO neurons showed in-
creased network activity caused due to weakened inhibitory activity leading to imbalanced 
excitatory-inhibitory network as measured by MEAs [35]. Likewise, to the rodent TSC model 
[35] also in the current study addition of mTOR inhibitor rapamycin reduced network activ-
ity in both patients, yet not to control levels. Further experiments on quantifying NP prolif-
eration rate and mTOR pathway regulation in neurons is warranted to link TSC patient cell 
phenotypes of the current model to mTOR-TSC pathway dysregulation. Indeed, to confirm 
presence of disease mechanisms and robustness of drug effects, inclusion of other cortical 
neuron differentiation protocols is advised. Overall, in addition to other models described 
earlier, the TSC iPSC-derived cultures described in this thesis (Chapter 4) provide a good 
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model for studying neuronal and glial properties in TSC and emphasise on the need to study 
TSC phenotypes in complex neuron-glia environment.
6.2.2 Neuronal and glial models for TSC
 TSC involves both neuronal and glial abnormalities as described in surgically re-
moved TSC patient brain tissue [44], as well as rodent models [45-47]. Astrocytes regulate 
functions like neuronal maturation, activity, survival and plasticity, synaptic plasticity and 
function [48-51], as well as cortical synchronization [52] and are broadly studied in TSC 
pathology. Astrocytic abnormalities in TSC are shown to directly contribute to tuber forma-
tion and epilepsy [53]. Other astrocytic defects like subependymal giant cell astrocytoma 
(SEGAs) and giant cell astrocytoma [54-56] are reported in TSC. Furthermore, presence of 
hyperactive mTOR pathway in astrocytes of cortical tubers [56] and an increase in astrocyte 
numbers [42, 54] have been reported in rodent and human models. Therefore, astrocytic 
involvement in TSC pathology is related to presence of mTOR hyperactivity in this cell 
type, and is regulated after treatment with mTOR inhibitor rapamycin. Similarly, OLs that 
produce myelin sheath to protect axons and make neurotransmission more efficient [57] 
are also involved in TSC pathology [39]. Interestingly, neuron-specific deletion of TSC1 in 
a mouse model lead to hypomyelination [39]. Similarly, a very recent study showed that 
neuronal connective tissue growth factor (CTGF) negatively regulates myelination in a TSC 
mouse model [58]. Moreover, role of mTOR and PI3K/Akt/mTOR signaling in promoting OL 
differentiation, maturation and myelination has also been studied [59-61], yet mTOR dys-
regulation in OLs related to hypomyelination and OL related neuronal abnormalities in TSC 
are less explored, specifically in human models. Therefore, astrocytic and neuronal abnor-
malities in TSC as also described in section 6.2.1 are studied in multiple rodent and human 
models, however there is a lack for human models to study OLs and neuron-OL interactions 
leading to white matter defects in TSC. 
 In general to study neuron-OL interactions several cultures have been developed 
in rodent models or rodent-human co-culture models. While there are several cell culture 
models for deriving both neurons and astrocytes from the hPSCs in one culture, almost none 
explore the possibility of deriving a pure pool of mature human OLs and cortical neurons. 
The challenge in generating hPSC-derived combined neuronal and OL culture arise from 
the combination of growth factors required to mature the neurons and OLs, which differ. 
Although these cell types originate from neuroepithelium and the ventricular zone [62, 63], 
they are derived from distinct progenitor cells and need specific concentrations of pattern-
ing growth factors during development, as discussed earlier in Chapter 1. Several growth 
factors necessary for OL and neuron differentiation as also discussed in Chapter 1, sections 
1.3 and 1.4 are described in established iPSC differentiation protocols. Ciliary neurotrophic 
factor (CNTF), platelet-derived growth factor (PDGF) and neurotrophin-3 (NT3) are com-
Chapter 6
154
monly used in OL differentiation protocols [64, 65], where CNTF is known to increase OL 
proliferation [66], and PDGF [67] and NT3 are important for OL maturation [68]. While 
these factors are beneficial for OL generation, it is hypothesized that these factors might in-
terfere differentiation and maturation of NP cells into neuronal fates, for instance when used 
to generate neurons and OLs simultaneously from iPSC stages. Therefore, to develop new 
neuron-OL iPSC-based models, in a part of this thesis (Chapter 4) we generated OLs as well 
as neurons from young to mature stages separately by specific differentiation protocols. Fol-
lowing this phase, these cells were co-cultured together in maturation medium to support 
both neurons and OLs and to derive a complex network after 4 weeks. OL cultures that were 
generated using OL maturation factors still contained a sub-population of GFAP-positive 
astrocytes. While the human iPSC-derived neuron-OL co-cultures in Chapter 4 showed OLs 
expressing OLIG2, myelin basic protein (MBP) and neurons with expression of dendritic 
MAP2 and axonal SMI312 marker these cultures still face challenges. For instance, high 
density of cells in these cultures; 1) limit the accurate assessment of neurite branches, 2) 
caused detachment of cell clumps from the Geltrex coated culture plates in a few specific 
iPSC-derived cell lines. Furthermore, obtaining myelination of human OLs on human neur-
ites in these cultures in an extensive challenge, which is still unachievable in hPSC-derived 
cultures. To overcome these limiations 3D organoid cultures could be utilized, which pro-
vide 3-dimensional incorporation of cell types similar to an in vivo environment. 
 In summary, Chapter 4 of this thesis describes an iPSC-derived neuron-OL co-culture 
system for assessment of neuron- and OL-induced abnormalities in TSC. TSC OLs showed 
highest increase in proliferation rate and reduced maturation only when co-cultured with 
TSC neurons (Chapter 4; Figure 5). Similarly, TSC neurons showed highest increase in axon-
al density when co-cultured with TSC OLs, however all co-cultures with either TSC neurons 
or OLs exhibited hypertrophy (Chapter 4; Figure 4). Similar to abnormalities found in vitro, 
the network of transplanted TSC neurons and OLs showed significantly increased OL pro-
liferation and neurite length compared to controls (Chapter 5; Figure 4). Therefore, patient 
iPSC-derived in vitro and in vivo models in this thesis suggest that in TSC, cellular abnor-
malities in one cell type might lead to abnormalities in the other and were congruent with 
earlier rodent studies that showed neuronal loss of TSC protein lead to OL defects [39, 58]. 
6.3 TSC models for drug development 
 TSC neuronal mono-culture and neuron-OL co-culture abnormalities were rescued/
altered by drug treatments in the current study (Chapter 4). Rapamycin effectively rescued 
increased OL proliferation and hypertrophy in TSC neuron-OL co-cultures, although it af-
fected maturation of controls OL cells. This indicates that rapamycin induces positive effects 
on abnormal TSC cells, however it affects functions of control cells and therefore it is neces-
sary to investigate the appropriate/ effective drug concentrations for treatment in TSC. How-
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ever, treatment with rapamycin reduced the increase in network activity of TSC neurons but 
not to control levels. Treatment with rapamycin failed to rescue increased axonal density in 
neuron-OL co-cultures. Also, other mTOR regulators like Guanabenz, showed the poten-
tial to improve OL maturation in current co-culture model, as shown in TSC rodent model 
described earlier [69], and could be studied more extensively. Therefore, mTOR regulators 
showed either an ineffective, partially effective or fully effective rescue of various cellular 
abnormalities in the current human TSC model. Therefore, this co-culture model could help 
evaluate drug effects on neuronal as well as neuron-glial co-cultures with aspects of more 
than one affected brain cell type in TSC and would also facilitate selection of cell types for 
nano drug deliveries to rectify cell specific abnormalities in TSC patients. 
 TSC is a disorder involving variable disease severity [70-72]. Interestingly even pa-
tients within single kindred, where affected individuals carry the same mutation(s), suffer 
with variable disease severity and phenotypes [70, 71]. A cohort study identified allele-spe-
cific differences in TSC1 and TSC2 mRNA expression of normal individuals and predicted 
this as a source of variable disease severity and symptoms among TSC patiens [71]. It is 
identified that TSC2 gene mutations in patients; a) cause a more severe phenotype, b) pres-
ent with TSC phenotypes earlier than TSC1 patients and c) affects more organs than TSC1 
patients [72, 73]. Moreover, about two thirds of reported TSC cases are caused by sporadic 
mutations, where mosaicism could be present [74]; i.e., a condition where only a fraction of 
cells, rather than all carry a mutation. Mosaicism in TSC could again lead to different disease 
severity in multiple organs. Altogether, these population variations among the TSC patients 
could lead to major lags in appropriate drug discovery and therapy for TSC. This limitation 
could be overcome by two different strategies. First approach; personalized disease models 
for individual patients could be used, as also suggested in general by physicians, howev-
er this is a time consuming process and is not cost-effective. Both the patient lines (one 
TSC1 and TSC2 patient) used in the current study presented with abnormalities compared 
to controls, however deviations among the 2 patients indeed lead to overall non-significant 
quantification of certain phenotypic changes. Interestingly, two clones of the same patient 
(Patient 1) presented with considerably less variation and therefore for personalized disease 
models use of multiple iPSC clones from a single patient would be advisible. Second ap-
proach; use of larger cohorts of TSC and control iPSCs could help reduce population varia-
tion in the patient iPSC-derived cell types. 
 Overall, population variation in TSC is currently a major limitation in diagnosis as 
well as therapy, and use of personalized disease models and large cohorts of patient ma-
terial might help improve this and develop effective drugs for TSC. A working model of 
the demonstrations of this thesis on TSC disease modelling are presented in Figure 1 and 
suggestions for future experiments aimed at improving TSC disease models and therapy are 
discussed in the next section.  
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Fig 1 – Working model. Phenotypic defects of TSC patient iPSC-derived CNS cells and effects of 
rapamycin (Graphical abstract of A.G.Nadadhur et al., 2018; Under review).  
6.4 Future directions
 This thesis aimed at generating a TSC patient iPSC-derived disease model involv-
ing neuron-glial networks with prospects to test drugs and to improve therapy. It further 
highlights the necessity for studying each CNS cell subtype and neuron-glial interactions 
involved in TSC. Parts of this thesis focused on characterizing and understanding regional 
identity of NPs derived from hPSCs, and generating appropriate cortical neuronal culture 
models to study neurodevelopment. Followed by this we assessed abnormalities in TSC 
patient iPSC-derived neurons and finally we performed one of the first human co-culture in 
vitro studies to model neuron-OL abnormalities in TSC.
 Regional identiy of iPSC-derived cells can differ depending on multiple factors as 
discussed in Chapter 2, and differences in regional identity of the cells of interest could 
interfere with appropriate disease modelling. So, future studies would benefit from adapa-
tions and more in depth characterization of culture models. Firstly, assessment of the right 
NP populations in neurodevelopmental studies using iPSCs is necessary before improved 
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co-culture models could be generated. Variations in regional specificity of NPs can affect 
the identity of mature cell types. For example, although astrocytes derived from different NP 
inductions looked morphologically similar, these populations showed differences in hind-
brain and midbrain markers. Secondly, culture models involving spontaneous neuron-glial 
differentiations are beneficial since this could provide insights into endogenous cellular 
pathways and mTOR regulation, as factors like IGF1 are not administered. For instance use 
of 3D organoid models, which provide structural neuron-glia interactive environment closer 
to naïve brain tissue and facilitate limited use of additional growth factors like IGF1 [22, 
75]. Next, to assess TSC patient iPSC-derived neuronal and glial cells after long-term mat-
uration, e.g. studying myelination defects, humanized mouse models could be considered. 
Humanized mouse models are mice carrying human genes, cells, or tissue, which have 
the potential to study human cell pathology in vivo without using actual patient material. 
These models might serve as personalized disease models for patients with varied disease 
severity like TSC and could serve analysis of phenotypes in an in vivo environment, using 
techniques like patch clamping on slices, myelin assays or behavioural studies. Moreover, 
specific neural defects like dendritic arborization in TSC neurons, which are difficult to 
study using 2D in vitro cultures, could be easily measured using GFP-labeled TSC neurons 
in humanized rodent brain. Lastly, defects in TSC brain can already be observed at prenatal 
stages [41, 76]. Since brain synchronization occurs mostly at fetal stages in humans [77, 
78], deriving synchronized networks of cortical neurons will be valuable. Synchronization 
events in cell culture models therefore need more in depth analysis. This would bring TSC 
cell models closer to the developing human brain and facilitate new drug trials in the clinic 
for TSC infants, since rodent models also suggest prenatal drug treatment might alleviate and 
rescue neurodevelopmental defects [79]. Therefore, careful selection of NPs and neural cell 
populations, personalized in vivo models and closer to human disease models for neurode-
velopmental disorders like TSC would help bring improvements in therapy.  
 Defects in the GABAergic excitatory to inhibitory switch via NKCC1-KCC2, where 
KCC2 is required for proper maturation of GABAergic neurons, has been reported in TSC 
patient brain tissue [80] as well as for other autism spectrum disorders like Rett syndrome 
[81]. Since, hyperactive mTOR causes an increase in number of synaptic vesicles and leads 
to increase in evoked synaptic responses of both glutamatergic and GABAergic neurons 
[82], the role of mTOR in synaptic transmission should be emphasized. Therefore, charac-
terization of synchronous activity, altered balance of NKCC-KCC channels as well as synap-
tic transmission in TSC patient iPSC-derived neurons would be an approach to relate these 
abnormalities to neuronal phenotypes of TSC patients. 
 To address abnormalities of neuron and glial interactions in TSC, future studies could 
focus on mechanisms underlying their communication e.g., myelination process. Studying 
the role of TSC proteins in initiation of myelination and involvement of promyelinating fac-
tors [83] would be useful to understand underlying mechanisms of hypomyelination in TSC. 
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Interestingly, cell adhesion molecules, like Polysialic acid (PSA) and neural cell adhesion 
molecule (NCAM), which inhibit intiation of myelination by attaching to the axonal surface 
and thereby prevent adhesion of myelinating OLs to axonal surfaces [83] also regulate mTOR 
via Akt, ERK, MAPK and CREB signaling [84, 85]. Similarly, another cell adhesion molecule 
namely Growth associated protein 43 (GAP-43), which functions similar to NCAM, was 
shown to be upregulated in TSC patient brain tissue and was correlated to reduced MBP 
expression [44]. Therefore, studying role of such cell adhesion molecules could reveal their 
direct/ in-direct involvement in myeline defects of TSC patients. Furthermore, it was shown 
that mTORC1 activity in OLs has a more significant role than mTORC2 in the process of 
myelination. It is hypothesized that the mTORC2 plays a combined role in the process of 
myelination, since double KO mice for Raptor/ Rictor (i.e., Proteins present in mTORC1 and 
mTORC2 complexes, respectively) showed the most severe effects on OL differentiation 
[86, 87]. While differential function of mTORC1 and mTORC2 in human neural cell types 
needs to be studied, this study again indicates differential regulation of mTOR complexes in 
different cell types. Overall, studies towards understanding intricate axon-OL interaction in 
TSC as well specific mTOR roles in each CNS cell type involved would provide new insights 
to TSC research.
 The TSC patient iPSC-derived in vitro models presented in this thesis could facilitate 
drug development studies. Although iPSCs could serve as personalized in vitro models, high 
throughput assays and screening techniques need to be involved for better understanding of 
patient-patient and cell-cell variability in TSC. To predict individual patient responses and 
selecting patient subgroups for clinical trials, biomarker studies will be advantageous (Re-
view on future directions for TSC [88]). Furthermore, since TSC is a multiple organ disorder 
with varying mTOR functions in each cell type, strategies with multi-cell oriented therapy, 
nano-therapeutic targeting could be an interesting approach for TSC. Finally, considering 
translational lags among animal models and human diseases [89-91], TSC patient iPSCs and 
humanized rodent models using hiPSCs form an important model, especially when a higher 
number of patients are included in such studies.  
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Summary
 Studying defective mechanisms underlying human neurodevelopmental disorders 
requires appropriate disease models. Human induced pluripotent stem cells (iPSCs) provide 
new tools to study pathological mechanisms underlying certain diseases or patient popula-
tions, with the final goal to improve therapy. The aim of this thesis was to assess the poten-
tial of human iPSCs in modeling a specific neurodevelopmental disorder called Tuberous 
sclerosis complex (TSC), which is placed under Autism spectrum disorders (ASDs). Towards 
developing proper TSC disease models, we studied several iPSC differentiation protocols 
for generating specific neural progenitors (NPs) and mature neural cell types, as well as the 
involvement of brain cell types in TSC phenotypes. 
 In chapter 2 we studied the effects of multiple neural induction factors, like dual 
SMAD inhibition, single SMAD inhibition and retinoic acid (RA) administration, on the 
regional identity of human PSC-derived NPs in vitro. We furthermore assessed the potential 
of these NPs to commit neuronal and / or astrocytic lineages. Dual SMAD inhibition-in-
duced NPs showed higher expression of glutamatergic neuronal lineage markers, whereas 
RA-induced NPs showed higher expression of GABAergic neuronal lineage markers. Single 
SMAD inhibition-induced NPs were less successful in generating cortical neurons, but were 
efficient in generating astrocytes. We concluded that the tested protocols generate NP popu-
lations with similar broadly used marker expression, although they differ in regional identity 
and differentiation potential.
 In chapter 3 we generated new cortical neuronal differentiation protocols, suitable 
to study neuron- and astrocyte-specific changes. We showed that these assays produced 
neuronal networks with balanced expression of GABAergic and glutamatergic synapses. 
Analysis of protein and mRNA expression at multiple differentiation stages showed expres-
sion of cortical neuronal lineage markers like CTIP2, SATB2, PROX1 and MEIS2. Functional 
assays like calcium imaging and patch clamping in presence of GABAergic and glutama-
tergic channel blockers AP5/DNQX and bicuculline, respectively confirmed presence of 
both types of neurons. Furthermore, the indirect contact cultures showed presence of pure 
neuronal populations as indicated by proteomic analysis. We concluded that the derived 
cortical neuronal cultures express a balanced network of cortical excitatory and inhibitory 
cells. Moreover, this model under indirect co-culture mode would also be useful to study for 
instance, patient neuron versus patient astrocyte effects. 
 In chapters 4 and 5, we studied TSC-patient iPSC-derived neuronal mono-cultures 
and co-culture networks of patient iPSC-derived neurons and oligodendrocytes (OLs). TSC 
patient iPSCs showed reduced expression of TSC proteins. While no morphological chang-
es were observed, TSC patient iPSC-derived neuronal mono-cultures expressed increased 
network activity, which was modulated by administration of clinically used drug Rapamy-
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cin. Interestingly, TSC patient neuron-OL co-cultures showed significant changes in axonal 
density as well as hypertrophy. Furthermore, OL proliferation was significantly increased 
and OL maturation was reduced in TSC neuron-OL co-cultures. These alterations were also 
altered or corrected by treatment with Rapamycin. Overall, we concluded that TSC-patient 
iPSC derived cells possess promising potential to model phenotypic defects of TSC and also 
respond to pharmacological drugs in a laboratory model. In chapter 5, we assessed long-
term survival of iPSC-derived cells in a mouse brain in vivo environment. The transplanted 
iPSC-derived cortical neurons incorporated well into the host brain and expressed GABAe-
rgic and glutamatergic markers in vivo. Next, we analyzed proliferation and morphological 
properties of transplanted TSC patient iPSC-derived neurons and OLs. Interestingly, similar 
to our in vitro results, the in vivo transplanted cells also showed increased OL proliferation 
and neurite length. This indicated that future studies with TSC patient iPSC-derived in vivo 
models could serve as humanized mouse models to study TSC phenotypes and help the 
process of therapy and drug testing.  
 Finally in chapter 6, an overview of the contributions of this thesis, in comparison 
to current updates in the field are presented. Finally, future prospects of stem cell research 
towards a better therapy for neurodevelopmental disorders like TSC are discussed.  
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